Official Protocol Title:
NCT number:
Document Date:
Phase 1 Open-label, Multicenter Study of MK-
1454 Administered by [CONTACT_762560]/Metastatic Solid Tumors or
Lymphomas

Product:   MK-1454 1
Protocol/Amendment No.: 001-08 
MK-1454 -001-08 Final Protocol 27-Jul-2021
ConfidentialTHIS PROTOCOL AMENDMENT AND ALL OF THE INFORMATION RELATING 
TO IT ARE CONFIDENTIAL AND PROPRIETARY PROPERTY OF MERCK 
SHARP & DOHME CORP., A SUBSIDIARY OF MERCK & CO., INC., 
WHITEHOUSE STATION, NJ, U.S.A .
SPONSOR:
[COMPANY_006] Sharp & Dohme Corp., a subsidiary of [COMPANY_006] & Co., Inc. 
(hereafter referred to as the Sponsor or [COMPANY_006])
One [COMPANY_006] Drive
P.O. Box [ADDRESS_1044708] information can be found in theInvestigator Trial File 
Binder (or equivalent) .
TITLE:
Phase 1 Open -label, Multicenter Study of MK-1454 Administered by [CONTACT_762561]/Metastatic Solid Tumors or Lymphomas
IND NUMBER:   [ADDRESS_1044709] NUMBER:   [ADDRESS_1044710] :  [STUDY_ID_REMOVED]
087V73
Product:   MK-1454 2
Protocol/Amendment No.: 001-08 
MK-1454 -001-08 Final Protocol 27-Jul-2021
ConfidentialTABLE OF CONTENTS
DOCUMENT HISTORY ................................ ................................ ................................ .....12
SUMMARY OF CHANGES ................................ ................................ ................................ 14
1.0 TRIAL SUMMARY ................................ ................................ ................................ ..18
2.0 TRIAL DESIGN ................................ ................................ ................................ ........ 20
Trial Design ................................ ................................ ................................ ........... 20
Part I –Dose Escalation and Confirmation Phase ................................ .............. 20
Part II –Expansion Phase ................................ ................................ .................... 23
Trial Diagram ................................ ................................ ................................ ........ 24
Trial Diagram for Part I -Dose Escalation and Confirmation ............................ 24
Trial Diagram for Part II –Expansion Cohorts ................................ .................. 26
3.0 OBJECTIVE(S) & HYPOTHESIS(ES) ................................ ................................ ..26
Primary Objective(s) & Hypothesis(es) ................................ .............................. 26
Secondary Objective(s) & Hypothesis(es) ................................ ........................... 27
Exploratory Objectives ................................ ................................ ......................... 27
4.0 BACKGROUND & RATIONALE ................................ ................................ .......... [ADDRESS_1044711] Population ................................ ....31
Rationale for Part I -Dose Escalation and Confirmation ............................ 31
Rationale for Part II -Expansion Cohorts ................................ .................... 32
[IP_ADDRESS].1 Microsatellite Instability Testing ................................ .......................... 33
Rationale for Dose Selection/Regimen ................................ ............................... 34
Starting Dose for This Trial ................................ ................................ ......... 34
Maximum Dose/Exposure for This Trial ................................ ..................... [ADDRESS_1044712]:   MK-1454 3
Protocol/Amendment No.: 001-08 
MK-1454 -001-08 Final Protocol 27-Jul-2021
Confidential
Rationale for Dose of MK -1454 Expansion Cohorts A and B (Part II) ....... 36
Rationale for Dose Schedule Expansion Cohorts A and B (Part II) ............ 37
Rationale for Endpoi nts................................ ................................ ...................... 37
Efficacy Endpoints ................................ ................................ ....................... 37
[IP_ADDRESS].[ADDRESS_1044713] (irR ECIST) ................................ .................. 38
[IP_ADDRESS].2 IWG Revised Response Criteria for Malignant Lymphomas ............... 38
[IP_ADDRESS].3 Response Assessment for CTCL ................................ .......................... 39
Safety Endpoints ................................ ................................ .......................... 39
Pharmacokinetic Endpoints ................................ ................................ ......... 39
Pharmacodynamic Endpoints ................................ ................................ ....... 39
Planned Exploratory Biomarker Research ................................ ................... 40
[IP_ADDRESS].1 Planned Genetic Analysis ................................ ................................ .....40
Future Biomedical Research ................................ ................................ ........ 41
Benefit/Risk ................................ ................................ ................................ ........... 42
5.0 METHODOLOGY ................................ ................................ ................................ ...42
Entry Criteria ................................ ................................ ................................ ........ 42
Diagnosis/Condition for Entry into the Trial ................................ ...................... [ADDRESS_1044714] Exclusion Criteria for Part I -Dose Escalation and Confirmation ........ 54
Exclusion Criteria for Arms 1, 2, and 3 ................................ ....................... 54
Exclusion Criteria for Cross over Into Arm 2 ................................ ............... 56
Exclusion Criteria for Part II -Expansion Cohorts ................................ ............. 57
Trial Treatment(s) ................................ ................................ ................................ 60
Dose Selection/Modification ................................ ................................ .............. 63
Dose Selection (Preparation) ................................ ................................ ....... 63
[IP_ADDRESS].1 Dose Selection in Part I -Dose Escalation and Confirmation 
(Arm 1, Arm 2, and Arm 3) ................................ ................................ ..63
[IP_ADDRESS].2 Dose Selection in Part II -Expansion Cohorts (Cohorts A and B) ....... [ADDRESS_1044715]:   MK-1454 4
Protocol/Amendment No.: 001-08 
MK-1454 -001-08 Final Protocol 27-Jul-2021
Confidential
Accelerated Titration Design in Arms 1, 2, and 3 ................................ ....... 65
Dose Escalation and Confirmation During Modified Toxicity 
Probability Interval Design ................................ ................................ .......... 66
Definition of Dose -Limiting Toxicity ................................ ................................ .68
Dose Modification Due to Adverse Events ................................ ......................... 69
Dose Modification for MK-1454 Drug -related AEs in Part I -Arm 1, 
Arm 2, and Arm 3................................ ................................ ........................ 70
Dose Modification for MK -1454 in Part II -Expansion Cohorts ................ 77
Immune -Related Events and Dose Modification (Withhold, Treat, 
Discontinue) ................................ ................................ ................................ .[ADDRESS_1044716] Dose Escalation ................................ ................................ ............... 85
Timing of Dose Administration ................................ ................................ .......... 86
Timing of MK-1454 Dose Administration in Part I -Dose Escalation 
and Confirmation ................................ ................................ ......................... 86
Timing of MK-1454 Dose Administration in Part II -Expansion 
Cohorts ................................ ................................ ................................ ......... 86
Timing of Pembrolizumab Administration ................................ .................. 86
Trial Blinding ................................ ................................ ................................ ......87
Replacement of Subjects During the DLT Evaluation Period ............................ 87
Randomization or Treatment Allocation ................................ ............................ 87
Stratification ................................ ................................ ................................ .......... 87
Concomitant Medications/Vaccinations (Allowed and Prohibited) ................. 87
Rescue Medications & Supportive Care ................................ ............................. 89
Supportive Care Guidelines ................................ ................................ ................ 89
Diet/Activity/Other Considerations ................................ ................................ .....[ADDRESS_1044717] Withdrawal/Discontinuation Criteria ................................ ................... [ADDRESS_1044718]:   MK-1454 5
Protocol/Amendment No.: 001-[ADDRESS_1044719] Replacement Strategy ................................ ................................ ............. 94
Beginning and End of the Trial ................................ ................................ ........... 94
Clinical Criteria for Early Trial Termination ................................ ................... 94
6.0 SCHEDULE OF ACTIVITIES ................................ ................................ ............... 95
Schedule of Activities for Part I -Dose Escalation and Confirmati on 
(Arms 1, 2, and 3) ................................ ................................ ................................ ..95
Schedule of Activities for Initial Screening for Arms 1 Through 3 and for 
Crossover Into Arm 2................................ ................................ .......................... 95
Schedule of Activities for the Treatment Period, Intratumoral 
Administration for Arm 1 (Monotherapy) and Arm 2 (Combination Therapy 
–Including Crossover to Arm 2)................................ ................................ ........ 98
Schedule of Activities for the Treatment Period of Arm 3 (Visceral IT 
Administration) ................................ ................................ ................................ .103
Discontinuation / End of Treatment and Posttreatment Follow -up for Arms 1 
to 3................................ ................................ ................................ .................... 107
Schedule of Activities for Part II -Expansion Cohorts ................................ ....109
Schedule of Activities for Part II -Expansion Cohorts Screening and 
Treatment Period, MK-1454 Intratumoral Administration With 
Pembroli zumab Combination Therapy ................................ ............................. 109
Discontinuation / End of Treatment and Posttreatment Follow -up for Part II 
–Expansion Cohorts ................................ ................................ ......................... 115
7.0 TRIAL PROCEDURES ................................ ................................ ......................... 117
Trial Procedures ................................ ................................ ................................ .117
Administrative Procedures ................................ ................................ ................ 117
Informed Consent ................................ ................................ ....................... 117
[IP_ADDRESS].1 General Informed Consent ................................ ................................ ..117
[IP_ADDRESS].2 Consent and Collection of Specimens for Future Biomedical 
Research ................................ ................................ .............................. 118
Inclusion/Exclusion Criteria ................................ ................................ ......[ADDRESS_1044720]:   MK-1454 6
Protocol/Amendment No.: 001-08 
MK-1454 -001-08 Final Protocol 27-Jul-2021
Confidential
Prior and Concomitant Medications Review ................................ ............. 119
[IP_ADDRESS].1 Prior Medications ................................ ................................ ................ 119
[IP_ADDRESS].2 Concomitant Medications ................................ ................................ ...119
Assignment of Screening Number ................................ ............................. 119
Assignment of Treatment/Randomization Number ................................ ...119
Trial Compliance (Medicatio n/Diet/Activity/Other) ................................ .120
Trial Communication Plan Summary ................................ ........................ 120
Clinical Procedures/Assessments ................................ ................................ ......120
Adverse Event Monitoring ................................ ................................ ......... 120
Full Physical Examination ................................ ................................ ......... 121
Vital Signs and Weight ................................ ................................ .............. 121
Electrocardiogram ................................ ................................ ...................... 121
Eastern Cooperative Oncology Group Performance Status ....................... 121
Tumor Imaging and Medical Photography ................................ ................ 122
Response Assessment ................................ ................................ ................ 122
[IP_ADDRESS].[ADDRESS_1044721] ................................ ................................ ....122
[IP_ADDRESS].[ADDRESS_1044722] (itRECIST) ........................... 124
[IP_ADDRESS].3 IWG Revised Response Criteria for Malignant Lymphomas ............. 124
[IP_ADDRESS].4 Response Assessment Cr iteria for CTCL ................................ ........... 126
Laboratory Procedures/Assessments ................................ ................................ 132
Laboratory Safety Evaluations (Hematology, Chemistry, and 
Urinalysis) ................................ ................................ ................................ ..132
Pharmacokinetic/Pharmacodynamic Evaluations ................................ ......133
[IP_ADDRESS].1 Blood Collection for MK -1454 and P embrolizumab PK ................... 133
[IP_ADDRESS].2 Blood Collection for Anti -Pembrolizumab Antibodies (ADA) .......... 133
[IP_ADDRESS].3 Blood for Pharmacodynamic Markers ................................ ................ 133
[IP_ADDRESS].4 Tumor Biopsy ................................ ................................ ..................... 133
Planned Genetic Analysis Sample Collection ................................ ............ 135
Future Biomedical Research Samples ................................ ....................... 135
Other Procedures ................................ ................................ ............................... 135
Withdrawal/Discontinuation ................................ ................................ ......135
[IP_ADDRESS].1 Withdrawal From Future Biomedical Research ................................ .136
[IP_ADDRESS].[ADDRESS_1044723]:   MK-1454 7
Protocol/Amendment No.: 001-[ADDRESS_1044724] Blinding/Unblinding ................................ ................................ .....[ADDRESS_1044725] ................................ ................................ .......... 142
Protocol -Specific Exceptions to Serious Adverse Even t Reporting .......... 142
Evaluating Adverse Events ................................ ................................ ............... 143
Sponsor Respon sibility for Reporting Adverse EventsSAEs ........................... 146
8.0 STATISTICAL ANALYSIS PLAN ................................ ................................ ......146
Statistical Analysis Plan Summary ................................ ................................ ...146
Responsibility for Analyses/In -house Blinding ................................ ................ 148
Hypotheses/Estimation ................................ ................................ ....................... 148
Analysis Endpoints ................................ ................................ ............................. 148
Efficacy/Pharmacokinetic Endpoints ................................ ................................ [ADDRESS_1044726]:   MK-1454 8
Protocol/Amendment No.: 001-[ADDRESS_1044727] of Baseline Factors ................................ ......... 152
Compliance (Medication Adherence) ................................ ................................ [ADDRESS_1044728]/Destruction/Returns and Reconciliation ................................ ............ [ADDRESS_1044729] Records ................................ ................................ ...155
Confidentiality of Investigator Information ................................ ...................... 155
Confidentiality of IRB/IEC Information ................................ ........................... [ADDRESS_1044730]:   MK-1454 9
Protocol/Amendment No.: 001-[ADDRESS_1044731] of Abbreviations and Definitions ................................ ............................... 180
13.0 SIGNATURES ................................ ................................ ................................ ......... 185
Sponsor's Representative ................................ ................................ ................... [ADDRESS_1044732]:   MK-1454 10
Protocol/Amendment No.: 001-[ADDRESS_1044733] OF TABLES
Table 1Adequate Organ Function Laboratory Values ................................ ........................ 43
Table 2Anti-PD-1/PD -L1 Antibody Refractory Definition ................................ ................ 52
Table 3Trial Treatment for MK -1454 IT Mon otherapy (Arm 1) ................................ ....... 60
Table 4Trial Treatment for MK-1454 IT in Combination with Pembrolizumab 
(Arm 2)................................ ................................ ................................ ................... 61
Table 5Trial Treatment for MK-1454 Visceral IT in Combination with 
Pembrolizumab (Arm 3)................................ ................................ ......................... 62
Table 6Determination of MK-1454 Injection Volume for Intratumoral Injection of 
Cutaneous Lesions Based on Lesion Size (Part I -Arm 1 and Arm 2) .................. 64
Table 7Determination of MK-1454 Injection Volume for Intratumoral Injection 
into Subcutaneous Lesions Based on Lesion Size (Part I Arm 1 and Arm 2) ........ 64
Table 8Trial Treatment for MK-1454 IT in Combination with Pembrolizumab Part 
II (Expansion Cohorts A, B, and C) ................................ ................................ ....... 65
Table 9Injectate Volume for Arm 3 Visceral IT (Part I) and Expansion Cohorts 
(Part II) ................................ ................................ ................................ ................... 65
Table 10Dose -finding Rules per mTPI [CONTACT_202473] ................................ ................................ .....68
Table 11MK-1454 Dose Modification Guidelines for Drug -related AEs in 
Monotherapy (Arm 1), Combination Therapy (Arm 2), and Combination 
Therapy Visceral IT (Arm 3)................................ ................................ .................. 71
Table 12Guidelines for Management of MK-1454 Intratumoral Injection Site 
Reactions ................................ ................................ ................................ ................ 77
Table 13Dose Modification and Toxicity Management Guidelines for Immune -
related Adverse Events Associated with Pembrolizumab Monotherapy, 
Coformulations or IO Combinations ................................ ................................ ......79
Table 14Pembrolizumab Infusion Reaction Dose Modification and Treatment 
Guidelines ................................ ................................ ................................ ............... 82
Table 15Cytokine Release Syndrome Treatment Guidelines ................................ ............... 84
Table 16Response Criteria for Malignant Lymphoma ................................ ....................... 125
Table 17Modified Severity Weighted Assessment Tool ................................ .................... 127
Table 18Response in Skin (CTCL) ................................ ................................ ..................... 128
Table 19Response in Lymph Nodes (CTCL) ................................ ................................ .....129
Table 20Response in Viscera (CTCL) ................................ ................................ ................ 130
Table 21Response in Blood (CTCL) ................................ ................................ .................. 131
Table 22Global Response Score for CTCL ................................ ................................ ........ 131
Table 23Laboratory Tests ................................ ................................ ................................ ...132
Table 24Evaluating Adverse Events ................................ ................................ ................... 144
Table 25Estimate and 95% CI of ORR (N=30) ................................ ................................ ..152
Table 26Estimate and 95% CI of ORR (N=60) ................................ ................................ ..[ADDRESS_1044734]:   MK-1454 11
Protocol/Amendment No.: 001-[ADDRESS_1044735]:   MK-1454 12
Protocol/Amendment No.: 001-[ADDRESS_1044736] Cancer Expansion Cohort to 
include anti-PD-1/PD -L1 refractory subjects and to add an upper limit for LDH for this 
cohort, remove dthe requirement for having a second lesion for biopsy in the Expansion 
Cohorts , added itRECIST as an exploratory objective, and update dthe contraception 
requirements .
MK-1454 -001-06 23 -AUG-2019 Document edthe Recommended Phase 2 Dose (RP2D) to be used in Expansion Cohorts A 
and B . 
MK-[ADDRESS_1044737] of the [LOCATION_002] (US) Food and 
Drug Administration (FDA), to allow the inclusion of subjects with head and neck 
squamous cell carcinoma (HNSCC) Stage III, IVa, IVb, and IVc disease per TNM Staging 
AJCC Eighth Edition.
MK-[ADDRESS_1044738] -2018 Designated Dose Escalation and Confirmation phase (Arms 1, 2, and 3) as Part I and 
updated sections accordingly. Added Expansion phase with 3 Expansion Cohorts (Cohorts 
A to C) as Part II of the study and added new subsections to describe design, entry criteria, 
dosing schedule, flow chart, and statistical analysis for the Expansion Cohorts in order to 
evaluate the safety and tolerability of MK-1454 intratumoral (IT) in combination with 
pembrolizumab in specific cancer tumor types . Updated sample size, secondary/exploratory 
objectives, treatments, and schedule of activities to reflect addition of the Expansion 
Cohorts .
Revised the dose escalation and confirmation rules for Arm 3 to include an accelerated 
titration design (ATD) phase starting at of MK-[ADDRESS_1044739] tolerance per modified toxicity 
probability interval (mTPI) design . This change was based on anFDA request to start 
visceral IT dosing in combination with pembrolizumab at the No observed adverse effect 
level (NOAEL) dose of  
CCI
CCI
087V73
Product:   MK-1454 13
Protocol/Amendment No.: 001-08 
MK-1454 -001-08 Final Protocol 27-Jul-2021
ConfidentialDocument Date of Issue Overall Rationale
MK-1454 -001-03 09-MAR -2018 Updated protocol sections to add rationale, background, entry criteria, schedule of activities, 
and procedures for Arm 3 for intratumoral (IT) injection of 
MK-1454 into visceral lesions in combinatio n with pembrolizumab treatment in order to 
allow inclusion of subjects with visceral lesions to be treated by [CONTACT_626918].
Updated the objectives, inclusion criteria, schedule of activities, and response assessment 
criteria for subjects with cutaneous T -celllymphoma (CTCL) .
MK-[ADDRESS_1044740] to add detailed 
supportive care guidelines for potential cytokine release syndrome (CRS) .
MK-1454 -001-01 07-DEC -2016 Entry criterion #3 text was revised from “for which there is no standard available therapy...” 
to “and who have received, or been intolerant to, all treatment known to confer clinical 
benefit.”  
Definition of a DLT was revised so that causality assessment by [CONTACT_762562]“related, probably related, or possibly related to the drug,excluding 
toxicities clearly not related to thedrug, such as disease progression, environmental factors, 
unrelated trauma, etc. ,” rather than “ unrelated to the underlying disease .” Additionally, Item 
#3 in the definition of a DLT was revised to clarify that exceptions to Grade 3 
nonhematologic toxicity (not laboratory) lasting >3 days as include: Grade 3 fatigue lasting 
≤3 days; Grade [ADDRESS_1044741] of care; Grade [ADDRESS_1044742] of care; Grade 3 fever and Grade 3 flu-like symptoms lasting ≤24 hours 
with negative infectious disease workup (includ ing negative blood and urine cultures).
MK-[ADDRESS_1044743]:   MK-1454 14
Protocol/Amendment No.: 001-08 
MK-1454 -001-08 Final Protocol 27-Jul-2021
ConfidentialSUMMARY OF CHANGES
PRIMARY REASON (S)FOR THIS AMENDMENT:
Section Number (s) Section Title (s) Description of Change (s) Rationale
[IP_ADDRESS] Immune -Related Events and 
Dose Modification (Withhold, 
Treat, Discontinue)The dose modification and 
toxicity management guidelines 
for irAEs and table were 
updated.Requested by [CONTACT_941] U SFDA in an effort 
to harmonize the presentation of safety 
information across all FDA -approved 
PD-1/L1 antibody prescribing 
information.
6.1.2
6.1.3
6.2.1
[IP_ADDRESS].4Schedule of Activities for the 
Treatment Period, Intratumoral 
Administration for Arm 1 
(Monotherapy) and Arm 2 
(Combination Therapy –
Including Crossover to Arm 2)
Schedule of Activities for the 
Treatment Period of Arm 3 
(Visceral IT Administration)
Schedule of Activities for Part 
II -Expansion Cohorts 
Screening and Treatment 
Period, MK -1454 Intratumoral 
Administration With 
Pembrolizumab Combination 
Therapy
Urine Co llection for MK -1454 
MetabolitesRemoved the requirement for a 
urine sample to be obtained for 
metabolite and renal clearance 
analysis.Analysis of MK-1454 plasma 
metabolites showed low risk, so MK-
1454 urine metabolite analysis is not 
needed. Analysis of renal excretion not 
needed at this time, based on current 
phase of clinical development. 
Section [IP_ADDRESS].4 Urine Collection for 
MK-1454 Metabolites removed ; this 
section number is now used for Tumor 
Biopsy.
087V73
Product:   MK-1454 15
Protocol/Amendment No.: 001-08 
MK-1454 -001-08 Final Protocol 27-Jul-2021
ConfidentialSection Number (s) Section Title (s) Description of Change (s) Rationale
9.[ADDRESS_1044744]:   MK-1454 16
Protocol/Amendment No.: 001-08 
MK-1454 -001-08 Final Protocol 27-Jul-2021
ConfidentialADDITIONAL CHANGE(S) FOR THIS AMENDMENT:
Section Number (s) Section Title (s) Description of Change (s) Rationale
[IP_ADDRESS] Acceptable Contraception 
MethodsDeleted instructional text regarding 
hormonal contraception that was 
inadvertently left from the template.Correction.
2.2.2 Trial Diagram for Part II –
Expansion CohortsUpdated the trial schema to add “locally 
advanced metastatic” to the Cohort B 
indication descriptionCorrected an error of omission
2.2.2 Trial Diagram for Part II –
Expansion CohortsCorrected figure legend from  
to Correction of typographical 
error.
[IP_ADDRESS] Subject Inclusion Criteria for 
Arms 1 and 2Corrected the renal function criterion 
for serum creatinine or creatinine 
clearance from “ ≥1.5 × upper limit of 
norma l (ULN) ” to “ ≤1.5 × ULN.”
Added “GFR in place of CrCl.”
Corrected the hepatic function criterion 
for total bilirubin from “≥1.5 × UL N” 
to “≤1.5 × ULN.”Correction of typographical 
errors and omission of GFR .
6.1.3 Schedule of Activities for the 
Treatment Period of Arm 3 
(Visceral IT Administration)Deleted the “X” for “Plasma MK-1454 
PK” in Cycle 3Correction – no samples are to 
be collected in Cycle 3.
CCI
CCI
087V73
Product:   MK-1454 17
Protocol/Amendment No.: 001-08 
MK-1454 -001-08 Final Protocol 27-Jul-2021
ConfidentialSection Number (s) Section Title (s) Description of Change (s) Rationale
6.2.1 Schedule of Activities for Part 
II -Expansion Cohorts 
Screening and Treatment 
Period, MK-1454 Intratumoral 
Administration With 
Pembrolizumab Combination 
TherapyRemoved extraneous language 
regarding ECOG performance status
“Obtain within 72 h prior to MK 1454 
IT administration. Does not need to be 
repeated on C1D1 if screening ECG 
was done within 72 hours of C1D1. ”Sentence was included in error.
[IP_ADDRESS] Laboratory Safety Evaluations 
(Hematology, Chemistry, and 
Urinalysis)Updated footnote c in Table [ADDRESS_1044745] Supplementary 
Figures –Figure 8Corrected word in figure legend 
describing responses in non injected
lesions from “blue” to “purple”Correction of typographical 
error
Throughout NA Updated the document style to remove 
spelled out abbreviations fr om the text, 
and corrected format and grammar.To adhere to current [COMPANY_006] 
template style for future 
content reuse.
087V73
Product:   MK-1454 18
Protocol/Amendment No.:   001-[ADDRESS_1044746] Identifiers MK-1454
Pembrolizumab (MK -3475 )
Trial Phase Phase 1/1b
Clinical Indication The treatment of subject s with advanced/metastatic solid tumors or 
lymphomas .
Trial Type Interventional
Type of control None
Route of administration Intratumoral (MK -1454)
Intravenous Infusion (pembrolizumab)
Trial Blinding Unblinded Open -label
Treatment Groups Subject swill be allocated by [CONTACT_762563] s:
Part I:  Dose Escalation and Confirmation
Arm 1 : MK-1454 IT as monotherapy  in 
cutaneous or subcutaneous l esions
Arm 2 : MK-1454 IT in combination with 
pembrolizumab in cutaneous or subcutaneous lesi ons
Arm 3 : MK-1454 IT(at escalating frequencies starting with
 
in combination with pembrolizumab (Q3W) in visceral 
lesions
Part II:  E xpansion Cohorts
Eligible subjects with advanced/metastatic solid tumors will be allocated 
by [CONTACT_762564] a combination of MK -1454 IT and 
pembrolizumab IV:
Cohort A: H NSCC , anti-PD-1/PD-L1refractory ;
Cohort B: A nti-PD-1/PD- L1 treatment -naïve or refractory unresectable 
locally advanced or metastatic TNBC
Cohort C: A nti-PD-1/PD- L1 treatment -naïve solid tumors with liver 
metastase s/lesions
Number of trial subjects Approx imately 235subjects will be enrolled.
Estimated duration of trial The Sponsor estimates that the study will require approximately 4.[ADDRESS_1044747] participant (or their legally acceptable 
representative) provides documented informed consent until the last 
participant’s last study -related contact.
CCI
CCI
CCI
CCI
087V73
Product:   MK-1454 19
Protocol/Amendment No.:   001-[ADDRESS_1044748] swill be allocated by [CONTACT_762565]. 
During Part I(Dose Escalation and Confirmation ), subjects will receive
treatment with MK-1454 as monotherapy (Arm 1) or ascombination 
therapy with pembrolizumab (Arm 2or Arm 3). Study treatment will 
begin on Day [ADDRESS_1044749] s enrolled in Arm 1
(treatment with MK-1454 as monotherapy ) and in Arm 2or Arm 3
(treatment with MK-1454 and pembrolizumab combination therapy) may
continue treatment for up to 35 cycles (approximately 2 years) from the 
start of treatment. 
Subjects who progress by [CONTACT_762566]-1454 (Arm 1), may cross over into the 
combination therapy arm of MK-1454 and pembrolizumab (Arm 2), 
provided they meet eligibility criteria . A crossover subject may receive 
up to 35cycles of treatment in Arm 2 (MK -1454 with pembrolizumab 
combination therapy) regardless of the duration of treatment received in 
Arm 1 (MK 1454 monotherapy).
Subjects treated with monotherapy MK-1454 (Arm 1) may participate in 
intrasubject dose escalation after the completion of Cycle 3. A subject 
may undergo dose escalation once during monotherapy with MK-[ADDRESS_1044750] dose 
escalation one time after receiving 3 cycles of treatment without a ≥ 
Grade [ADDRESS_1044751] s may continue treatment until one of the following occurs:
disease progression, unacceptable AE(s), intercurrent illness that 
prevents further administration of treatment, investigator’s decision to 
withdraw the subject , subject withdraws consent, pregnancy of the 
subject , noncompliance with trials treatment or procedure requirements, 
or administrat ive reasons requiring cessation of treatment . After the 
EOT, each subject will be followed up for 30days for monitoring all 
AEs. SAEs and ECI will be collected for 130days after the EOT or for 
30days after the EOT if the subject initiates new anticancer therapy, 
whichever is earlier . 
The Expansion phase (Part II)will open to enroll subjects in Cohorts A 
to Cto evaluate the safety and efficacy of MK-1454 IT in combination 
with pembrolizumab 200mg IV. Cohort A will evaluate MK-1454 in 
30subjects with anti-PD-1/PD -L1refractory HNSCC : Cohort B will 
include 30 subjects with anti-PD-1/PD -L1 treatment -naïve or refractory 
TNBC, and Cohort C will include 60subjects with anti-PD-1/PD -L1 
treatment -naïve solid tumors with liver metastases, with a cap at 
15subjects each with colorectal cancer (CRC) or pancreatic cancer . The 
starting dose for expansion Cohorts A and B will be the preliminary 
RP2D established in Arm 2. Thestarting dose and frequency for Cohort 
C will be the RP2D e stablished for visceral IT administration in Arm 3.
All subject s, except for those who withdraw consent or are lost to follow -
up, will be followed up for survival . Subject swho experience confirmed 
disease progression or start a new anticancer therapy, will move into the 
Survival Follow -Up Phase and should be contact[CONTACT_457] [ADDRESS_1044752]:   MK-1454 20
Protocol/Amendment No.:   001- [ADDRESS_1044753] of abbreviations used in this document 
can be found in Appendix 12. 6. Not e: Both “subject” or “participant” may be used to refer to 
individuals enrolled in clinical trials. 
2.0TRIAL DESIGN
Trial Design
This is a nonrandomized, multisite, open -label trial of MK-[ADDRESS_1044754] s with 
advanced/metastatic solid tumors or lymphomas. MK-1454 will be administered IT. Each 
cycle within the trial is a 21-day cycle . The trial will begin with theDose Escalation and 
Confi rmation phase (Part I) comprising Arms 1, 2, and 3. Subsequently, an expansion phase 
will initiate to further examine safety and efficacy of MK-1454 IT in combination with 
pembrolizumab .
Part I – D ose Escalation and Confirmation Phase
Unless deemed medically unsafe by [CONTACT_093] , all subjects will be required to undergo
a biopsy of the lesion to be injected with MK-1454 ,and a biopsy ofa noninjected distant ,
discrete lesion, during the screening period (prior to MK-1454 administration) . Also, in 
Arm [ADDRESS_1044755] dose 
administration of MK-1454 on C1D1. The inpatient observation period on C1D1 may be 
extended up to 48 hours at the discretion of the investigator , and/or per local IRB/IEC , and/or 
Health Authority mandate . 
In the Part I, MK-[ADDRESS_1044756] 3 cycles of Arm 1 and Arm2 is and dosing in 
Cycles 4and beyond is  MK-1454 dosing frequency in Arm 3 to visceral lesions will 
begin at  and is intended toescalate to a maximum frequency of  
thereafter . 
Dose escalation will proceed based on emerging safety and tolerability data of MK-1454 as 
monotherapy and as combination therapy with pembrolizumab. For each dose level, an 
assessment will be made of the safety and tolerability data in order to define the next dose 
level to be tested (see Section 5.2 andTable 3andTable 4). Arm1,Arm 2, and Arm 3will 
start with an ATD phase followed by [CONTACT_762567] [INVESTIGATOR_762533]/or MAD of 
MK-1454 monotherapy (Arm 1) or MK-[ADDRESS_1044757]:   MK-1454 21
Protocol/Amendment No.:   001-08 
MK-1454 -001-08 Final Protocol 27-Jul-2021
Confidential(Arm 2and Arm 3). T he Dose Escalation and Confirmation phase in Arms 1 and 2 of this 
study will aimto identify a preliminary RP2D of intratumorally administered MK-1454 in 
monotherapy and in combination with pembrolizumab IV infusion . In Arm 3, the aim will be 
to identify the RP2D of MK-1454 IT administered to visceral lesions in combination with 
pembrolizumab IV infusion . The RP2D may be the same as the MTD/MAD, or the RP2D 
may be modified from the MTD/MAD based on overall exposure, emerging safety data, 
pharmacodynamic data, and clinical benefit data from this stu dy. 
Starting with a dose of  of MK-[ADDRESS_1044758] cohorts (Arm 1, PartA), the trial 
will proceed in an ATD up to a dose that meets at least 1 of the following 3 triggering 
criteria:  1) The cohort is completed , 2) ≥ Grade 2 toxicity as assessed by [CONTACT_762568], probably related, or possibly related to the drug at any dose level, 
or 3) Elevation of systemic TNF -αin blood above baseline level s by ≥3-fold for a given 
subject at any time during the first cycle of MK- [ADDRESS_1044759] 1of the above triggering criteria , the 
monotherapy arm (Arm 1) of the study will proceed to dose escalation and confirmation 
using an mTPI [CONTACT_8345] (Part B). In addition, Arm 2 (Part C), the combination therapy arm, 
will initiate once [ADDRESS_1044760] been cleared by [CONTACT_762569] 1 .
Arm 2 (Part C), MK-[ADDRESS_1044761] 1 of 
the 3 triggering criteria . Arm 2 will then proceed to mTPI [CONTACT_16303] (Arm 2, Part D) to determine 
the MTD/MAD of the combination of MK-[ADDRESS_1044762] remains on study drug after receiving 3 cycles of 
treatment without ≥Grade 2drug-related toxicity ,and provided that the dose escalation has 
proceeded beyond the next dose level . The subject ’s dose may be escalated to the highest 
dose level that has been cleared by [CONTACT_762570] . Intra subject dose escalation is not 
permitted in Arm 2 ( Parts C and D ).
Arm [ADDRESS_1044763] 1of the following 
2criteria ismet: 1)The  cohort in combi nation is completed, 2) ≥ Grade 2 toxicity as 
assessed by [CONTACT_178759], probably related, or possibly related to the drug at 
any dose level in combination . Arm 3 will use the same dose escalation and confirmation 
rules as in the mTPI [INVESTIGATOR_762534] w ith a minimum of 3 subjects per dose level in order to establish 
an MTD/MAD in visceral lesions for the combination of MK-1454 IT and pembrolizumab 
IV. In mTPI [CONTACT_16303], visceral IT dosing of MK-1454 will increase in frequency up to  
thereafter. Once safety and tolerability of dosingfrequency of MK-1454 
visceral ITis established, dose escalation will continue per mTPI . See Section [IP_ADDRESS] for the 
Arm [ADDRESS_1044764] dose escalation may be permitted in Arm 3 subjects 
allotted to doses evaluated in the ATD (PartE) part once they have completed 3 cycles of 
treatment without a ≥Grade [ADDRESS_1044765]:   MK-1454 22
Protocol/Amendment No.:   001-[ADDRESS_1044766] sper cohort to account for simultaneous enrollment . During MK-1454 dose 
escalation in Ar m 1 (Part sA and B ),Arm 2 (Part sC and D) ,and Arm 3 (Part s Eand F ), there 
will be at least [ADDRESS_1044767] s at each dose level . 
Dose escalation of MK-1454 to determine the MTD/MAD for all 3 treatment arms will be 
guided by [CONTACT_203326] [CONTACT_8345], targeting a DLT rate of 30%. Doses of MK-[ADDRESS_1044768] 2dose levels behind the monotherapy 
MK-1454 dose and will not exceed the MTD for monotherapy . If anMTD for the 
monotherapy arm is established, then the dose of MK-1454 in combination may continue 
escalation up to that dose. For example, if the MTD for monotherapy (Arm 1, Part A) is 
, then the starting do se for combination therapy (Arm 2, Par t C),if no DLTs occurred 
in monotherapy, may be  with a maximum dose escalation to . If the MTD for 
monotherapy (Arm 1, Part A) is  then the starting dose for combination therapy will 
be  In monotherapy (Arm 1, Part A), if the dose level is completed, then the 
starting dose in c ombination therapy ( Arm 2, Part C) will be  
Once a dose level in the mTPI [INVESTIGATOR_762535], and a decision made to 
escalate to the next dose level, the cohort may be expanded to a total of [ADDRESS_1044769] s to obtain 
additional pharmacokinetic and pharmacodynamics data. Dose -limiting toxicity information 
from these “back -filling” cohorts will not be formally included in the mTPI [INVESTIGATOR_762536]2D determination . 
For each new dose level in the mTPI [CONTACT_16303] , there may be a minimum of 3subjects and up to 
[ADDRESS_1044770] s may continue their assigned treatment for 
up to 35 cycles (approxim ately 2 years) from the start of treatment . 
Treatment may continue until one of the following occurs: disease progression, unacceptable 
AEs, intercurrent illness that prevents further administration of treatment, investigator 
decision to withdraw the subject, subject withdraws consent, pregnancy of the subject , 
noncompliance with trials treatment or procedure requirements, or administrative reasons 
requiring cessation of treatment. 
Subject swho progress by [CONTACT_762571] m onotherapy with 
MK-1454 (Arm 1), may cross over into the combination therapy arm of MK-1454 and 
pembrolizumab (Arm 2), provided they meet crossover eligibility criteria in Section 5.1.[ADDRESS_1044771]
assignment between arms , starting with Arm 1. Establishment of the MTD/MAD in 
combination therapy of MK-1454 and pembrolizumab (Arm 2) requires that at least half of 
the [ADDRESS_1044772] no prior exposure to MK-1454 ( ie, non -crossover subject s). 
When Arm 3is opened, eligible subjects will beallocated in a nonrandomized fashion by 
[CONTACT_10966].
CCI
CCI
CCI
CCI
CCI
CCI
CCI
087V73
Product:   MK-1454 23
Protocol/Amendment No.:   001- [ADDRESS_1044773] s enrolled in the Dose Escalation and Confirmation parts of the 
study will depend on the empi[INVESTIGATOR_762537] (DLT observations, the dose that triggers the
mTPI [CONTACT_16303], and the preliminary recommended Phase 2 dose) . For example, in a scenario 
where MK-[ADDRESS_1044774] dose, the sample size across Parts C 
and Dmay beapproximately 40subjects . For combination therapy of MK-1454 IT in 
visceral lesions with pembrolizumab 200 mg IV (Arm 3), if dosing starts at  of 
MK-[ADDRESS_1044775] s. An administrative analysis may be conducted to enable future 
trial planning at the Sponsor’s discretion. The data will be examined on a continuous basis to 
allow for dose escalat ion and confirmation decisions .
Part II –Expansion Phase
Initiation of Expansion Cohorts will be staggered based on emerging safety and tolerability 
data from Part I. Unless deemed medically unsafe by [CONTACT_093] , all subjects will be 
required to unde rgo a biopsy of the lesion to be injected with MK-1454 during the screening 
period (prior to MK-1454 administration) . Subjects with an amenable lesion at theinjected 
sitewill also undergo tumor biopsies on Cycle 2Day 1 and optionally on Cycle 3Day 1, 
unless deemed medically unsafe by [CONTACT_093] . The expansion phase of the trial 
(Figure 3) will evaluate MK-1454 in combination with pembrolizumab 200mgIVin the 
following populations:
Cohort A:  Subjects with HNSCC who are anti -PD-1/PD-L1refractory 
Cohort B:  Subjects with either anti-PD-1/PD -L1 treatment -naïve or refractory
unresectable locally advanced or metastatic TNBC
Cohort C:  Subjects with other anti-PD-1/PD -L1 treatment -naïve solid tumors with
liver metastases 
Cohort s A and Bwill begin at the preliminary RP2D from Arm 2. MK-1454 IT will be 
administered  from Cycle 3 and beyond , 
in combination with pembrolizumab 200mg IV Q3W beginning on C1D1 ). The RP2D dose 
and the dose for expansion is confirmed to be  MK-1454, administered intratumorally 
to a minimum of 1lesion per subject per treatment day and a maximum of 3lesions per 
subject per treatment day, in combination with pembrolizumab IV.
Cohorts A and B will initiate prior to initiation of Cohort C. 
Cohort C will begin at the preliminary RP2D and frequency established from Arm 3 . 
Treatment duration in each cohort inPartII will be up 35 cycles (approximately 2 years).
Cohort sA and B will each enroll a maximum of 30subjects , while Cohort Cwill enroll up to 
60subjects, for a total of up to [ADDRESS_1044776]:   MK-1454 24
Protocol/Amendment No.:   001- 08 
MK-1454 -001-08 Final Protocol 27-Jul-2021
ConfidentialThe trial will be conducted in conformance with GCP .
AEswill be evaluated according to criteria outlined in the NCI CTCAE v4.
Specific procedures to be performed during the trial, as well as their prescribed times and 
associated visit windows, are outline d in the Schedule of Activities -Section 6.0. Details of 
each procedure are provided in Section 7.0 –Trial Procedures.
Trial Diagram
Trial Diagram for Part I -Dose Escalation and Confirmation
The trial design for the dose escalation and confirmation phase is depi[INVESTIGATOR_356289] 1.
Figure 1Part I -Dose Escalation and Confirmation Phase
ATD = accelerated titration design; IT = intratumoral; MTD = maximum tolerated dose; mTPI = Modified Toxic ity Probability 
Interval; Q3W = once every 3 weeks; RP2D = Recommended Phase 2 Dose .
* Triggering criteria for the start of the mTPI [INVESTIGATOR_762538] 1 and 2: 1) The  cohort is completed, 2) ≥Grade 2 toxicity as 
assessed by [CONTACT_178759], probably related, or possibly related to the drug at any dose level, or 3) Elevation of 
systemic TNF -α in blood above baseline by ≥ 3-fold at any time during the first cycle . For example, baseline TNF -α value of 20 
pg/mL increases to 60 pg/mL during the first cycle . 
** Triggering criterion for the start of the mTPI [INVESTIGATOR_762539] 3:  1) The cohort is completed, 2) ≥Grade [ADDRESS_1044777] treated at each dose level . Arm 3 (visceral IT) will begin at  Arm 3, Part F mTPI [INVESTIGATOR_762540]
a dosing frequency of followed by [CONTACT_762572] [CONTACT_8345] . 
CCI
CCI
CCI
CCI
CCI
CCI
087V73
Product:   MK-1454 25
Protocol/Amendment No.:   001-[ADDRESS_1044778]:   MK-1454 26
Protocol/Amendment No.:   001- 08 
MK-1454 -001-08 Final Protocol 27-Jul-2021
Confidential
Trial Diagram for Part II –Expansion Cohorts
Figure 3Part II - Expansion Cohorts
IT –intratumoral; IV = intravenous; PD-1 = Programmed death -1PD-L1 = programmed death ligand 1;  
 Q3W = every 3 weeks; RP2D = recommended Phase 2 dose.
3.0OBJECTIVE(S) & HYPOTHESIS(ES)
Male/Female subjects of at least 18 years of age with advanced/metastatic solid tumors or 
lymphomas will be enrolled in this trial.
Primary Objective(s) & Hypothesis (es)
(1)Objective:  For Parts I and II, to determine the safety and tolerability and toestablish 
apreliminary recommended Phase [ADDRESS_1044779]:   MK-1454 27
Protocol/Amendment No.:   001-08 
MK-1454 -001-08 Final Protocol 27-Jul-2021
Confidential
Secondary Objective(s) & Hyp othesis(es)
(1)Objective :  For Parts I and II,to evaluate the pharmacokinetics of MK-1454 
administered via ITinjection as monotherapy and to evaluate the pharmacokinetics of
MK-1454 administered via ITinjection ascombination therapy with pembrolizumab
IV infusion . 
(2)Objective:   For Parts I and II, to evaluate the pharmacokinetics of pembrolizumab IV 
infusion in combination with MK -1454 administered via ITinjection .
(3)Objective:   Separately for each tumor type in Part II*,to evaluate the ORR of 
MK-1454 at the preliminary RP2D in combination with pembrolizumab as assessed 
by [CONTACT_762573] 1.1 
(RECIST 1.1)modified to follow a maximum of 10 total target lesions with a 
maximum of 5 target lesion per organ .
Exploratory Objectives 
(1)Objective:   For Part I, to evaluate the ORR and PFS of MK-[ADDRESS_1044780] v1.1 modified to follow a 
maximum of 10total target lesions with a maximum of 5 target lesions per organ . In 
lymphoma s, assessment will be based on the IWG revised response criteria [1]. For 
subject s with CTCL, response assessment will be based on the Global Response 
Score (see Table 22)[2].
(2)Objective :  Separately for each tumor type in Part II*, evaluate PFS of MK-[ADDRESS_1044781] 1.1 modified to follow a maximum of 10total target lesions 
and a maximum of 5 target lesions per organ .
(3)Objective :In PartsIand II, to evaluate the effect of the study intervention on lesions 
not treated with IT injections , as assessed by [CONTACT_1697]. The measurements of effect 
will include the ORR for noninjected lesions and the maximal reduction in the sum of 
diameters of noninjected target lesions, as described in itRECIST [3].
(4)Objective :  In Part I, to evaluate overall survival (OS) of subjects treatedwith 
MK-1454 both as monotherapy and as combination therapy with pembrolizumab.
Note: Efficacy analyses for each Part II expansion cohort will pool Part I subjects who meet the inclusion 
criteria for the respective Part II tumor type and received the same dose level of MK-[ADDRESS_1044782]:   MK-1454 28
Protocol/Amendment No.:   001-08 
MK-1454 -001-08 Final Protocol 27-Jul-2021
Confidential(5)Objective :  Separately for each tumor type in Part II*,to evaluate OS of MK-1454 at 
the preliminary RP2D in combination with pembrolizumab. 
*Note: Efficacy analyses for each Part II expansion cohort will pool Part I subjects 
who meet the inclusion criteria for the respective Part II tumor type and received the 
same dose level of MK -1454 in combination with pembrolizumab.
(6)Objective :  To identify molecular (genomic, metabolic and/or proteomic) biomarkers 
that may beindicative of clinical response/resistance, safety, pharmacodynamic 
activity, and/or the mechanism of action of MK-1454 as monotherapy and in 
combination with pembrolizumab and other treatments.
a.To investigate TNF -α and other cytokines that may correlate with tumor response.
b.To investigate other biomarkers in circulating blood cells or in tumor tissue that 
may correlate with tumor responses ,and to evaluate differences in tumor tissue 
characteristics in biopsies taken prior to treatment and following treatment with 
MK-1454 .
c.To investigate the relationship between the SNP of the STING gene ,and to 
investigate the toxicity/efficacy of MK-1454 as monotherapy and ascombination 
therapy with pembrolizumab.
4.0BACKGROUND & RATIONALE
Background
Detail ed background information on preclinical pharmacology, pharmacokinetics, 
pharmacodynamics, and metabolism of MK-[ADDRESS_1044783] with activity across species . 
DNA in the cytoplasm of mammalian cells represents a cellular danger signal, and the cGAS -
AMP /STING pathway is activated to respond to that potential threat (Figure 4). Free 
cytosolic DNA is recognized by [CONTACT_631800], catalyzing the generation of the cyclic -dinucleotide 
2’-3’ cGAMP . Cyclic -dinucleotide 2’-3’ cGAMP strongly binds to the endoplasmic 
reticulum -trans membrane adapter protein STING . This leads to a conformational change of 
the STING dimer, enabling the binding and activation ofTBK1 and inducing downstream 
phosphorylation and activation of transcription factors IRF-[ADDRESS_1044784]:   MK-1454 29
Protocol/Amendment No.:   001-08 
MK-1454 -001-08 Final Protocol 27-Jul-2021
ConfidentialFigure 4Schematic Diagram Showing Mechanism of the Enhancement of T Cell Dri ven 
Antitumor I mmunity through the Action of Cyclic -Dinucleotide STING Agonists
Abbreviations: APC = antigen -presenting cells; cGAMP = cyclic guanosine monophosphate -adenosine 
monophosphate ; cGAS = cyclic (guanosine monophosphate -adenosine monophosphate) synthase ; CXCL 9/10 = 
chemokine C-X-C motif ligand 9/10; DC = dendritic cell ; dsDNA = double -stranded deoxyribonucleic acid; ER 
= endoplasmic reticulum; IFN = interferon ; IRF7 = interferon regulatory factor 7; STING = stimulator of 
interferon genes;  TB K1 = tank-binding kinase 1 .
STING is expressed in numerous cell types, but functional responses (cytokine production in 
response to dsDNA) were demonstrated only in a small subset of STING expressing cells, 
mainl y innate immune cells. Single nucleotide polymorphism analysis and sequencing 
studies have revealed the existence of [ADDRESS_1044785] prevalent non-WT STING 
variants are present at allelic frequencies of up to 20% in the human population, the 
prevalence of homozygous non -WTSTING carriers for any of the identified STING variants 
is estimated to be less than 5 %. 
Recent studies showed that all tested STING variants demonstrated compa rable response to 
synthetic CDN -derivative STING agonist . 
Enhancing the capacity of the innate immune system to present tumor -associated antigens to 
CD8+ T cells,through antigen cross -presentation is critical for immune -mediated tumor 
destruction, and STING agonism enhances this response. 
087V73
Product:   MK-1454 30
Protocol/Amendment No.:   001-08 
MK-1454 -001-08 Final Protocol 27-Jul-2021
Confidential
Pharmaceutical and Therapeutic Background
MK-1454 Background
Published and internal data demonstrate that ITdelivery of STING agonists leads to 
complete tumor regression or significant tumor growth inhibition in both anti-programmed 
cell death -1(PD-1)-responsive and nonresponsive mouse syngeneic tumor models, and can 
also induce immune -mediated clearance of noninjected tumors [4] [5] [6] .
Importantly , tumor -bearing mice whose tumors completely regress through the action of a 
CDN STING agonist become protected against subsequent challenges with the same tumor, 
indicating that induction of tumor -specific T cell memory has occurred [4].Recently 
presented external [7]and in -house data demonstrated a discrepancy between the CDN doses 
associated with full eradication of the injected tumor and with maximal protection against 
tumor re-growth in rechallenge studies. These findings suggest that a “bell-shaped ”
relationship may exist between CDN STING agonist doses and the potential for abscopal 
action of intratumorally -dosed CDN STING agonist. It is hypothesized that these preclinical 
findings are driven, at higher CDN doses, by [CONTACT_762574], cytokine 
produc tion and function in such a robust manner that it hampers the ability of the adaptive 
immune system to develop anti tumor adaptive immune memory.
With the success of checkpoint inhibitors in the clinic, combination therapi[INVESTIGATOR_762541]’s innate immune system to activate adaptive immune 
antitumor responses are increasingly being advanced in preclinical studies and clinical trials 
[8]. 
With this in mind, the Sponsor is develop inga CDN STING agonist that demonstrates 
antitumor efficacy in multiple syngeneic mouse models ,with an acceptable safety profile . 
Attributes of MK-1454 include induction of T cell memory, as evidenced by [CONTACT_762575], and enhanced antitumor efficacy in combination with anti-PD-1
mAb .
The mechanism of action (Figure 4) suggests that a CDN STING agonist could provide 
efficacy either as a stand -alone agent or in combination with the anti-PD-1 mAb
pembrolizumab. Based on preclinical data, combination therapy with MK-1454 and 
pembrolizumab may demonstrate efficacy in patients who either did not respond to 
pembrolizumab or who progressed on pembrolizumab therapy, as well as those patients who 
are predicted to be poor responders based on PD-L1 expression in the tumor. MK-1454 will 
be presented in the clinic as a sterile liquid in a single use vial for ITinjection . The active 
formulation will be available in low and high concentration s, along with diluent to enable 
customization of the d osing concentration per tumor size/ administered volume. 
Pembrolizumab Background
The importance of intact immune surveillance function in controlling outgrowth of neoplastic 
transformations has been known for decades [9]. Accumulating evidence shows a correlation 
between tumor -infiltrating lymphocytes in cancer tissue and favorable prognosis in various 
087V73
Product:   MK-1454 31
Protocol/Amendment No.:   001-08 
MK-1454 -001-08 Final Protocol 27-Jul-2021
Confidentialmalignancies . In particular, the presence of CD8+ Tcells and the ratio of CD8+ effector 
Tcells/FoxP3+ regula tory Tcells correlates with improved prognosis and long-term survival 
in solid malignancies, such as ovarian, colorectal, and pancreatic cancer; hepatocellular 
carcinoma; malignant melanoma; and renal cell carcinoma . Tumor -infiltrating lymphocytes 
can be expanded ex vivo and reinfused, inducing durable objective tumor responses in 
cancers such as melanoma [10] [11] . 
The PD-[ADDRESS_1044786] hijacked by [CONTACT_55548] . The normal function of PD-1, expressed on the cell surface of activated 
Tcells under healthy conditions, is to down -modulate unwanted or excessive immune 
responses, including autoimmune reactions . PD-1 (encoded by [CONTACT_13228]1) is an Ig 
superfamily member related to CD28 and CTLA -4 that has been shown to negatively 
regulate antigen receptor signaling upon engagement of its ligands (PD-L1 and/or 
programmed cell death -1 ligand 2 [PD-L2]) [12] [13] . 
The structure of murine PD-1 has been resolved [14]. PD-1 and family members are type I 
transmembrane glycoproteins containing an Ig Variable –type domain responsible for ligand 
binding and a cytop lasmic tail responsible for the binding of signaling molecules . The 
cytoplasmic tail of PD-1 contains 2 tyrosine -based signaling motifs, an immunoreceptor 
tyrosine -based inhibition motif, and an immunoreceptor tyrosine -based switch motif . 
Following Tcell stimulation, PD-1 recruits the tyrosine phosphatases, SHP-1 and SHP-2, to 
the immunoreceptor tyrosine -based switch motif within its cytoplasmic tail, leading to the 
dephosphorylation of effector molecules such as CD3ζ , protein kinase C-θ, and ZAP70 , 
which are involved in the CD3 Tcell signaling cascade [15] [16], [17]. The mechanism by 
[CONTACT_13209] -[ADDRESS_1044787] from, that of CTLA -4, 
because both molecules regulate an overlappi[INVESTIGATOR_77971] [18] [19]. As a 
consequence, the PD-1/PD -L1 pathway is an attractive target for therapeutic intervention in 
solid tumors and lymphomas (see the IB).
Pembrolizumab is a potent and highly selective humanized monoclonal antibody (mAb) of 
the IgG4/kappa isotype designed to directly block the interaction between PD-1 and its 
ligands, PD-L1,and PD-L2. Pembrolizumab has shown clinical activity in multiple tumor 
types [20]. Please refer to the current label . 
Pembrolizumab will be presented in the clinic as a sterile lyophilized powder for 
reconstitution in a single use vial for dilution to be administered as an IV infusion.
Rationale
Rationale for the Trial and Selected Subject Population
Rationale for P artI -Dose Escalation and Confirmation 
Internal data demonstrate STING expression in multiple tumor types, supporting the broad 
inclusion of such tumor types as advanced/metastatic solid tumors and lymphomas . 
Endogenous STING pathway activation within the tumor induces spontaneous T cell priming 
that is necessary for the generation of adaptive immunity . In mouse tumor models, STING 
087V73
Product:   MK-1454 32
Protocol/Amendment No.:   001-[ADDRESS_1044788] induces regression of established tumors and generates 
systemic immune responses, mediating rejection of distant metastases and providing 
immunologic (T cell) memory in mice [21] [4]. Therefore ,a synthetic CDN , such as MK-
1454, has potential as a cancer therapeutic . 
Tumor treatment site selection initially will be based on accessibility of the tumor site to IT
injection . The FIH Phase I study of MK-[ADDRESS_1044789] s with refractory solid 
tumors and lymphomas with cutaneous, subcutaneous, and/or nodal lesions that are visible, 
palpable, or detectable by [CONTACT_762576] , as well assubject s with 
metastatic liver lesions amenable to injection via ultrasound or cross -sectio nal imaging 
(CT/MRI) guidance . Subject smust have at least one lesion thatis amenable to IT injection . 
For solid tumor subjects, this lesion must be ≥1 cm for solid tumors or ≥1.5 cm for nodal 
lesions ,and≤10cm in longest diameter for both solid tumors and nodal lesions in solid 
tumor subject s. For lymphoma subject s, a nodal lesion ≥1.5 cm in short axis, or an extranodal 
lesion ≥1 cm in 2 dimensions . Nodal lesions ≥1.0 cm and <1.[ADDRESS_1044790] be ≤[ADDRESS_1044791] subsequent 
challenges with the same tumor, indicating that induction of a durable tumor -specific T cell 
memory h as occurred [4] [5] [6] .
Existing and emerging, external and internal data suggest that the observed antitumor
efficacy of STING agonism is primarily obtained through enhancing the capacity of the 
innate immune system to present tumor -associated antigens to CD8+T cells as well as 
through a direct anti -proliferative effect on tumor cells.
087V73
Product:   MK-1454 33
Protocol/Amendment No.:   001-08 
MK-1454 -001-08 Final Protocol 27-Jul-2021
ConfidentialBased on preclinical data and mechanism of action of STING agonism, combination therapy 
of MK-1454 with the anti-PD-1 mAb pembrolizumab may demonstrate efficacy in patients 
who did not respond to pembrolizumab or are predicted to be poor responders based on gene 
expression profiling [22], PD-L1 expression and/or low tumor mutational burden . In these 
patients, a two-step process is hypothesized to occur, STING agonism -driven priming and 
initial expansion of anti tumor CD8+T cellsand pembrolizumab -driven expansion of relevant 
tumor -specific T cells with prevention of T cellexhaustion.
Therefore, MK -[ADDRESS_1044792] of care regimen(s).
[IP_ADDRESS].1 Microsatellite Instability Testing
Pembrolizumab is approved for the treatment of patients with MSI-H or dMMR cancer, 
agnostic of tumor type. This accelerated approval was based on an ORR of 39.6% in a 
population of 149subjects with 15 different cancer types . This high response rate 
necess itates accounting for MSI-H/dMMR status in any study evaluating the efficacy of 
pembrolizumab therapy, either alone or in combination with additional agents. Additionally, 
in patients with tumors that are not MSI-H/dMMR, where a higher unmet medical need 
exists, agents in combination might enhance responses to pembrolizumab treatment . As such, 
in any expansion cohort in this trial, only subjects with tumors that are not MSI -H/dMMR by 
[CONTACT_762577].
Prior to this tumor type -agnostic approval of pembr olizumab in MSI -H/dMMR cancer, tumor 
MSI/ dMMR local testing was already in clinical use and recommended for management of 
patients with a number of different malignancies . Subsequent to this approval, testing for 
MSI-H/dMMR is now recommended for the management of multiple additional 
malignancies . As such, local testing of tumors for MSI/dMMR is now regularly performed 
and therefore widely available.
For this trial, MSI/dMMR testing must have been performed on any patient being consi dered 
for expansion cohort enrollment, using either an archival or a newly obtained tumor sample. 
MSI/dMMR status must be determined by [CONTACT_762578] (1) 5 tumor microsatellite loci 
using PCR -based assay, or (2) protein expression by [CONTACT_762579] 4MMR enzyme s 
(MLH1/MSH2/MSH6/PMS2), respectively . MSI testing methods based on DNA sequencing 
are also being developed and may be utilized for eligibility testing for this study, provided 
details of such a test are provided to and approved by [CONTACT_1034].
Tumors are classified as MSI-H when at least [ADDRESS_1044793] an MSI -H/dMMR tumor if any of these 
tests yields an MSI -H/dMMR result . 
087V73
Product:   MK-1454 34
Protocol/Amendment No.:   001- 08 
MK-1454 -001-08 Final Protocol 27-Jul-2021
Confidential
Rationale for Dose Selection/Regimen
Starting Dose for This Trial
The FIH starting dose of MK-[ADDRESS_1044794] non -severely toxic dose or
the severely toxic dose to 10% of animals would be above the dose predicted to demonstrate 
efficacy in patients with tumors of certain volumes . Given the potential ofMK-[ADDRESS_1044795] the FIH starting dose is presented here (see the IB 
for a detailed description and relevant data).
The readout of biological activity that has been used for translation from tumor -bearing mice 
to patients is antitumor efficacy . The dose-efficacy response relationship following at least 
one IT dose for multiple CDN STING agonists including MK-[ADDRESS_1044796] IT dose to mice . By [CONTACT_762580], the normalized dose 
at any level of efficacy could be scaled to patients after adjusting for differences in potency 
between mouse and human cells and initial tumor volume between tumor -bearing mice and 
patients.
Antitumor efficacy was expressed as a percent GRI and was modeled using an assumption 
that tumor growth dynamics are exponential [23]. A dose-efficacy response relationship that 
relates the percent GRI versus the normalized dose was described by a maximum effect 
model (E maxmodel) and the variability of the model by a 95% confidence band. 
The rationale for FIH dose selection is to choose a safe dose that is not associated with a 
significant change in systemic measures of pharmacology as measured by [CONTACT_51004] -α. This dose 
corresponds to 135% GRI in mice suggesting signs of efficacy at this starting dose. In mice, 
135% GRI corresponds to a level of inhibition that will result in tumor volume reduction 
from 80 mm3 to a tumor volume below the limit of quantification within 5 days. A value of 
135% GRI in mice was assumed to be a percent GRI that will result in clinical response in 
patients . The selected FIH starting dose is for a total injectable tumor ≥0.5 cm3 ([ADDRESS_1044797] dimension for a single lesion) . The injectate volume will be determined based 
on tumor size (see Table 6and Table 7).
Cytokine TNF -α was measured to corroborate the efficacy response expected at FIH starting 
dose with a pharmacological readout suggesting no remarkable pharmacological response at 
that dose . In tumor -bearing mice, the pl asma concentration of cytokine TNF -α was measured 
CCI
087V73
Product:   MK-1454 35
Protocol/Amendment No.:   001- 08 
MK-1454 -001-08 Final Protocol 27-Jul-2021
Confidentialat 4 hours after IT dose using 6 different CDN STING agonists including MK-1454. No 
remarkable change in cytokine TNF -α concentration was observed at the normalized dose to 
mice (3.3μg for 80 mm3 tumor) that equates to the FIH starting dose of  for any total 
injectable tumor volume ≥0.5 cm3 . The rationale for the upper dose limit of  is based 
on the maximum dose studied in dogs (3 mg). The therapeutic dose is expected to be less 
than  The  dose level is near the predicted efficacious dose of MK -1454 for a 
lesion volume of 33.5 cm3 (approximately 4 cm in diameter). Therefore,  was selected 
as a triggering dose for progression from the ATD phase to the mTPI [CONTACT_16303] .
This conservat ive approach is being taken to ensure an acceptable safety profile, while 
continued patient safety will be ensured through appropriate dose escalation design and 
monitoring in the clinic . 
The planned dose of pembrolizumab for this trial is 200 mg Q3W . Based on the totality of 
data generated in the Keytruda development program, 200 mg Q3W is the appropriate dose 
of pembrolizumab across all indications and regardless of tumor type. Please refer to the IB 
for details on the clinical development of pembrolizumab.
Maximum Dose/Exposure for This Trial
The determination of a preliminary RP2D for MK-[ADDRESS_1044798] s treated at potentially subtherapeutic doses 
of MK-1454. The ATD will utilize 1-3 subjects per cohort with up to a 300% dose increment 
increase from the prior dose of MK-1454, followed by a model -based dose escalation mTPI 
[INVESTIGATOR_762542] 3-[ADDRESS_1044799] s per cohort using dose increment increases of 30% to 100% of 
the prior dose . Transition from ATD to mTPI [INVESTIGATOR_762543] 1 
of the following 3 events :  1) The  cohort is completed, 2)≥ Grade 2 toxicity as 
assessed by [CONTACT_178759], probably related, or possibly related to the drug at 
any dose level, or 3)Elevation of systemic TNF -α in blood above baseline levels by ≥3-fold
for a given subject at any time during the first cycle of MK -1454. 
Dose escalation decisions will be made upon ongoing review of safety and available
PK/pharmacodynamic data at the current dose level . Weekly safety teleconferences will be 
held with the investigators from all sites. At these weekly safety teleconferences, safety data 
and PK/pharmacodynamic data will be reviewed for the current dose level, and dose 
escalation decisions will be made upon a consensus assessment. Subsequent dose levels will 
be communicated to all sites at the weekly safety teleconferences, and through written 
correspondence subsequent to the safety teleconference . Dose level escalations are Sponsor -
controlled through IWRS , which include the opening and closing of dose level cohorts upon 
dose escalation.
CCI
CCI
CCI
CCI
CCI
CCI
CCI
087V73
Product:   MK-1454 36
Protocol/Amendment No.:   001- [ADDRESS_1044800] 2 dose levels behind the monotherapy dose,even if combination therapy was
triggered to start earlier , and will not exceed the MTD/MAD for monotherapy . Ifan 
MTD/MAD for monotherapy is established, the dose of MK-[ADDRESS_1044801] dose escalation of 
MK-1454 to the next dose level is permitted in Arm 1 ( Parts A and B) at the discretion of the 
investigator provided that the subject remains on study after receiving 3cycles of treatment 
without a ≥Grade [ADDRESS_1044802] dose escalation is not permitted in Arm 2 (Parts C and D)or 
in Arm 3(Part s Eand F ).
The starting dose for Arm [ADDRESS_1044803] one 
of the following 2 triggers are met: 1)The coho rt in combination is completed, 2) ≥ 
Grade 2 toxicity as assessed by [CONTACT_178759], probably related, or possibly 
related to the drug at any dose level in combination . Dose escalation andincreasing dosing
frequency of MK-1454 visceral IT injection (see Table 5andFigure 2)will be based on 
subject tolerance per mTPI [INVESTIGATOR_762544] . The starting dose of MK-1454 in Arm 3 is based on 
the preclinical NOAEL dose level, andthe rationale is to reduce redundancy of evaluating 
dose levels in Arm 3 for which safety evaluation of MK-1454 in combination with 
pembrolizumab had already occurred in Arm 2.
Rationale for Visceral Intratumoral Injection
The rationale for the addition of a visceral intratumoral arm of MK-1454 is to expand the 
tumor location for IT therapy to deeper tumor lesions and tovisceral organs ,such as the 
liver. In addition, the visceral IT arm will evaluate the safety, tolerability, PK/PD, and early 
efficacy of MK-1454 injected into visceral organs and deeper tumor lesions . To mitigate the 
potential safety risk of repeated visceral and deeper lesion IT injections, the IT dosing will 
begin at Q3W . Increased frequency and/or dosage of visceral IT administration as shown in
Figure 2will be based on subject tolera nceand clinical assessment of safety.
Rationale for Dose of MK -1454 Expansion Cohorts A and B (Part II)
The recommended Phase 2dose for MK-1454 was based on analysis of the safety, 
pharmacodynamic, and early efficacy data from Part I of thisPhase 1 study. In Part Idose 
escalation, responses were observed at doses of  
Preclinical data in mice suggested a bell-shaped dose response for immunologic 
memory induced by [CONTACT_762581] . In combination therapy with pembrolizumab, greater 
reduction in injected and noninjected target lesions was seen at MK-1454 doses of  
MK-1454 doses of , suggesting improved efficacy at 
the lower MK-1454 doses evaluated in Part I (dose escalation) of this Phase [ADDRESS_1044804]:   MK-1454 37
Protocol/Amendment No.:   001- [ADDRESS_1044805] per treatment visit . 
Rationale for Dose Schedule Expansion Coh orts A and B (PartII)
The starting dose for expansion C ohorts A and B will be the preliminary RP2D established in 
Arm 2, based on emerging safety, tolerability, and PK/pharmacodynamic data. The rationale 
for weekly dosing for the first 6 weeks (Cycle 1 and Cycle 2), followed by[CONTACT_51034] 3 
weeks thereafter ,is to allow for congruence of thedosing schedule of visceral intratumoral 
administration (Part I:  Dose Escalation and Confirmation Arm 3) to the dosing schedule for 
cutaneous and subcutaneous intratumoral administration .
The starting dose and frequency for Cohort Cwillbe the preliminary RP2D established in 
Arm 3.
Rationale for Endpoints
Efficacy Endp oints
An exploratory objective for this trial is to evaluate the anti tumor activity of MK-[ADDRESS_1044806] ’sclinical condition is stable . Immune -related RECIST will be used to assess efficacy.
Sites are encouraged to have a multidisciplinary treatment and assessment plan to determine 
in advance that lesions will be treated, biopsied, and/or target ed for tumor assessment . A 
lesion that is designated as target for assessment by[CONTACT_393] 1.1, irRECIST, or revised IWG 
criteria should ideally not undergo core or punch biopsy. 
CCI
CCI
087V73
Product:   MK-1454 38
Protocol/Amendment No.:   001-08 
MK-1454 -001-08 Final Protocol 27-Jul-2021
Confidential4.[IP_ADDRESS] Immune -related RECIST (irRECIST)
RECIST 1.[ADDRESS_1044807] 1.1 may 
thus not provide an accurate response assessment of immunothe rapeutic agents . With other 
immunotherapeutic agents, up to 7% of evaluable patients experienced delayed or early 
tumor pseudoprogression . Of note, patients who had PDby [CONTACT_393] 1.[ADDRESS_1044808] (irRECIST) is RECIST 1.1 ad apted to account for the unique tumor 
response seen with immuno therapeutics as described by [CONTACT_180704], et al. [24]. The assessment 
of unidimensional target lesions and response categories per irRECIST are identica l to 
RECIST 1.1. However, [COMPANY_006] has implemented an adaptation related to new lesions, 
nontarget and tumor burden assessment in order to confirm radiographic progression . 
Immune -related RECIST will be used by [CONTACT_762582] s to assess tumor respons e and 
progression, and to make treatment decisions for solid tumors . For lymphomas, a similar 
modification of the revised IWG criteria will be applied.
[IP_ADDRESS].[ADDRESS_1044809] s with malignant lymphoma, the antitumor activity of MK-1454 and 
pembrolizumab will be evaluated as part of the primary and secondary analyses using the 
IWG Revised Response Criteria for Malignant Lymphoma s[25] as detailed in Section 
[IP_ADDRESS].2.
The revised response criteria include several components: 1) assessment of nodal and 
extranodal lesions by [CONTACT_4654] (for size) and FDG -PET (for viability), 2) physical exam 
assessment of liver, spleen, and other possible findings not included in imaging, 3) eval uation 
of B-symptoms and 4) determination by [CONTACT_762583].
Theresponse criteria will be applied by [CONTACT_762584] (eg, discontinuation of study 
therapy).
Because of the possibility of immunotherapy -related flare, subject s who show initial 
radiographic progression, if they are clinically stable, may be continued on therapy at the 
discretion of the investigator . Afollow -up scan should be obtained at least [ADDRESS_1044810]:   MK-1454 39
Protocol/Amendment No.:   001-08 
MK-1454 -001-08 Final Protocol 27-Jul-2021
Confidential4.[IP_ADDRESS] Response Assessment for C TCL
For subject s with CTCL, determination of eligibility will be made in accordance with the 
modified ISCL/Cutaneous Lymphoma Task Force of the EORT C revision of the 
classification of mycosis fungoides/Sézary syndrome [26]. The antitumor activity of MK-
1454 and pembrolizumab will be evaluated using response criteria described by [CONTACT_206888] , the 
[LOCATION_002] Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force 
of the EORTC [2].
The CTCL response criteria include a scoring system for assessing tumor burden in skin, 
lymph nodes, blood, and viscera, anda composite global response score, which are detailed 
in Section [IP_ADDRESS].[ADDRESS_1044811] s with advanced / 
metastatic solid tumors and lymphomas . The primary safety analysis will bebased on 
subject s who experience toxicities as defined by [CONTACT_55550] . Safety will be assessed by 
[CONTACT_762585] s who have received 
MK-[ADDRESS_1044812].
Safety will be assessed by [CONTACT_193439], Version 4.0. The 
attribution to drug, time ofonset, duration of the event, its resolution, and any concomitant 
medications administered willbe recorded . Adverse event s thatwill be analyzed includ e,but 
are not limited to ,all AEs, SAEs, fatal AEs, and laboratory changes.
Safety parameters commonly used for evaluating investigational systemic anticancer 
treatments are included as safety endpo ints for the study including, but not limited to, the 
incidence of, causality to, and outcome of AEs/SAEs; changes in vital signs and laboratory 
values . AEswill be assessed as defined by [CONTACT_3989], Version 4.0.
Pharmacokinetic Endpoints
Secondary objective sof this trial areto characterize the PK profile of MK-[ADDRESS_1044813] step in pharmacologic activity, receptor engagement is fundamental to 
dosing strategies . To evaluate target engagement, a systemic cytoki ne/chemokine activation 
assay that compares a panel of cytokine/chemokine activation pre-and post–administration 
087V73
Product:   MK-1454 40
Protocol/Amendment No.:   001-[ADDRESS_1044814] in the evaluation of target engagement and potential safety events
associated with immune stimulation and cytokine release . The c ytokines that will be assessed 
include but arenot be limited to T NF-α, IFNβ, IL-6, MIP-1α, MCP -2, IP -10,and CXCL11.
Planned Exploratory Biomarker Research
Introduction:  Cancer immunotherapi[INVESTIGATOR_762545] . However, the mechanism of action of these exciting new therapi[INVESTIGATOR_762546] . Thus, to aid future patients, it is important to investigate the determinants 
of response or resistance to cancer immunotherapy, as well as determinants of AEs in the 
course of our clinical trials . These efforts will identify novel predictive/pharmacodynamic 
biomarkers and generate information that will better guide single -agent and combination 
therapy with immuno -oncology drugs . Toidentify novel biomarkers, biospecimens (ie, blood 
components, tumor material) will be collected to support analyses of cellular components 
(eg, protein, DNA, RNA, metabolites) and other circulating molecules . Investigations may 
include but are not limite d toplanned genetic analysis, as outlined in Section [IP_ADDRESS].1.
[IP_ADDRESS].1 Planned Genetic Analysis
Germline (blood) Genetic Analyses (eg, SNP analyses, whole exome sequencing, whole 
genome sequencing):   This research will evaluate whether genetic variation within aclinical 
trial population correlates with response to the treatment(s) under evaluation . If genetic 
variation is found to predict efficacy or AEs, the data might inform optimal use of therapi[INVESTIGATOR_401117] . Furthermore, it is important to evaluate germline DNA variation 
across the genome in order to interpret tumor -specific DNA mutations . Finally, microsatellite 
instability (MSI) may be evaluated as this is an importan t biomarker for some cancers (ie, 
colorec tal cancer) . 
Genetic (DNA) analyses from tumor : The application of new technologies, such as next 
generation sequencing, has provided scientists the opportunity to identify tumor -specific 
DNA changes (ie, mutations, methylation status, MSI). Key molecula r changes of interest to 
immune -oncology drug development include (for example) the mutational burden of tumors 
and the clonality of Tcells in the tumor microenvironment . Increased mutational burden 
(sometimes referred to as a “hyper -mutated ”state) may generate neo-antigen presentation in 
the tumor microenvironment . To conduct this type of research, it is important to identify 
tumor -specific mutations that occur across all genes in the tumor genome . Thus, genome -
wide approaches may be used for this effort . Note that in order to understand tumor -specific 
mutations; it is necessary to compare the tumor genome with the germline genome . 
Microsatellite instability may also be evaluated as this is an important biomarker for some 
cancers (ie, colorectal cancer).
087V73
Product:   MK-1454 41
Protocol/Amendment No.:   001-08 
MK-1454 -001-08 Final Protocol 27-Jul-2021
ConfidentialThis research contributes to understanding genetic determinants of efficacy and safety 
associated with the treatments in this study.
Tumor and blood RNA analyses :  Both genome -wide and targeted mRNA expression 
profiling and sequencing in tumor tissue and in blood may be performed to define gene 
signatures that correlate clinical response to treatment with MK-1454 and pembrolizumab . 
Pembrolizumab induces a response in tumors that likely reflects an inflamed/ immune 
phenotype . Specific immune -related gene setmay be evaluated, and new signatures may be 
identified . Individual genes related to the immune system may also be evaluated (eg, IL-10). 
MicroRNA profiling may also be pursued.
Proteomics and immunohistochemistry (IHC) using blood or tumor :  Tumor and blood 
samples from this study may undergo proteomic analyses (eg, PD-L1, CD8, CD4 IHC) . PD-
L1 protein level in tumor sections, assessed by [CONTACT_4658], has been shown to correlate with 
response to pembrolizumab in patients with NSCLC, and an in vitro diagnostic device has 
been developed for use with pembrolizumab in NSCLC . Preliminary data indicates that this 
association may also be true i n additional cancer types (ie, TNBC , head and neck cancer, and 
gastric cancer ). Additional tumor or blood -derived proteins may also correlate with response 
to pembrolizumab . Therefore, tumor tissue may be subjected to proteomic analyses using a 
variety of platforms that could include but are not limited to immunoassays, liquid 
chromatography/mass spectrometry . This approach could identify novel protein biomarkers 
that could aid in patient selection for MK -1454 therapy.
Other Blood -derived Biomarkers :  In addition to expression within the tumor tissue, tumor -
derived proteins (eg, PD-L1) or tumor -derived DNA can be shed from tumor and released 
into the blood . In the case of proteins, enzyme -linked immunosorbent assay can measure 
such proteins in serum and plasma and correlate this expression with response to 
pembrolizumab therapy, as well aslevels of protein in the tumor . Deoxynucl eic acid can be 
analyzed using next generation sequencing or polymerase chain reaction -based technologies . 
Advantages to this method are that blood is aless invasive compartment from which tumor -
derived protein or nucleic acid biomarkers may be measured.
Future Biomedical Research
The Sponsor will conduct Future Biomedical Research on specimens consented for future 
biomedical research during this clinical trial.  This research may include genetic analyses 
(DNA), gene expression profiling (RNA), proteomics, metabolomics (serum, plasma) and/or 
the measurement of other analytes , depending on which specimens are consented for future 
biomedical research .
Such research is for biomarker testing to address emergent questions not described elsewhere 
in the protocol and will only be conducted on specimens from appropriately consented 
subjects. The objective of colle cting /retaining specimens for Future Biomedical Research is 
to explore and identify biomarkers that inform the scientific understanding of diseases and/or 
their therapeutic treatments. The overarching goal is to use such information to develop safer, 
more effective drugs /vaccines , and/or to ensure that subjects receive the correct dose of the 
correct drug/vaccine at the correct time.  The details of this Future Biomedical Research are 
087V73
Product:   MK-1454 42
Protocol/Amendment No.:   001-08 
MK-1454 -001-08 Final Protocol 27-Jul-2021
Confidentialpresented in Section 12.2 –Collection and Management of Specimens for Future Biomedical 
Research.
Benefit/Risk
It cannot be guaranteed that subject s in clinical trials will directly benefit from treatment 
during participation ,as clinical trials are designed to provide information about the safety 
and effectiveness of an inves tigational medicine.
Additional details regarding specific benefits and risks for subject s participating in this 
clinical trial may be found in the accompanying IB and Informed Consent documents.
5.0METHODOLOGY
Entry Criteria
Diagnosis/Condition for Entry int o the Trial
Male/Female subjects of at least 18 years of age with advanced/metastatic solid tumor sor 
lymphoma swill be enrolled in this trial.
Subject Inclusion Criteria for Part I -Dose Escalation and Confirmation
Subject Inclusion Criteria for Arms [ADDRESS_1044815]:
1.Be ≥[ADDRESS_1044816] a histologically or cytologically confirmed advanced/metastatic solid tumor or 
lymphoma by [CONTACT_762586], or have been intolerant to,all 
treatment known to confer clinical benefit . Solid tumors and lymphomas of any type are 
eligible for enrollment . Tumor types of greatest interest include, but are not limited to, 
malignant melanoma, HNSCC , breast adenocarcinoma, and lymphomas . 
4.Have Stage III or Stage IV disease that is not surgically resectable . Stage IIB
(T3N0M0B0-1)CTCL subject s are eligible [26]. 
5.Have at least 1injectable lesion which is amenable toinjection and biopsy . Biopsy may 
be performed via visual inspection , ultrasound guidance , or cross -sectional imaging.
Intratumoral injection for cutaneous lesion s may be performed viavisual inspection . 
Intratumoral injection for subcutaneous lesions may be performed via ultrasound 
guidance or via palpation . This injectable lesion must bemeasurable and meet one of the 
following criteria :
 A cutaneous or subcutaneous lesion ≥[ADDRESS_1044817] diameter for solid tumors, or 
≥1.[ADDRESS_1044818]:   MK-1454 43
Protocol/Amendment No.:   001-[ADDRESS_1044819] be ≤10cm for both solid tumors and nodal 
lesions in solid tumor subject s.
 Multiple coalescing, superficial lesions which in aggregate have a longest 
diameter of ≥1cm and ≤10 cm . 
 For lymphoma subject s, a nodal lesion ≥1.5 cm in short axis, or an extranodal 
lesion ≥1 cm in 2 dimensions . Nodal lesions ≥1.0 cm and <1.[ADDRESS_1044820] be ≤10cm. 
6.Have at least 1 distant and/or discrete noninjected lesion that is amenable to biopsy via 
visual inspection or amenable to biopsy via image guidance , such as ultrasound or 
CT/MRI . This lesion must bemeasurable as defined by [CONTACT_762587] (RECIST 1.1 for solid tumors or revised IWG criteria for lymphomas).
 For RECIST 1.1, ≥[ADDRESS_1044821] diameter for non-nodal lesions , or ≥1.5 cm in 
short axis for nodal lesion s.
 For revised IWG , a nodal lesion >1.5cm in longest diameter or >1.0 cm in short 
axis, or an extranodal lesion ≥[ADDRESS_1044822] an ECOG Performance Status of 0 or 1.
8.Demonstrate adequate organ function as defined by [CONTACT_50489] 1. 
All screening labs should be performed within 7 days prior to treatment initiation . 
Table 1 Adequate Organ Function Laboratory Values
System Laboratory Value
Hemat ological
Absolute neutrophil count ≥1,500/mcL (>1,000/mcL for lymphoma 
subject s)  
Platelets ≥100,00 0/mcL (≥75,000/mcL for lymphoma 
subject s)
Hemoglobin ≥9 g/dL or ≥5.6 mmol/La(≥8g/dL or 
≥5.0mmol/L for lymphoma subject s)
Renal
Serum Creatinine or
CrCl (measured or calculatedb)or
GFR in place of CrCl≤1.5 ×ULN or
≥60mL/min for subject with creatinine 
levels >1.[ADDRESS_1044823]
Hepatic
Total bilirubin ( serum) ≤1.5 ×ULN or
Direct bilirubin ≤ULN for subject s with 
total bilirubin levels >1.[ADDRESS_1044824] and ALT ≤2.5 ×ULN 
≤5 × ULN for subject s with liver metastases
087V73
Product:   MK-1454 44
Protocol/Amendment No.:   001-08 
MK-1454 -001-08 Final Protocol 27-Jul-2021
ConfidentialSystem Laboratory Value
Coagulation
INR or PT
PTT or aPTT≤1.5 ×ULN 
≤1.5 ×ULN
Abbreviations: ALT = Alanine aminotransferase ;aPTT = activated partial thromboplastin time; AST = 
aspartate aminotransferase INR = International Normalized Ratio ;PT = prothrombin time; PTT = partial 
thromboplastin time; ULN = upper limit of normal
a Criteria must be met without packed red blood cell transfusion within the prior [ADDRESS_1044825] s can be on 
stable dose of erythropoietin ( ≥ approximately 3 months).
bCrCl should be calculated per institutional standard .
9.A female participant is eligible to participate if she is not pregnant or breastfeeding, and 
at least one of the following conditions applies: 
 Is not a WOCBP
OR
 Is a WOCBP and using a contraceptive method that is highly effective (with a 
failure rate of <1% per year), with low user dependency, or be abstinent from 
heterosexual intercourse as their preferred and usual lifestyle (abstinent on a long -
term and persistent basis), as described in Section 5.7.[ADDRESS_1044826] dose of study intervention and agrees 
not to donate eggs (ova, oocytes) to others or freeze/store for her own use for the 
purpose of reproduction during this period. The investigator should evaluate the 
potential for contraceptive metho d failure (ie, noncompliance, recently initiated) 
in relationship to the first dose of study intervention. 
 A WOCBP must have a negative highly sensitive pregnancy test (urine or serum) 
within [ADDRESS_1044827] cannot be confirmed as negative (eg, an ambiguous result), a serum 
pregnancy test is required. In such cases, the participant must be excluded from 
participation if the serum pregnancy result is positive.
 Additional requirements for pregnancy testin g during and after study intervention 
are located in Section 5.7.2.
 The investigator is responsible for review of medical history, menstrual history, 
and recent sexual activity to decrease the risk for inclusion of a woman with an 
early undetected pregnan cy.
 Contraceptive use by [CONTACT_740249].
087V73
Product:   MK-1454 45
Protocol/Amendment No.:   001-[ADDRESS_1044828] dose of study intervention:
 Refrain from donating sperm
PLUS either:
 Be abstinent from heterosexual intercourse as their preferred and usual lifestyle 
(abstinent on a long -term and persistent basis) and agree to remain abstinent
OR
 Must agree to use contraception unless confirmed to be azoospermic 
(vasectomized or secondary to medical cause [ Section 5.7.2 ]) as detailed below:
 Agree to use a male condom plus partner use of an additional contraceptive 
metho d when having penile -vaginal intercourse with a WOCBP who is not 
currently pregnant. Note: Men with a pregnant or breastfeeding partner must 
agree to remain abstinent from penile -vaginal intercourse or use a male condom 
during each epi[INVESTIGATOR_19329] -vagina l penetration.
 Contraceptive use by [CONTACT_762588].
11.HIV-infected subject s must meet these additional criteria: 
 Have HIV-[ADDRESS_1044829] or HIV E/CIA 
test kit at any time prior to study entry (Day 1) and confirmed by a licensed 
Western blot or a second antibody test by a method other than the initial rapid 
HIV and/or E/CIA, or by [CONTACT_10840] -1 p24 antigen, or pla sma HIV -1 RNA VL .
 Have well -controlled HIV on ART, defined as: 
-must have a CD4+ T cell count >350 cells/mm3at time of screening;
-must have achieved and maintained virologic suppression defined as 
confirmed HIV RNA level below 50 or the LLOQ (below the limit of 
quantification ) using the locally available assay at the time of screening and 
for at least 12 weeks prior to screening; 
-must have been on a stable regimen, without changes in drugs or dose 
modification, for at least 4 weeks prior to study entry (Day 1).
Subject Inclusion Criteria for Crossover Into Arm [ADDRESS_1044830]:
1.Have either clinical or radiographic disease progression , or progression by [CONTACT_762589] [ADDRESS_1044831]:   MK-1454 46
Protocol/Amendment No.:   001-[ADDRESS_1044832] be measurable and meet 
one of the following criteria:
A cutaneous or subcuta neous lesion ≥[ADDRESS_1044833] diameter for solid tumors, or 
≥1.[ADDRESS_1044834] be ≤10cm for both solid tumors and nodal 
lesions in solid tumor subjects.
Mult iple coalescing, superficial lesions which in aggregate have a longest 
diameter of ≥1cm and ≤10 cm. 
For lymphoma subjects, a nodal lesion ≥1.5 cm in short axis, or an extranodal 
lesion ≥1 cm in 2dimensions . Nodal lesions ≥1.0 cm and <1.[ADDRESS_1044835] be ≤[ADDRESS_1044836] one distant and/or discrete noninjected lesion that is amenable to biopsy via 
visual inspection or amenable to biopsy via image guidance . Biopsy may be performed 
via visual inspection, ultrasound guidance, or cross -sectional imaging guidance. This 
lesion must be measurable as defined by [CONTACT_762590] 
(RECIST 1.1 for solid tumors or IWG revised criteria for lymphomas).
For RECIST 1.1, ≥[ADDRESS_1044837] diameter for non-nodal lesions, or ≥1.5 cm in 
short axis for nodal lesions.
For revised IWG, a nodal lesion >1.[ADDRESS_1044838] diameter or >1.0 cm in short 
axis, or an extranodal lesion ≥[ADDRESS_1044839] one of the following c onditions applies: 
 Is not a WOCBP
OR
 Is a WOCBP and using a contraceptive method that is highly effective (with a 
failure rate of <1% per year), with low user dependency, or be abstinent from 
heterosexual intercourse as their preferred and usual lifestyle (abstinent on a long -
term and persistent basis), as described in Section 5.7.[ADDRESS_1044840] dose of study intervention and agrees 
not to donate eggs (ova, oocytes) to others or freeze/sto re for her own use for the 
purpose of reproduction during this period. The investigator should evaluate the 
potential for contraceptive method failure (ie, noncompliance, recently initiated) 
in relationship to the first dose of study intervention. 
 A WOCBP must have a negative highly sensitive pregnancy test (urine or serum) 
within [ADDRESS_1044841]:   MK-1454 47
Protocol/Amendment No.:   001-[ADDRESS_1044842] cannot be confirmed as negative (eg, an ambiguous result), a serum 
pregnancy test is required. In such cases , the participant must be excluded from 
participation if the serum pregnancy result is positive.
 Additional requirements for pregnancy testing during and after study intervention 
are located in Section 5.7.2.
 The investigator is responsible for review of medical history, menstrual history, 
and recent sexual activity to decrease the risk for inclusion of a woman with an 
early undetected pregnancy.
 Contraceptive use by [CONTACT_762591] r those participating in clinical studies.
7.Male subject s are eligible to participate if they agree to the following during the 
intervention period and for at least 130days) after the last dose of study intervention:
 Refrain from donating sperm
PLUS either:
 Be abstinent from heterosexual intercourse as their preferred and usual lifestyle 
(abstinent on a long -term and persistent basis) and agree to remain abstinent
OR
 Must agree to use contraception unless confirmed to be azoospermic 
(vasectomized or secondary to medical cause [ Section 5.7.2 ]) as detailed below :
Agree to use a male condom plus partner use of an additional contraceptive 
method when having penile -vaginal intercourse with a WOCBP who is not 
currently pregnant. Note: Men with a pregnant or breastfeeding partner must 
agree to remain abstinent from penile -vaginal intercourse or use a male condom 
during each epi[INVESTIGATOR_19329] -vaginal penetration.
Contraceptive use by [CONTACT_762592] l studies.
8.HIV-infected subject s must meet these additional criteria: 
 Have HIV-[ADDRESS_1044843] or HIV enzyme 
or chemiluminescence immunoassay (E/CIA) test kit at any time prior to study 
entry (Day 1) and confirmed by a licensed Western blot or a second antibody test 
by a method other than the initial rapid HIV and/or E/CIA, or by [CONTACT_10840]-1 p24 
antigen, or plasma HIV -1 RNA VL.
 Have well -controlled HIV on ART, defined as: 
-must have a CD4+ T cell count >350 cells/mm3 at time of screening;
-must have achieved and maintained virologic suppression defined as 
confirmed HIV RNA level below 50 or the LLOQ (below the limit of 
quantification) using the locally available assay at the time of screening and 
for at least 12 weeks prior to screening; 
087V73
Product:   MK-1454 48
Protocol/Amendment No.:   001-[ADDRESS_1044844] 4 weeks prior to study entry (Day 1).
Subject Inclusion Criteria for Arm [ADDRESS_1044845] meet the 
following inclusion criteria :
1.Be ≥[ADDRESS_1044846] a histologically -or cytologically confirmed advanced/metastatic solid tumor or 
lymphoma by [CONTACT_762593] . Solid tumors and lymphomas of any type are 
eligible for enrollment . Tumor types of greatest interest include, but are not limited to, 
malignant melanoma, HNSCC , breast aden ocarcinoma, and lymphomas . 
4.Have Stage III or Stage IV disease that is not surgically resectable. 
5.Has metastatic liver involvement that does not exceed one-third of the total liver volume 
in subjects to be treated by [CONTACT_762594] . Hepatocellular carcinoma subjects are 
excluded from eligibility of intratumoral liver injection . In addition, has at least one 
injectable liver lesion with the following: 
 The injectable liver lesion is amenable to image -guided intratumoral injection and 
biopsy via ultrasou nd guidance or cross -sectional imaging (CT/MRI) . 
 Injectable lesion (s)must be ≥[ADDRESS_1044847] diameter and ≤[ADDRESS_1044848] 1 distant and/or discrete noninjected lesion that is amenable to biopsy via 
visual inspection or amenable to biopsy via image guidance , such as ultrasound or 
CT/MRI . This lesion must be measurable as defined by [CONTACT_762587] (RECIST 1.1 for solid tumors or revised IWG criteria for 
lymphomas).
 For RECIST 1.1, ≥[ADDRESS_1044849] diameter for non-nodal lesions , or ≥1.5 cm in 
short axis for nodal lesions.
 For revised IWG, a nodal lesion >1.[ADDRESS_1044850] diameter or >1.0cm in short 
axis, or an extranodal lesion ≥[ADDRESS_1044851]:   MK-1454 49
Protocol/Amendment No.:   001-[ADDRESS_1044852] one of the following conditions applies: 
 Is not a WOCBP
OR
 Is a WOCBP and using a contraceptive method that is highly effective (with a 
failure rate of <1% per year), with low user dependency, or be abstinent from 
heterosexual intercourse as their preferred and usual lifestyle (abstinent on a long -
term and persistent basis), as described in Section 5.7.[ADDRESS_1044853] dose of study intervention and agrees 
not to donate eggs (ova, oocytes) to others or freeze/store for her own use for the 
purpose of reproduction during this period. The investigator should evaluate the 
potential for contraceptive method failure (ie, noncompliance, recently initiated) 
in relationship to the first dose of study intervention. 
 A WOCBP must have a negative highly sensitive pregnancy test (urine or serum) 
within [ADDRESS_1044854] cannot be confirmed as negative (eg, an ambiguous result), a serum 
pregnancy test is required. In such cases, the participant must be excluded from 
participation if the serum pregnancy result is positive.
 Additional requirements for pregnancy testing during and after study intervention 
are located in Section 5.7.2.
 The investigator is responsible for review of medical history, menstrual history, 
and recent sexual activity to decrease the risk for inclusion of a woman with an 
early undetected pregnancy.
 Contraceptive use by [CONTACT_740249].
10. Male subject s are eligible to participate if they agree to the following during the 
intervention period and for at least 130days after the last dose of study intervention:
 Refrain from donating sperm
PLUS either:
 Be abstinent from heterosexual intercourse as their preferred and usual lifestyle 
(abstinent on a long -term and persistent basis) and agree to remain abstinent
OR
 Must agree to use contraception unless confirmed to be azoospermic 
(vasectomized or secondary to medical cause [ Section 5.7.2 ]) as detailed below:
Agree to use a male condom plus partner use of an additional contraceptive 
method when having penile -vaginal intercourse with a WOCBP who is not 
currently pregnant. Note: Men with a pregnant or breastfeeding partner must 
agree to remain abstinent from penile-vaginal intercourse or use a male condom 
during each epi[INVESTIGATOR_19329] -vaginal penetration.
087V73
Product:   MK-1454 50
Protocol/Amendment No.:   001-[ADDRESS_1044855] meet these additional criteria: 
 Have HIV-[ADDRESS_1044856] or HIV E/CIA 
test kit at any time prior to study entry (Day 1) and confirmed by a licensed 
Western blot or a second antibody test by a method other than the initial rapid 
HIV and/or E/CIA, or by [CONTACT_10840] -1 p24 antigen, or plasma HIV -1 RNA VL.
 Have well -controlled HIV on ART, defined as: 
-must have a CD4+ T cell count >350 cells/mm 3at time of screening;
-must have achieved and maintained virologic suppression defined as 
confirmed HIV RNA level below 50 or the LLOQ (below the limit of 
quantification ) using the locally available assay at the time of screening and 
for at least 12 weeks prior to screening; 
-must have been on a stable regimen, without changes in drugs or dose 
modification, for at least 4 weeks prior to study entry (Day 1).
Subject Inclusion Criteria for Part II -Expansion Cohorts
1.Be ≥[ADDRESS_1044857] meet one 
of the following criteria:
 A cutaneous or subcutaneous lesion ≥[ADDRESS_1044858] diam eter for solid tumors, or 
≥1.[ADDRESS_1044859] be ≤10cm for both solid tumors and nodal 
lesions in solid tumor subjects.
OR
 Multiple coalescing, superficial lesions which in aggregate have a longest 
diameter of ≥1cm and ≤[ADDRESS_1044860]:   MK-1454 51
Protocol/Amendment No.:   001-[ADDRESS_1044861] one 
injectable liver lesion that meets both the following conditions : 
 The injectable liver lesion is amenable to image -guided intratumoral injection and 
biopsy via ultrasound guidance or cross -sectional imaging (CT/MRI). 
AND
 Injectable lesion(s) must be ≥[ADDRESS_1044862] diameter and ≤[ADDRESS_1044863] 
diameter.
5.Subjects with any one of the following solid malignancies who meet all listed conditions 
of eligibility for an expansion cohort:
 Cohort A:  HNSCC of the oral cavity, oropharynx, hypopharynx, or larynx; 
anti-PD-1/PD-L1 refractory (see Table 2)metastatic or recurrent .Subjects may 
not have a primary tumor site of the nasopharynx (any histology) . 
oHave histologically confirmed Stage III, IVa,orIVb disease per TNM 
staging ,AJCC Eigh th edition ,with recurrent or persistent disease after 
definitive chemoradiation, deemed unresectable and considered refractory to 
both platinum -based combination chemotherapy and anti-PD-1/PD-L1
antibody therapy .
OR
oHave histologically confirmed Stage IVc disease per TNM staging ,AJCC 
Eighth edition ,considered refractory to platinum -based combination 
chemotherapy and anti -PD-1/PD -L1antibod y therapy .
 Cohort B: Either anti-PD-1/PD -L1 treatment -naïve or refractory (see Table 2) 
TNBC
oHave confirmed unresectable locally advanced or metastatic TNBC as locally 
determined according to the ASCO -CAPguidelines [27] on a newly obtained 
core or excisional biopsy from a not previously irradiated, tumor lesion. 
oHave received at least one prior systemic treatment for breast cancer and have 
documented disease progression on or after their most recent therapy . 
oHave been previously treated with an anthracycline and/or taxane in the 
(neo)adjuvant or metastatic setting unless there was a medic al 
contraindication to this treatment regimen.
oHave LDH <2.5×ULN [28] [29] [30] .
 Cohort C:  Other anti-PD-1/PD -L1 treatment -naïve solid tumors with liver 
metastases (including pancreatic cancer , non -MSI-H CRC, and other solid tumors . 
MSI-H status is to be determined by [CONTACT_26773]) .
oHave histologically or cytologically confirmed Stage IV solid tumor that is 
not surgically resectable. 
087V73
Product:   MK-1454 52
Protocol/Amendment No.:   001-08 
MK-1454 -001-08 Final Protocol 27-Jul-2021
ConfidentialTable 2 Anti-PD-1/PD-L1Antibody Refractory Definition
Patients must have progressed on treatment with an anti -PD-1/PD-L1monoclonal antibody 
(mAb) administered either as monotherap y, or in combination with other checkpoint 
inhibitors or other therapi[INVESTIGATOR_014]. anti-PD-1/PD-L1treatment progression is defined by [CONTACT_609420]:
a)Has received at least 2 doses of an approved anti -PD-1/PD-L1mAb. 
b)Has demonstrated disease progression after anti-PD-1/PD-L1as defined by 
[CONTACT_393] v1.1. The initial evidence of disease progression (PD) is to be 
confirmed by a second assessment no less than [ADDRESS_1044864] documented PD, in the absence of rapid clinical progres sion.1,2.
c)Progressive disease has been documented within 12weeks from the last 
dose of anti -PD-1/PD-L1mAb. 
1.Seymour et al; iRECIST: Guidelines for response criteria for use in trials testing 
immunotherapeutics. Lancet Oncol 18: e143 -[ADDRESS_1044865](s) of the most recent prior chemotherapy to Grade 1 
or baseline (except alopecia). If the subject received major surgery or radiation therapy of 
>[ADDRESS_1044866] recovered from the toxicity and/or complications from the 
intervention.
7.Have an ECOG Performance Status of [ADDRESS_1044867] one of the following conditions applies: 
 Is not a WOCBP
OR
 Is a WOCBP and using a contraceptive method that is highly effective (with a 
failure rate of <1% per year), with low user dependency, or be abstinent from 
heterosexual intercourse as their preferred and usual lifestyle (abstinent on a long -
term and persistent basis), as described in Section 5.7.[ADDRESS_1044868] dose of study intervention and agrees 
not to donate eggs (ova, oocytes) to others or freeze/store for her own use for the 
purpose of reproduction during this period. The investigator should evaluate the 
potential for contraceptive metho d failure (ie, noncompliance, recently initiated) 
in relationship to the first dose of study intervention. 
 A WOCBP must have a negative highly sensitive pregnancy test (urine or serum) 
within [ADDRESS_1044869]:   MK-1454 53
Protocol/Amendment No.:   001-08 
MK-1454 -001-08 Final Protocol 27-Jul-2021
Confidential If a urine test cannot be confirmed as negative (eg, an ambiguous result), a serum 
pregnancy test is required. In such cases, the participant must be excluded from 
participation if the serum pregnancy result is positive.
 Additional requirements for pregnancy testin g during and after study intervention 
are located in Section 5.7.2.
 The investigator is responsible for review of medical history, menstrual history, 
and recent sexual activity to decrease the risk for inclusion of a woman with an 
early undetected pregnanc y.
 Contraceptive use by [CONTACT_740249].
10.Male subject s are eligible to participate if they agree to the following during the 
intervention p eriod and for at least 130days after the last dose of study intervention:
 Refrain from donating sperm
PLUS either:
 Be abstinent from heterosexual intercourse as their preferred and usual lifestyle 
(abstinent on a long -term and persistent basis) and agree to remain abstinent
OR
 Must agree to use contraception unless confirmed to be azoospermic 
(vasectomized or secondary to medical cause [ Section 5.7.2 ]) as detailed below:
 Agree to use a male condom plus partner use of an additional contraceptive 
metho d when having penile -vaginal intercourse with a WOCBP who is not 
currently pregnant. Note: Men with a pregnant or breastfeeding partner must 
agree to remain abstinent from penile -vaginal intercourse or use a male condom 
during each epi[INVESTIGATOR_19329] -vagina l penetration.
Contraceptive use by [CONTACT_762588].
11.HIV-infected subject s must meet these additional criteria: 
Have HIV-[ADDRESS_1044870] or HIV enzyme or 
chemiluminescence immunoassay (E/CIA) test kit at any time prior to study entry 
(Day 1) and confirmed by a licensed Western blot or a second antibody test by a 
method other than the initial rapid HIV and/or E/CIA, or by [CONTACT_10840]-1 p24 antigen, or 
plasma HIV -1 RNA VL.
Have well -controlled HIV on ART, defined as: 
omust have a CD4+ T cell count >350 cells/mm3 at time of screening;
omust have achieved and maintained virologic suppression defined as 
confirmed HIV RNA level below 50 or the LLOQ (below the limit of 
quantification) using the locally available assay at the time of screening and 
for at least 12 weeks prior to screening; 
087V73
Product:   MK-1454 54
Protocol/Amendment No.:   001-[ADDRESS_1044871] 4 weeks prior to study entry (Day 1).
Subject Exclusion Criteria for Part I -Dose Escalation and Confirmation
The subject must be excluded from participating in any arm of the trial if the subject:
Exclusion Criteria for Arms 1, 2, and 3
1.Has had chemotherapy, definitive radiation, or biological cancer therapy within 
4weeks (2weeks for palliative radiation) prior to the first dose of study therapy, 
or has not recovered to baseline or CTCAE G rade 1 (Grade 2 alopecia is allowed) 
from the AEs due to cancer therapeutics administered more than 4 weeks earlier.
2.Is currently participating and receiving study therapy or has participated in a study 
of an investigational agent and has received study therapy or has used an 
investigational device within 28 days of administration of MK -1454 . 
Note:   Prior exposure to immunotherapeutics is allowed, including PD-1 and 
PD-L1 inhibitors, provided patient did not experience a≥Grade 3 drug-related 
toxicity on monotherapy with a PD-1 or PD -L1 inhibitor .
3.Is expected to require any other form of antineoplastic therapy while on study.
4.Is on chronic systemic steroid therapy in excess of replacement doses (prednisone 
≤10mg/day is acceptable) , or on any other form of immunosuppressive 
medication . For CTCL, continued use of either prednisone ≤10mg/day or 
continued use of topi[INVESTIGATOR_194625].
Note:   The use of physiol ogic replacement doses of corticosteroids may be 
approved after consultation with the Sponsor Medical Monitor or designee .
5.Has a history of a second malignancy, unless potentially curative treatment has 
been completed, with no evidence of malignancy for 2years.
Note: The time requirement does not apply to subjects who underwent successful 
definitive resection of basal cell carcinoma of the skin, superficial bladder cancer 
or in situ cervical cancer.
6.Has clinically active central nervous system metastases and/or carcinomatous 
meningitis . Subjects with previously treated brain or meningeal metastases may 
participate and be eligible for treatment provide d they are stable and 
asymptomatic (without evidence of progression by [CONTACT_762595] 4 weeks after treatment), have no evidence of new or 
enlarging brain metastases, are evaluated within [ADDRESS_1044872] 
2years (ie,with use of disease modifying agents, corticosteroids or 
087V73
Product:   MK-1454 55
Protocol/Amendment No.:   001-08 
MK-1454 -001-08 Final Protocol 27-Jul-2021
Confidentialimmunosuppressive drugs) except vitiligo or resolved childhood asthma/atopy . 
Replacement therapy, such asthyroxine, insulin, or physiologic corticosteroid 
replacement therap y for adrenal or pi[INVESTIGATOR_13002], is not considered a 
form of systemic treatment . 
9.Has a history of vasculitis.
10.Has an active infection requiring therapy.
11.Has a history of (non-infectious) pneumonitis that required steroids or current 
pneumonitis .
12.Has undergone prior allogeneic hematopoietic stem cell transplantation within the 
last 5 years. 
Note:   Subjects who have had a transplant greater than 5years ago are eligible as 
long as there are no symptoms of GVHD.
13.HasHepatitis B or C infections, or is known to be positive for Hepatitis B surface 
antigen/Hepatitis B virus (HBsAg/HBV )DNA or Hepatitis C Antibody (Hep C 
Ab) or ribonucleic acid (RNA) . Active Hepatitis C virus (HCV) is defined by a 
known positive Hep C Ab result and known quantitative HCV RNA results 
greater than the lower limits of detection of the assay.
14.Has a history or current evidence of any condition, therapy, or laboratory 
abnormality that might confound the results of the study, interfere with the 
subject’s participation for the full duration of the study, would make 
administration of the study drugs hazardous or make it difficult to monitor 
adverse effects such that it is not in the best interest of the subject to participate, 
in the opi[INVESTIGATOR_80021] .
15.Has known psychiatric or substance abuse disorders that would interfere in
cooperation with the requirements of the trial.
16.Is pregnant or breastfeeding, or expecting to conceive or father children within the 
projected duration of the study.
17.Has not fully recovered from any effects of major surgery, and isfree of 
significant detectable infection . Surgeries that required general anesthesia must be 
completed at least [ADDRESS_1044873] study drug administration . Surgery
requiring regional/epi[INVESTIGATOR_412254] [ADDRESS_1044874] dose.
19.Has a history of re -irradiation for HNSCC at the projected injection site .
20.Has a tumor(s) in direct contact [CONTACT_762596] a major blood vessel ,and has
ulceration and/or fungation onto the skin surface at the projected injection site . 
21.HIV-infected subject s with history of Kaposi’s sarcoma and/or multicentric 
Castleman’s disease .
22.HIV-infected subject s who have had an HIV-related opportunistic infection 
within [ADDRESS_1044875]:   MK-1454 56
Protocol/Amendment No.:   001-[ADDRESS_1044876]:
1.Has had chemotherapy, definitive radiation, or biological cancer therapy within 
4weeks (2weeks for palliative radiation) prior to the first dose of study therapy, 
or has not recovered to baseline or CTCAE G rade 1 (Grade 2 alopecia is allowed) 
from the AEs due to cancer therap eutics administered more than 4 weeks earli er.
2.Is currently participating and receiving study therapy or has participated in a study 
of an investigational agent and has received study therapy or has used an 
investigational device within 28 days of administration of MK -1454 . 
Note:   Prior exposure to MK-[ADDRESS_1044877] 14 days anddid not experience Grade 3 or higher drug-related 
toxicity . 
Note:   Prior exposure to immunotherapeutics is allowed, including PD-1 and 
PD-L1 inhibitors, provided patie nt did not experience a ≥ Grade 3 drug-related 
toxicity on monotherapy with a PD -1 or PD -L1 inhibitor 
3.Is expected to require any other form of antineoplastic therapy while on study.
4.Is on chronic systemic steroid therapy in excess of replacement doses (prednisone 
≤10mg/day is acceptable) , or on any other form of immunosuppressive 
medication.
Note :  The use of physiologic replacement doses of corticosteroids may be 
approved after consultation with the Sponsor Medical Monitor.
5.Has clinically active central nervous system metastases and/or carcinomatous 
meningitis . Subjects with previously treated brain or meningeal metastases may 
participate and be eligible for treatment provided they are stable and 
asymptomatic (without evidence of progression by [CONTACT_762595] 4 weeks after treatment), have no evidence of new or 
enlarging brain metastases, are evaluated within [ADDRESS_1044878] 
2 weeks from enrollment.
6.Has had a severe hypersensitivity reaction to treatment with a monoclonal 
antibody.
7.Has an active infection requiring therapy.
8.Has a history of (non-infectious) pneumonitis that required steroids or current 
pneumo nitis.
087V73
Product:   MK-1454 57
Protocol/Amendment No.:   001-[ADDRESS_1044879]’s participation for the full duration of the study, would make 
administration of the study drugs hazardous or make it difficult to monitor 
adverse effects such that it is not in the best interest of the subject to participate, 
in the opi[INVESTIGATOR_80021] .
10.Is pregnant or breastfeeding, or expecting to conceive or father children within the 
projected duration of the study.
11.Has not fully recovered from any effects of major surgery, and be free of 
significant detectable infection . Surgeries that required general anesthesia must be 
completed at least [ADDRESS_1044880] study drug administration . Surgery 
requiring regional/epi[INVESTIGATOR_412254] [ADDRESS_1044881] dose.
13.Has a history of re -irradiation for SCCHN at the projected injection site.
14.Has a tumor (s) in direct contact [CONTACT_762596] a major blood vessel and has
ulceration and/or fungation onto the skin surface at the projected injection site .
Exclusion Criteria for Part II -Expansion Cohorts
1.Has had chemotherapy, definitive radiation, or biological cancer therapy within 
4weeks (2weeks for palliative radiation) prior to the first dose of study therapy, 
or has not recovered to baseline or CTCAE Grade 1 (Grade 2 alopecia is allowed) 
from the AEs due to cancer therapeutics administered more than 4 weeks earlier
(this includes subject s with previous immunomodulatory therapy with residual 
immune -related AEs). Subject s receiving ongoing replacement hormone therapy 
for endocrine immune -related AEs will not be excluded from participation in this 
study .
2.Is currently participating and receiving study therapy or has participated in a study 
of an investigational agent and has received study therapy or has used an 
investigational device within 28 days of administration of MK -1454 . 
Note:   Where prior exposure to immunotherapeutics is allowed, including PD-1 
and PD-L1 inhibitors, patient has experience daGrade 3 or higher drug-related 
toxicity on monotherapy with a PD-1 or PD-L1 inhibitor requiring steroid 
treatment (>10 mg/day prednisone or equivalent) for >12 weeks or CTCAE Grade 
2 or higher pneumonitis regardless of steroid treatment . 
3.Is expected to require any other form o f antineoplastic therapy while on study.
4.Is on chronic systemic steroid therapy in excess of replacement doses (prednisone 
≤10mg/day is acceptable), or on any other form of immunosuppressive 
medication. 
Note:   The use of physiologic replacement doses of corticosteroids may be 
approved after consultation with the Sponsor Medical Monitor or designee.
087V73
Product:   MK-1454 58
Protocol/Amendment No.:   001-08 
MK-1454 -001-08 Final Protocol 27-Jul-2021
Confidential5.Has a history of a second malignancy, unless potentially curative treatment has 
been completed, with no evidence of malignancy for 2 years.
Note:   The time req uirement does not apply to subjects who underwent successful 
definitive resection of basal cell carcinoma of the skin, superficial bladder cancer ,
in situ cervical cancer , or other in situ cancers .
6.Has clinically active central nervous system metastases and/or carcinomatous 
meningitis . Subjects with previously treated brain or meningeal metastases may 
participate and be eligible for treatment provided they are stable and 
asymptomatic (without evidence of progression by [CONTACT_762595] 4 weeks after treatment), have no evidence of new or 
enlarging brain metastases, are evaluated within [ADDRESS_1044882] 
2 years (ie, with use of disease modifying agents, corticosteroids or 
immunosuppress ive drugs) except vitiligo or resolved childhood asthma/atopy . 
Replacement therapy, such as thyroxine, insulin, or physiologic corticosteroid 
replacement therapy for adrenal or pi[INVESTIGATOR_13002], is not considered a 
form of systemic treatment . 
9.Has a history of vasculitis.
10.Has a history of interstitial lung disease.
11.Has an active infection requiring therapy.
12.Has a history of (non-infectious) pneumonitis that required steroids or current 
pneumonitis.
13.Has a history or current evidence of a gastrointestinal (GI) condition (eg, 
inflammatory bowel disease, Crohn’s disease, ulcerative colitis) or impaired liver 
function or diseases that in the opi[INVESTIGATOR_762547]; any condition, therapy, or 
laboratory abnormality that might confound the results of the study, interfere with 
the subject ’s participation for the full duration of the study, make administration 
of the study drugs hazardous, or make it difficult to monitor adverse effects such 
that it is not in the best interest of the subject to participate, in the opi[INVESTIGATOR_209822].
14.Has undergone prior allogeneic hematopoietic stem cell transplantation within the 
last 5 years. 
Note:   Subjects who have had a transplant greater than 5 years ago are eligible as 
long as there are no symptoms of GVHD.
15.Has Hepatitis B or C infections, or is known to be positive for HBsAg/HBV DNA 
or Hep C Ab or RNA . Active HCV is defined by a known positive Hep C Ab 
087V73
Product:   MK-1454 59
Protocol/Amendment No.:   001-[ADDRESS_1044883] s with history of Kaposi’s sarcoma and/or multicentric 
Castleman’s disease .
17.HIV-infected subject s who have had an HIV-related opportunistic infection 
within [ADDRESS_1044884] (eg, MK -1454, ADU -S100).
20.Has a histor y or current evidence of any condition, therapy, or laboratory 
abnormality that might confound the results of the study, interfere with the 
subject’s participation for the full duration of the study, would make 
administration of the study drugs hazardous or make it difficult to monitor 
adverse effects such that it is not in the best interest of the subject to participate, 
in the opi[INVESTIGATOR_80021] .
21.Has known psychiatric or substance abuse disorders that would interfere in 
cooperation with the requirements of the trial.
22.Is pregnant or breastfeeding or expecting to conceive or father children within the 
projected duration of the study.
23.Has not fully recovered from any effects of major surgery and be free of 
significant detectable infection . Surgeries that required general anesthesia must be 
completed at least [ADDRESS_1044885] study drug administration . Surgery 
requiring regional/epi[INVESTIGATOR_412254] [ADDRESS_1044886] dose.
25.Has a history of re-irradiation for SCCHN at the projected injection sitein the 
head and neck .
26.Has a tumor(s) in direct contact [CONTACT_762596] a major blood vessel and has
ulcer ation and/or fungation onto the skin surface at the projected injection site in 
the head or neck. 
27.Has experienced weight loss >10% over [ADDRESS_1044887] dose of study 
therapy.
28.Has clinically relevant ascites at baseline (defined as requiring paracentesis) or 
with moderate radiographic ascites. A minimal amount of radiographic ascites is 
allowed .
087V73
Product:   MK-1454 60
Protocol/Amendment No.:   001- 08 
MK-1454 -001-08 Final Protocol 27-Jul-2021
Confidential29.For Cohort C, subjects with MSI -H CRC are excluded.
Trial Treatment(s)
The human starting dose of MK-1454 for ITinjection is based on an integration of 
nonclinical toxicological, pharmacological, and efficacy data (see Section 4.2.2) . The 
treatments to be used in Arm 1 and Arm 2 of this trial are outlined below inTable 3and 
Table 4 , respectively, and for Arm 3 are provided in Table 5 .
Dose escalation will proceed based on emerging safety and tolerability data of MK-1454 as 
monotherapy and in combination with pembrolizumab. For each dose level, an assessment 
will be made of the safety and tolerability data in order to define the next dose level to be 
tested. For the ATD phase, in both Arm 1 and Arm 2, dose escalation may proceed in 
increments of up to 300% . For example, during ATD, in the absence of DLTs and toxicity, 
dose escalation may proceed from  For the 
mTPI [CONTACT_16303], in both Ar m 1 and Arm 2, dose escalation may proceed in increments of 30% to 
100% . For example, during mTPI, in the absence of DLTs and toxicity, dose escalation may 
proceed from Intermediate doses between  
ments are within a 300% increase 
from prior dose for the ATD phase and within a 30% to 100% increase from prior dose for 
the mTPI [CONTACT_16303] . For example, in the ATD phase with toxicity findings, dose escalation may 
proce ed from See Section 5.2.2 for dose delays fulfilling DLT 
criteria during for directions on how to proceed in the case of an 
AE.
Arm 3 will initiate in an ATD at  and escalate as shown in Figure 2 andTable 5 .
Table 3 Trial Treatment for MK -1454 IT Monotherapy (Arm 1)
Drug, 
Vaccine, 
Biologic, 
Device, 
etc.Dose/
PotencyDose 
FrequencyRoute of 
AdministrationRegimen/
Treatment 
Period Use
MK-1454 Range: Intratumoral
Via visual 
inspection for 
cutaneous 
lesions, and via 
ultrasound 
guidance or 
palpation for 
subcutaneous 
lesions ,as 
neededExperimental
aDose levels will be determined based on emerging safety data.
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
087V73
Product:   MK-1454 61
Protocol/Amendment No.:   001-08 
MK-1454 -001-08 Final Protocol 27-Jul-2021
ConfidentialTable 4 Trial Treatment for MK -1454 IT in Combination with Pembrolizumab ( Arm 2)
Drug, Vaccine, 
Biologic, Device, 
etc.Dose/
PotencyDose 
FrequencyRoute of 
AdministrationRegimen/
Treatment 
PeriodaUse
Pembrolizumab 200 mg IV infusionDay 1 of each 
21-day cycleExperimental
MK-1454b Range: Intratumoral 
Via visual 
inspection for 
cutaneous lesions, 
and via ultrasound 
guidance or 
palpation for 
subcutaneous 
lesions ,as neededExperimental
aCohorts staggered at least [ADDRESS_1044888] 1 of the following: 1) T he  MK -1454 
cohort is completed, 2) ≥ Grade 2 toxicity as assessed by [CONTACT_178759], probably related, or possibly 
related to the drug at any dose level, or 3) Elevation of systemic TNF -α in blood above baseline levels by ≥3-fold for a 
given subject at any time during the first cycle of MK -1454 (eg, increase from 20 pg/mL t o 60 pg/mL) . 
bMK-[ADDRESS_1044889]:   MK-1454 62
Protocol/Amendment No.:   001-08 
MK-1454 -001-08 Final Protocol 27-Jul-2021
ConfidentialTable 5 Trial Treatment for MK -1454 Visceral IT in Combination with Pembrolizumab 
(Arm 3)
Drug, 
Vaccine, 
Biologic, 
Device, etc.Dose/ 
Potency Dose FrequencyRoute of 
AdministrationRegimen/ 
Treatment 
PeriodaUse
Pembrolizumab 200 mg Q3W IV infusionDay 1 of each 
21-day cycleExperimental
MK-1454 ATD phase –Q3W
mTPIb:
Dose frequency to 
escalate as follows:Intratumoral 
(Visceral)
Via ultrasound or 
cross -sectional 
imaging 
(CT/MRI) 
guidance for liver 
lesions, as neededExperimental
ATD = Accelerated titration design; mTPI = modified toxicity probability interval
aMK-[ADDRESS_1044890] frequency and cleared by [CONTACT_306834] [CONTACT_8345], the next 
dose level may begin.
Trial treatment should begin on the day of treatment allocation/ randomization or as close as 
possible to the date on which the subject is allocated/assigned.
All supplies indicated in Table 3through Table 5above will be provided centrally by [CONTACT_762597] t he trial site, subsidiary or designee, depending on local country 
operational or regulatory requirements.
For any commercially available product that is provided by [CONTACT_21655], subsidiary or 
designee every attempt will be made to source these supplies from a single lot/batch number. 
The trial site is responsible for recording the lot number, manufacturer, and expi[INVESTIGATOR_113743] .
CCI
CCI
CCI
087V73
Product:   MK-1454 63
Protocol/Amendment No.:   001-08 
MK-1454 -001-08 Final Protocol 27-Jul-2021
ConfidentialThe investigator shall take responsibility for and shall take all steps to maintain appropriate 
records and ensure appropriate supply, storage, handling, distri bution and usage of trial 
treatments in accordance with the protocol and any applicable laws and regulations.
Dose Selection/Modification
Dose Selection (Preparation)
[IP_ADDRESS].1 Dose Selection in Part I -Dose Escalation and Confirmation (Arm 1, Arm 2, 
and Arm 3)
MK-1454 will be administered as a sterile aqueous solution with atotal volume of injectate 
of up to 4 mL per treatment visit for all injected lesions combined for Arm 1 and Arm 2. For 
Arm 3, the maximum injectate volume will be 3 mL. MK-1454 will be administered by 
[CONTACT_762598], subcutaneous, and/or nodal lesions that are visible, palpable, or 
detectable by [CONTACT_762599] -sectional imaging guidance as clinically 
appropriate . As well as into liver lesions that aredetectable by [CONTACT_762599] -
sectional imaging guidance as clinically appropriate . 
During dose escalation in both Arm 1 and Arm 2(Parts A-D), each subject at a given dose 
level will receive a fixed dose of MK-[ADDRESS_1044891] is of 4mL for subjects in Arm 1 and Arm 2, and 3 mL for subjects in Arm 3. 
Documentation of dose volume admi nistered per lesion will be obtained . 
For lesions that are no longer visible following treatment, discuss with Sponsor for continued 
injection . Distant lesion(s) assessed for abscopal response should not be injected , unless 
approved by [CONTACT_748929] . Deviation from the injectate volume s
specified in Table 6for individual lesions may be permitted upon approval by [CONTACT_762600] .
087V73
Product:   MK-1454 64
Protocol/Amendment No.:   001-08 
MK-1454 -001-08 Final Protocol 27-Jul-2021
ConfidentialTable 6 Determination of MK -1454 Injection Volume for Intratumoral Injection of
Cutaneous Lesions Based on Lesion Size (Part I - Arm 1 and Arm 2) 
Lesion Size (longest dimension) Injection Volume
>5 cm ≤4 mL
>2.5 cm to 5 cm ≤2 mL
>1.5 cm to 2.5 cm ≤1 mL
≥1.[ADDRESS_1044892] ration of MK-1454 are provided in the 
Procedures Manual.
Table 7 Determination of MK -1454 Injection Volume for Intratumoral Injection into 
Subcutaneous Lesions Based on Lesion Size (Part I Arm 1 and Arm 2)
Lesion Size (longest dimension) Injection Volume
>5 cm ≤4 mL
>2.5 cm to 5 cm ≤2 mL
>1.5 cm to 2.5 cm ≤1.5mL
≥1.0 cm to 1.5 cm 1.0 mL
[IP_ADDRESS].2 Dose Selection in P artII -Expansion Cohorts (Cohort s Aand B)
The starting dose for Cohort s Aand B is confirmed to be based on the safety, PK, and 
PD data from dose escalation and confirmation of MK-1454 IT in combination with 
pembrolizumab in Arm 2(Table 8). The minimum number of lesions per subject per 
treatment visit to be injected is1lesion, and the maximum number of lesions to be injected 
per subject pertreatment visit is3 lesions . Each subject at this  dose level will receive 
a fixed dose of intratumoral MK-1454 prepared in a volume of 1 mL to 3 mL of injectate, 
based on lesion size (s ee Table 9). 
The starting dose for Cohort C will be the preliminary RP2D (both dose level and frequency) 
from the dose escalation and confirmation of MK-[ADDRESS_1044893]:   MK-1454 65
Protocol/Amendment No.:   001- 08 
MK-1454 -001-08 Final Protocol 27-Jul-2021
ConfidentialTable 8 Trial Treatment for MK -1454 IT in Combination with Pembrolizumab Part II 
(Expansion Cohort s A, B, and C )
Drug, Vaccine, 
Biologic, Device, 
etc.Dose/ 
PotencyDose 
FrequencyRoute of 
AdministrationRegimen/ 
Treatment 
Period Use
Pembrolizumab 200 mg Q3W IV infusionDay 1 of each 
21-day cycleExperimental
MK-1454aCohorts A 
and B : 
Cohort C : 
Preliminary 
RP2D 
established in 
Arm 3Cohort s Aand
B:  
Cohort C :
TBDbIntratumoral
Via visual 
inspection for 
cutaneous lesions, 
or via ultrasound 
or cross -sectional 
imaging 
(CT/MRI) 
guidance, as 
neededCohort s Aand
B:  
 
 
 
Cohort C :
TBDbExperimental
CT = computed tomography; MTD/MAD = maximum tolerated dose/maximum administered dose; MRI = magnetic 
resonance imaging; QW = onceeach week; Q3W = once every 3weeks; RP2D = Recommended Phase 2 Dose ; TBD = 
to be determined.
aMK-1454 will be administered within 0.5 to 4 hours following completion of pembrolizumab infusion.
bDose frequency will be determined in Arm 3.
Table 9 Injectate Volume for Arm 3 Visceral IT (Part I) and Expansion Cohorts (Part II)
Lesion Size (longest dimension) Injection Volume
>5 cm 3 mL
>2.5 cm to 5 cm 2 mL
≥1.0 cm to 2.5 cm 1 mL
Accelerated Titration Design in Arms 1, 2 , and 3
The initial dose escalation in Arms 1, 2, and 3 will proceed following an ATD . 
Single subjects will be enrolled into sequential dose levels with up to 300% dose increment 
increases from the previous dose, eg Dose ranges are outlined inTable 3, 
Table 4, and Table 5. Up to [ADDRESS_1044894] 7 days apart .The subsequent dose level to be tested in the next 
cohort of subjects will be communicated to the investigator or designee following each dose 
escalation decision meeting. 
The dose for ending ATD will be the dose level atwhich one of the following occurs:
The  cohort is completed.
≥ Grade [ADDRESS_1044895]:   MK-1454 66
Protocol/Amendment No.:   001-08 
MK-1454 -001-08 Final Protocol 27-Jul-2021
ConfidentialElevation of systemic TNF -αin blood above baseline levels by ≥3-fold in a given 
subject during the first cycle of MK -1454 (Arm 1 and 2 only) .
Dose Escalation and Confirmation During Modified Toxicity Probability 
Interval Design
Dose escalation and confirmation of MK -1454 will proceed from ATD phase (Part A ,Part C , 
or PartE) tomTPI [CONTACT_16303] ( Part B ,Part D , or Part F)once at least 1 of the 3 triggering criteria 
is met (see Section 2.1)[31]. Subjects will be enrolled via IWRS according to the dose 
escalation and confirmation guidelines outlined in Section 5.2. The target DLT rate is30%, 
with a tolerance interval of 3%. The specific dose levels for the ATD and mTPI [INVESTIGATOR_762548]. For the mTPI [CONTACT_16303], dose 
escalation will proceed at dose increments between 30% and 100% of theprior dose level . 
The dose to be tested in the next cohort of subjects will be communicated to the investigator
or designee following each dose escalation decision meeting . Depending on the accrual rate, 
there may be a minimum of [ADDRESS_1044896] 7days apart . Based on the occurrence of DLTs, up to 14 subjects 
may enroll per dose level . Enrollment will be monitored through IWRS . 
Dose escalation based on the mTPI [INVESTIGATOR_762549] 10,which
provides the rules for determining the next dose [32] [33] . InTable 10, the columns show the
number of patients treated at adose level, and the rows correspond to thenumber ofsubjects 
who experienc e aDLT . The entries of the table are dose-finding decisions: E, S, D, and DU,
which represent the following parameters: Escalating the dose, Staying at the same dose, 
De-escalating the dose, and excluding the Dose from thetrial due toUnacceptable toxicity . 
For example, if [ADDRESS_1044897] 3 subjects of a given dose level develops a DLT, then the current dose level cohort 
will be expanded by [CONTACT_762601] 10. The same principle will be 
applied whether 3, 4, 5 or 6 subjects are initially enrolled in the same dose cohort according 
to Table 10.
The number of subjects who are enrolled at each dose is capped to minimize the exposure to 
a dose that may be unacceptably toxic (denoted as DU inTable 10). To find out how many 
more subjects may be enrolled, count steps in a diagonal direction (down and to the right) 
from the cell (3 subjects, 1 DLT) to the first cell marked DU. For example, if 1/3of the 
subjects have experienced a DLT at a given dose level, then no more than an additional 
3subjects should be enrolled at this dose level until additional DLT data areavailable . This 
is because this dose level would be considered unacceptably toxic if all 3 of the additional 
subjects experience a DLT (ie, 4/6 subjects with DLT in Table 10). 
De-escalation (D) or excluding the dose from the trial due to unacceptable toxicity (DU) at 
the starting dose level ofArm 1 of the study indicates stoppi[INVESTIGATOR_84953]. Escalation (E) at 
the highest dose level indicates staying at that level . During dose escalation and 
confirmation, it may be acceptable to de-escalate to an intermediate, not predefined and not 
087V73
Product:   MK-1454 67
Protocol/Amendment No.:   001-[ADDRESS_1044898] been enrolled at any of the tested doses (including intermediate doses ), dose 
finding will stop if the mTPI [INVESTIGATOR_762550] “S” for staying at current dose. Otherwise, up to 
[ADDRESS_1044899] s may be enrolled at a lower dose if “D” or “DU ” is indicated, or at a higher 
dose if “E” is indicated . Establishment of the MTD/MAD for the combination of MK-[ADDRESS_1044900] half of the 14subjects in the MTD/MAD 
cohort have had no prior exposure to MK-1454 (ie, non-crossover subjects) . Priority for 
enrollment in the MTD/MAD confirmation cohort of Arm [ADDRESS_1044901] 
2 dose levels behind the MK-1454 monotherapy dose, and will not exceed the MTD for 
monotherapy . IfanMTD for monotherapy (Arm 1) is established, then the dose of MK-[ADDRESS_1044902]:   MK-1454 68
Protocol/Amendment No.:   001-[ADDRESS_1044903] 1 DLT 3 4 5 6 7 8 9 10 11 12 13 14
0 E E E E E E E E E E E E
1 S S S E E E E E E E E E
2 D S S S S S S S E E E E
3 DU DU D S S S S S S S S S
4 DU DU DU D D S S S S S S
5 DU DU DU DU DU D S S S S
6 DU DU DU DU DU DU D S S
7 DU DU DU DU DU DU DU D
8 DU DU DU DU DU DU DU
9 DU DU DU DU DU DU
10 DU DU DU DU DU
11 DU DU DU DU
12 DU DU DU
13 DU DU
14 DU
D = De -escalate to the next lower dose
DU = The current dose is unacceptably toxic
E = Escalate to the next higher dose
S = Stay at the current dose
Target toxicity rate = 30%
Flat non -informative prior Beta (1,1) is used as a prior and ε1=ε2=0.0 3[31] [34]
Definition of Dose -Limiting Toxicity
Dose -limiting toxicities will be defined from toxicities observed during the first cycle of 
treatment (21days) for each dose level . See Section 5.9for rules on replacement of subjects 
in the DLT period.
Subjects who experience a DLT in Cycle [ADDRESS_1044904] is deriving clinical benefit from the study 
treatment (for example a marked reduction in tumor burden), the subject may be allowed to 
continue on the study at a reduced dose level of MK-1454 upon resolution of the DLT to a 
≤Grade 1 AEs or to baseline, and upon discussion with the Sponsor Therefore, flexibility of 
rechallenge of MK -1454 at a lower dose per dose modification guidance below subsequent to 
a DLT may be considered.
The occurrence of any of the following toxicities during Cycle 1, if assessed by [CONTACT_762602], probably related, or possibly related to the drug will be considered 
a DLT , excluding toxicities clearly not related to the drug, such as disease progression, 
environmental factors , unrelated trauma, etc.:
1.Grade 4 nonhematologic toxicity (not laboratory)
087V73
Product:   MK-1454 69
Protocol/Amendment No.:   001-08 
MK-1454 -001-08 Final Protocol 27-Jul-2021
Confidential2.Grade 4 hematologic toxicity lasting ≥7 days, except thrombocytopenia
a.Grade 4 thromboc ytopenia of any duration
b.Grade 3 thrombocytopenia is a DLT if associated with clinically significant 
bleeding
3.Any nonhematologic AE ≥ Grade 3 in severity should be considered a DLT, with the 
following exceptions: Grade 3 fatigue lasting ≤3 days; Grade 3 nausea, vomiting, or 
diarrhea lasting ≤[ADDRESS_1044905] of 
care; Grade [ADDRESS_1044906] of care; Grade 3 fever and Grade 3 flu -like symptoms lasting ≤24 hours with 
negative infectious disease workup (including neg ative blood and urine cultures)
4.Any Grade 3 or Gr ade 4 nonhematologic laboratory abnormality, if
medical intervention is required, or
the abnormality leads to hospi[INVESTIGATOR_059], or
the abnormality persists for >1 week
5.Febrile neutropenia Grade 3 or Grade 4
6.Any drug-related toxicity that cause streatment discontinuation or dose delay >7days 
between consecutive doses during Cycle [ADDRESS_1044907] or ALT lab value that is ≥3× ULN and an elevated total bilirubin 
lab value that is ≥2× ULN and an alkaline phosphatase lab value that is <2× ULN , in 
which no alternative reasons can be found to explain the combination of increased 
AST/ALT and total bilirubin, such as viral Hepatitis A, B or C, preexisting or acute 
liver diseases, or another drug capable of causing the observed injury
9.Any ≥Grade 2 immune -mediated uveitis
10.Grade 5 toxicity
Dose Modification Due to Adverse Events
The Common Terminology Criteria for Adverse Events ,version 4.0 (CTCAE 4.0) must be 
used to grade the severity of AEs. The investigator may attribute each toxicity event to 
MK-[ADDRESS_1044908] a maximum of 2dose modification sofMK-1454 throughout the course of 
the study for toxicities , as described inSection [IP_ADDRESS]. If further toxicity occurs or the 
criteria for resuming treatment are not met, the subject must be discontinued from the agent . 
If a subject experiences several toxicities and there are conflicting recommendations, follow 
the most conservative dose adjustment recommended (dose reduction appropriate to the most 
severe toxicity).
087V73
Product:   MK-1454 70
Protocol/Amendment No.:   001-08 
MK-1454 -001-08 Final Protocol 27-Jul-2021
ConfidentialReduction or holding of one agent and not the other agent is appropriate if, in the opi[INVESTIGATOR_13046] , the toxicit y is clearly related to one of the study drugs . For example, in the 
combination arms(Arm 2and Arm 3), if MK-1454 is held due to an AEattributed to that 
drug, then pembrolizumab may continue to be administered . Appropriate documentation is 
required regarding which drug the investigator is attributing the AEto. If, in the opi[INVESTIGATOR_13046] , the toxicity is related to the combination of 2agents, then both drugs should 
be held according to recommended dose modifications. 
AEs(both nonserious and serious) associated with MK-[ADDRESS_1044909]:   MK-1454 71
Protocol/Amendment No.: 001-08 
MK-1454 -001-08 Final Protocol 27-Jul-2021
ConfidentialTable 11 MK-1454 Dose Modification Guidelines for Drug-r elated A Esin Monotherapy (Arm 1) , Combination Therapy (Arm 2),
and Combination Therapy Visceral IT (Arm 3)
ToxicityHold 
TreatmentCriteria for 
Restarting Treatment Dose/Schedule for Restarting TreatmentCriteria for Discontinuation 
after Consultation with 
Sponsor
Hematological toxicities:
Any Grade 1
hematological toxicityNo N/A N/A N/A
Any Grade 2
hematological toxicityPer medical 
assessment 
of the 
investigatorPermedical assessment 
of the investigatorPer medical assessment of the investigator :  
First, decrease dose by [CONTACT_762603], and upon discussion with 
Sponsor, then consider modification of dosing 
schedule per below:
Arm 1 and Arm 2: 
Cycle 1, 2, and 3 :Reduce dosing schedule to 
Arm 3:
Cycle 1 and 2: Reduce dosing schedule to 
Arm 1 and Arm 2:  
Cycle 4 and beyond :  
Maintain dosing schedule at  unless AE 
persists for 2 additional cycles , then reduce 
dosing schedule to
Arm 3:
Cycle 3 and beyond :  
Maintain dosing schedule at unless AE 
persists for [ADDRESS_1044910]:   MK-1454 72
Protocol/Amendment No.: 001-08 
MK-1454 -001-08 Final Protocol 27-Jul-2021
ConfidentialToxicityHold 
TreatmentCriteria for 
Restarting Treatment Dose/Schedule for Restarting TreatmentCriteria for Discontinuation 
after Consultation with 
Sponsor
Any Grade 3a
hematological toxicityYesaTreatment may be 
restarted when AE 
resolves back to 
baseline or to Grade 1bFirst, decrease dose by [CONTACT_762603], and upon discussion with 
Sponsor, then consider modification of dosing 
schedule per below:
Arm 1 and Arm 2 :
Cycle 1, 2, and 3 :Reduce dosing schedule to 
Arm 3:
Cycle 1 and 2: Reduce dosing schedule to 
Arm 1 and Arm 2 :
Cycle 4 and beyond:   
Maintain dosing schedule at  unless AE 
persists for 2 additional cycles , then reduce 
dosing schedule to 
Arm 3:
Cycle 3 and beyond:
Maintain dosing schedule at unless AE 
persists for [ADDRESS_1044911]:   MK-1454 73
Protocol/Amendment No.: 001-08 
MK-1454 -001-08 Final Protocol 27-Jul-2021
ConfidentialToxicityHold 
TreatmentCriteria for 
Restarting Treatment Dose/Schedule for Restarting TreatmentCriteria for Discontinuation 
after Consultation with 
Sponsor
Any Grade [ADDRESS_1044912], decrease dose by [CONTACT_762604], and upon discussion with 
Sponsor, then consider modification of dosing 
schedule per below:
Arm 1 and Arm 2 :
Cycle 1, 2, and 3 :Reduce dosing schedule to 
Arm 3:
Cycle 1 and 2:Reduce dosing schedule to 
Arm 1 and Arm 2:
Cycle 4 and beyond :  
Maintain dosing schedule at s unless AE 
persists for 2 additional cycles , then reduce 
dosing schedule to 
Arm 3:
Cycle 3and beyond :  
Maintain dosing schedule at  unless AE 
persists for [ADDRESS_1044913] dose of study drug 
administered
Permanent discontinuation 
should be considered for any 
severe or life -threat ening event
Nonhematological toxicities:
Any Grade 1 
nonhematological toxicity 
Grade 2 alopecia
Grade 2 fatigueNo N/A N/A N/A
CCI
CCI
CCI
CCI
CCI
CCI
087V73
Product:   MK-1454 74
Protocol/Amendment No.: 001-08 
MK-1454 -001-08 Final Protocol 27-Jul-2021
ConfidentialToxicityHold 
TreatmentCriteria for 
Restarting Treatment Dose/Schedule for Restarting TreatmentCriteria for Discontinuation 
after Consultation with 
Sponsor
Any Grade 2 
nonhematological toxicity 
except Grade 2 alopecia 
and Grade 2 fatiguePer medical 
assessment 
of the 
investigatorPermedical assessment 
of the investigatorPer medical assessment of the investigator : 
First, d ecrease dose by [CONTACT_762603], and upon discussion with 
Sponsor, then consider modification of dosing 
schedule per below:
Arm 1 and Arm 2:
Cycle 1, 2, and 3 :Reduce dosing schedule to 
Arm 3:
Cycle 1 and2:Reduce dosing schedule to 
Arm 1 and Arm 2:
Cycle 4 and beyond :  
Maintain dosing schedule at  unless AE 
persists for 2 additional cycles , then reduce 
dosing schedule to 
Arm 3:
Cycle 3and beyond :  
Maintain dosing schedule at  unless AE 
persists for [ADDRESS_1044914]:   MK-1454 75
Protocol/Amendment No.: 001-08 
MK-1454 -001-08 Final Protocol 27-Jul-2021
ConfidentialToxicityHold 
TreatmentCriteria for 
Restarting Treatment Dose/Schedule for Restarting TreatmentCriteria for Discontinuation 
after Consultation with 
Sponsor
Any Grade [ADDRESS_1044915], decrease dose by [CONTACT_762604], and upon discussion with 
Sponsor, then consider modification of dosing 
schedule per below:
Arm 1 and Arm 2:
Cycle 1, 2, and 3 :Reduce dosing schedule to 
Arm 3:
Cycle 1 and2:Reduce dosing schedule to 
Arm 1 and Arm 2:
Cycle 4 and beyond :  
Maintain dosing schedule at  unless AE 
persists for 2 additional cycles , then reduce 
dosing schedule to
Arm 3:
Cycle 3and beyond :  
Maintain dosing schedule at  unless
AE persists for [ADDRESS_1044916]:   MK-1454 76
Protocol/Amendment No.: 001-08 
MK-1454 -001-08 Final Protocol 27-Jul-2021
ConfidentialToxicityHold 
TreatmentCriteria for 
Restarting Treatment Dose/Schedule for Restarting TreatmentCriteria for Discontinuation 
after Consultation with 
Sponsor
Any Grade [ADDRESS_1044917], decrease dose by [CONTACT_762605], and upon discussion with 
Sponsor, then consider modification of dosing 
schedule per below:
Arm 1 and Arm 2:
Cycle 1, 2, and 3 :Reduce dosing schedule to 
Arm 3:
Cycle 1 and2:  Reduce dosing schedule to 
Arm 1 and Arm 2:
Cycle 4 and beyond :  
Maintain dosing schedule at unless AE 
persists for 2 additional cycles , then reduce 
dosing schedule to 
Arm 3:
Cycle 3and beyond :  
Maintain dosing schedule at unless AE 
persists for [ADDRESS_1044918] dose of study drug 
admin istered
Permanent discontinuation 
should be considered for any 
severe or life-threatening event
AE = adverse event; Q3W = every 3 weeks;
aFor Lymphoma subjects, the dose modification for Grade [ADDRESS_1044919] the same dose modification guidelines for both solid tumor and lymphoma subjects.
bIn case toxicity does not resolve back to baseline or to Grade 1 within 12 weeks following dose modification, MK-1454 should be considered for 
discontinuat ion after consultation with the Sponsor. 
cAfter any Grade 4 drug -related AE, subjects should not restart study treatment without consultation with the Sponsor . (Toxicity must have resolved to baseline 
or to Grade 1 prior to restarting study treatment) 
CCI
CCI
CCI
CCI
CCI
CCI
CCI
087V73
Product:   MK-1454 77
Protocol/Amendment No.: 001-08 
MK-1454 -001-08 Final Protocol 27-Jul-2021
Confidential
Dose Modification for MK -1454 in Part II -Expansion Cohorts
Guidelines for dose modification and/or treatment discontinuation for treatment -related 
injection site reactions and for CRS AEs are provided in Table 12. 
Table 12 Guidelines for Management of MK-1454 Intratumoral Injection Site Reactions
NCI CTCAE Grade MK-1454 Dose Modification Treatment
Grade 1
Tenderness with or without 
associated symptoms ( eg, warmth, 
erythema, itching)No dose reduction warranted. Observe . Dose to be held per 
medical assessment of the 
investigator. 
Analgesia as needed.
Grade 2
Pain; lipodystrophy; edema; 
phlebitis  Per medical assessment of the 
investigator:
Consider holding dose until 
resolution to Grade 1 or 
baseline.
Consider decreasing dose of IT 
MK-1454 to 450 µg and limit 
injections to a maximum of 
2lesions per study visit. 
If AE persists, discuss 
continuation with Sponsor. Observe. Local care to injection 
site.
Analgesia as nee ded.
Consider injection into a different 
lesion, if available.
Grade 3
Ulceration or necrosis; severe 
tissue damage; operative 
intervention indicatedHold dose until resolution to 
Grade 1 or Baseline. 
Decrease dose of IT MK -1454 
to 450 µg and limit injections to 
a maximum of 2 lesions per 
study visit . 
If AE persists, discuss 
continuation with Sponsor.Wound care with consultation from 
institutional wound care specialist.
Analgesia as needed.
Consider injection into a different 
lesion, if available.
Grade 4
Life-threatening consequences; 
urgent intervention indicatedPermanently discontinue IT 
MK-[ADDRESS_1044920]:   MK-1454 78
Protocol/Amendment No.: 001-08 
MK-1454 -001-08 Final Protocol 27-Jul-2021
Confidential
Immune -Related Events and Dose Modification (Withhold, Treat, Discontinue)
Dose Modification and Toxicity Management for Immune -related AEs Associated with 
Pembrolizumab
AEs associated with pembrolizumab exposure may represent an immune -related response. 
These irAEs may occur shortly after the first dose or several months after the last dose of 
pembrolizumab treatment and may affect more than one body system simultaneously. 
Therefore, early recognition and initiation of treatment is critical to reduce complications. 
Based on existing cli nical study data, most irAEs were reversible and could be managed with 
interruptions of pembrolizumab, administration of corticosteroids and/or other supportive 
care. For suspected irAEs, ensure adequate evaluation to confirm etiology or exclude other 
causes. Additional procedures or tests such as bronchoscopy, endoscopy, skin biopsy may be 
included as part of the evaluation. Based on the severity of irAEs, withhold or permanently 
discontinue pembrolizumab and administer corticosteroids. 
Dose Modification and Toxicity Management Guidelines for irAEs associated with 
pembrolizumab monotherapy, coformulations, or IO combinations are provided in Table 13.
087V73
Product:   MK-1454 79
Protocol/Amendment No.: 001-08 
MK-1454 -001-08 Final Protocol 27-Jul-2021
ConfidentialTable 13 Dose Modification and Toxicity Management Guidelines for Immune -related Adverse Events Associated with 
Pembrolizumab Monotherapy, Coformulations or IO Combinations
General instructions:
1.Severe and life-threatening irAEs should be treated with IV corticosteroids followed by [CONTACT_13215]. Other immunosuppressive treatment should 
begin if the irAEs are not controlled by [CONTACT_13216].
2.Pembrolizumab monotherapy, coformulations or IO combinations must be permanently discontinued if the irAE do es not resolve or the corticosteroid 
dose is not ≤10mg/day within [ADDRESS_1044921] treatment. 
3.The corticosteroid taper should begin when the irAE is ≤ Grade [ADDRESS_1044922] been withheld, treatment may resume after the irAE decreased to ≤Grade 1 
after corticosteroid taper.
irAEsToxicity Grade 
(CTCAEv4.0)Action With 
Pembrolizumab 
Monotherapy, 
Coformulations ,or 
IO CombinationsCorticosteroid and/or Other 
Therapi[INVESTIGATOR_19340] -up
Pneumonitis Grade 2 Withhold Administer corticosteroids 
(initial dose of 1-2 mg/kg 
prednisone or equivalent) 
followed by [CONTACT_13217]Monitor participants for signs and symptoms of 
pneumonitis
Evaluate participants with suspected pneumonitis 
with radiographic imaging and initiate corticosteroid 
treatment
Add prophylactic antibiotics for opportunistic 
infectionsRecurrent Grade 2 
or Grade 3 or 4 Permanently 
discontinue
Diarrhea / Colitis Grade 2 or 3 Withhold Administer corticosteroids 
(initial dose of 1-2 mg/kg 
prednisone or equivalent) 
followed by [CONTACT_13217]Monitor participants for signs and symptoms of 
enterocolitis (ie, diarrhea, abdominal pain, blood or 
mucus in stool with or without fever) and of bowel 
perforation (ie, peritoneal signs and ileus)
Participants with ≥Grade 2 diarrhea suspecting colitis 
should consider GI consultation and performing 
endoscopy to rule out colitis
Participants with diarrhea/colitis should be advised to 
drink liberal quantities of clear fluids. If sufficient 
oral fluid intake is not feasible, fluid and electrolytes 
should be substituted via IV infusion.Recurrent Grade [ADDRESS_1044923]:   MK-1454 80
Protocol/Amendment No.: 001-08 
MK-1454 -001-08 Final Protocol 27-Jul-2021
ConfidentialirAEsToxicity Grade 
(CTCAEv4.0)Action With 
Pembrolizumab 
Monotherapy, 
Coformulations ,or 
IO CombinationsCorticosteroid and/or Other 
Therapi[INVESTIGATOR_19340] -up
AST / ALT 
Elevation or 
Increased 
BilirubinGrade 2 Withhold Administer corticosteroids 
(initial dose of 0.5 -1 mg/kg 
prednisone or equivalent) 
followed by [CONTACT_13217]Monitor with liver function tests (consider weekly or 
more frequently until liver enzyme value returned to 
baseline or is stable)
Grade 3 or 4 Permanently 
discontinueAdminister corticosteroids 
(initial dose of 1-2 mg/kg 
prednisone or equivalent) 
followed by [CONTACT_13217]
T1DM or 
HyperglycemiaNew onset T1DM 
or 
Grade 3 or 4 
hyperglycemia 
associated with 
evidence of β-cell 
failureWithhold aInitiate insulin 
replacement therapy for 
participants with T1DM
Administer anti-
hyperglycemic in 
participants with 
hyperglycemiaMonitor participants for hyperglycemia or other signs 
and symptoms of diabetes
Hypophysitis Grade 2 Withhold Administer corticosteroids 
and initiate hormonal 
replacements as clinically 
indicatedMonitor for signs and symptoms of hypophysitis 
(including hypopi[INVESTIGATOR_44791])
Grade 3 or 4 Withhold or 
permanently 
discontinue a
Hyperthyroidism Grade 2 Continue Treat with non-selective 
beta-blockers (eg, 
propranolol) or 
thionamides as appropriate·Monitor for signs and symptoms of thyroid disorders
Grade [ADDRESS_1044924]:   MK-1454 81
Protocol/Amendment No.: 001-08 
MK-1454 -001-08 Final Protocol 27-Jul-2021
ConfidentialirAEsToxicity Grade 
(CTCAEv4.0)Action With 
Pembrolizumab 
Monotherapy, 
Coformulations ,or 
IO CombinationsCorticosteroid and/or Other 
Therapi[INVESTIGATOR_19340] -up
Hypothyroidism Grade 2 -4 Continue Initiate thyroid 
replacement hormones (eg, 
levothyroxine or 
liothyronine) per standard 
of careMonitor for signs and symptoms of thyroid disorders
Nephritis and 
renal dysfunctionGrade 2 Withhold Administer corticosteroids 
(prednisone 1-2 mg/kg or 
equivalent) followed by 
[CONTACT_13217]Monitor changes of renal function
Grade 3 or 4 Permanently 
discontinue
Myocarditis Grade 1 Withhold Based on severity of AE 
administer corticosteroidsEnsure adequate evaluation to confirm etiology 
and/or exclude other causes
Grade 2, 3,or 4 Permanently 
discontinue
All Other irAEs Persistent Grade 2 Withhold Based on severity of AE 
administer corticosteroidsEnsure adequate evaluation to confirm etiology or 
exclude other causes
Grade 3 Withhold or 
discontinue b
Recurrent Grade 3 
or Grade 4 Permanently 
discontinue
AE(s)=adverse event(s); ALT= alanine aminotransferase; AST=aspartate aminotransferase; CTCAE=Common Terminology Criteria for Adverse Events; 
DRESS=Drug Rash with Eosinophilia and Systemic Symptom; GI=gastrointestinal; IO=immuno -oncology; ir=immune related; IV=intravenous; 
SJS=Stevens -Johnson Syndrome; T1DM=type 1 diabetes mellitus; TEN=Toxic Epi[INVESTIGATOR_19342]; ULN=upper limit of normal.
Note: Non -irAE will be ma naged as appropriate, following clinical practice recommendations.
aThe decision to withhold or permanently discontinue pembrolizumab monotherapy, coformulations or IO combinations is at the discretion of the 
investigator or treating physician. If con trol achieved or ≤ Grade 2, pembrolizumab monotherapy, coformulations or IO combinations may be resumed.
bEvents that require discontinuation include, but are not limited to: Guillain -Barre Syndrome, encephalitis, myelitis, DRESS, SJS, TEN and other clinically 
important irAEs (eg, vasculitis and sclerosing cholangitis).
087V73
Product:   MK-1454 82
Protocol/Amendment No.: 001-08 
MK-1454 -001-08 Final Protocol 27-Jul-2021
ConfidentialDose modification and toxicity management of infusion -reactions related to 
pembrolizumab
Pembrolizumab may cause severe or life-threatening infusion -reactions including severe 
hypersensitivity or anaphylaxis. Signs and symptoms usually develop during or shortly after 
drug infusion and generally resolve completely within 24 hours of completion of infusion. 
Dose modification and toxicity management guidelines on pembrolizumab associated 
infusion reaction are provided in Table 14. 
Table 14 Pembrolizumab Infu sion Reaction Dose Modification and Treatment Guidelines
NCI CTCAE Grade TreatmentPremedication at 
Subsequent Dosing
Grade 1
Mild reaction; infusion 
interruption not indicated; 
intervention not indicatedIncrease monitoring of vital signs as medically 
indicated until the subject is deemed medically 
stable in the opi[INVESTIGATOR_871].None
Grade 2
Requires therapy or 
infusion interruption but 
responds promptly to 
symptomatic treatment ( eg, 
antihistamines, NSAIDs, 
narcotics, IV fluids); 
prophylactic medications 
indicated for ≤24 hrs.Stop Infusion.
Additional appropriate medical therapy may 
include but is not limited to:
IV fluids
Antihistamines
NSAIDs
Acetaminophen
Narcotics
Increase monit oring of vital signs as medically 
indicated until the subject is deemed medically 
stable in the opi[INVESTIGATOR_871].
If symptoms resolve within 1 hour of stoppi[INVESTIGATOR_108607], the infusion may be restarted at 
50% of the original infusion rate (e. g. from 100 
mL/hr to 50 mL/hr) . Otherwise dosing will be 
held until symptoms resolve and the subject 
should be premedicated for the next scheduled 
dose.
Subjects who develop Grade [ADDRESS_1044925] may be 
premedicated 1.5h (± 30 
minutes) prior to infusion of 
pembrolizumab with:
Diphenhydramine 50 mg po 
(or equivalent dose of 
antihistamine).
Acetaminophen 500 -1000 
mg po (or equivalent dose 
of analgesic).
087V73
Product:   MK-1454 83
Protocol/Amendment No.: 001-08 
MK-1454 -001-08 Final Protocol 27-Jul-2021
ConfidentialNCI CTCAE Grade TreatmentPremedication at 
Subsequent Dosing
Grades 3 or 4
Grade 3:
Prolonged ( ie, not rapi[INVESTIGATOR_38194]/or brief 
interruption of infusion); 
recurrence of symptoms 
following initial 
improvement; 
hospi[INVESTIGATOR_12197] 
(eg, renal impairment, 
pulmonary infiltrates)
Grade 4:
Life-threatening; pressor or 
ventilatory support 
indicatedStop Infusion.
Additional appropriate medical therapy may 
include but is not limited to:
Epi[INVESTIGATOR_238]**
IV fluids
Antihistamines
NSAIDs
Acetaminophen
Narcotics
Oxygen
Pressors
Corticosteroids
Increase monitoring of vital signs as medically 
indicated until the subject is deemed medically 
stable in the opi[INVESTIGATOR_871].
Hospi[INVESTIGATOR_13021].
**In cases of anaphylaxis, epi[INVESTIGATOR_159822].
Subject is permanently discontinued from 
further study drug treatment.No subsequent dosing
Appropriate resuscitation equipment should be available at the bedside and a physician readily available during the 
period of drug administration.
For further information, please refer to the Common Terminology Criteria for Adverse Events v4.0 (CTCAE) at 
http://ctep.cancer.gov
Other allowed dose interruption for pembrolizumab 
Pembrolizumab may be interrupted for situations other than treatment -related AEs such as 
medical orsurgical events and/or unforeseen circumstances not related to study therapy. 
However, study therapy is to be restarted within [ADDRESS_1044926]’ s study record.
087V73
Product:   MK-1454 84
Protocol/Amendment No.: 001-08 
MK-1454 -001-08 Final Protocol 27-Jul-2021
Confidential
Treatment for Cytokine Release Syndrome
Table 15 Cytokine Release Syndrome Treatment Guidelines
NCI CTCAE Grade TreatmentPremedication at
subsequent dosing
Grade 1
Mild reaction: Therapy i nterruption 
not indicated . Intervention not 
indicated.Increase monitoring of vital signs 
and oxygen saturation, as 
medically indicated, until the 
subject is deemed medically stable 
in the opi[INVESTIGATOR_113747] 2
Therapy interruption indicated but 
responds promptly to symptomatic 
treatment ( eg,NSAIDS, narcotics, 
IV fluids) . Prophylactic 
medications indicated for ≤[ADDRESS_1044927] is deemed medically stable 
in the opi[INVESTIGATOR_103633] r
Additional appropriate medical 
therapy may include, but is not 
limited to:
IV fluids
NSAIDS
Acetaminophen
Narcotics
Oxygen
Perform fever work upto exclude 
infectious etiologies; treat 
neutropenia if presentSubject may be premedicated 
1.5 hours (± 30minutes) prior to 
MK-1454 administration with 
acetaminophen 500 to 1000 mg 
po (or equivalent dose of 
antipyretic)
Grade 3
Prolonged ( eg,not rapid ly 
responsive to symptomatic 
medication); recurrence of 
symptoms following initial 
improvement; hospi[INVESTIGATOR_31563] ( eg,
renal impairment, pulmonary 
infiltrates)Additional appropriate medical 
therapy may include, but is not 
limited to:
IV fluids
NSAIDS
Acetaminophen
Narcotics
Oxygen
Pressors
Corticosteroids
Anti-IL6 ( egtocilizumab)
Empi[INVESTIGATOR_762551] ≥Grade 3 CRS need 
to be monitored very closely, likely 
in an intensive care settingFor Grade 3 CRS, discuss with 
Sponsor prior to restart of MK -
1454 treatment. Upon approval 
by [CONTACT_2728], MK -1454 may be 
restarted at a reduced dose when 
AE resolves back to baseline or 
to Grade 1 (see Table 11).
Subject may be premedicated 
1.5 hours
(± 30 minutes) prior to MK -
1454 administration with 
acetaminophen 500 to 1000 mg 
po (or equivalent dose of 
antipyretic)
087V73
Product:   MK-1454 85
Protocol/Amendment No.: 001-08 
MK-1454 -001-08 Final Protocol 27-Jul-2021
ConfidentialNCI CTCAE Grade TreatmentPremedication at
subsequent dosing
Grade 4
Life-threatening consequences; 
pressor or ventilatory support 
indicatedAdditional appropriate medical 
therapy may include, but is not 
limited to:
IV fluids
NSAIDS
Acetaminophen
Narcotics
Oxygen
Pressors
Corticosteroids
Anti-IL6 ( egtocilizumab)
Empi[INVESTIGATOR_762551] ≥Grade 3 CRS need 
to be monitored very closely, likely 
in an intensive care settingPermanently discontinue MK -
1454 in subjects who develop 
Grade 4 CRS  
Treatment by [CONTACT_762606]/or radiation therapy of isolated or symptomatic progressing 
lesions in the setting of improving baseline disease may be permitted for palliative or 
potentially curative management following completion ofCycle 2. Subsequently, all 
interventions ,including continuation of study drug, should be discussed with the Sponsor 
Medical Monitor or designee.
Intra subject Dose Escalation
Intra subject dose escalation will be allowed for subject sin Arm 1 (Parts A and B) 
monotherapy at the discretion of the investigator provided that the subject remains on study 
after receiving 3cycles of treatment with MK-1454 monotherapy without a ≥Grade [ADDRESS_1044928] dose escalation one time while enrolled in this 
treatment arm . 
Subjects enrolled in the ATD phase of Arm 3 may undergo dose escalat ionone time after 
receiving 3 cycles of treatment without a ≥Grade [ADDRESS_1044929] dose level (and frequency for Arm 3) that has been 
cleared by [CONTACT_762570] . This dose will be communicated to the site via written consent 
from the Sponsor and administered by [CONTACT_10966]. De-escalation from this dose will be based on 
occurrence of DLTs per dose escalation guidelines for either the ATD or the mTPI [CONTACT_16303] (see 
Section 5.2.1 ), as appropriate . Dose modification will be based on CTC AEs per Dose 
Modification Guidelines (see Section 5.2.3 ).
087V73
Product:   MK-1454 86
Protocol/Amendment No.: 001-[ADDRESS_1044930] may undergo up to 35 cycles (approximately 2 years) of MK-1454 treatment in 
both the monotherapy arm (Arm 1) and the combination therapy arms (Arm 2 and Arm 3 ),as 
well as the Expansion Cohorts (Cohort A to C).
After C1D1, trial treatment may be administered up to 3 days before, or up to 3 days after the 
scheduled treatment day within each cycle . Dosing interruptions are permitted in the case of 
medical/surgical events or logistical reasons that are not related to study therapy (eg, elective 
surgery, unrelated medical events, patient vacation, and/or holid ays). Subjects should be 
placed back on study therapy within [ADDRESS_1044931]’s study record.
Timing of MK-[ADDRESS_1044932]:   MK-1454 87
Protocol/Amendment No.: 001-08 
MK-1454 -001-08 Final Protocol 27-Jul-2021
Confidential
Trial Blinding 
This is an open -label trial; therefore, the Sponsor, investigator and subject will know the 
treatment administered.
Replacement of Subjects During the DLT Evaluation Period
Subjects discontinuing withi n [ADDRESS_1044933] dose should not be replaced . See Section 8.5.1 for description 
of safety analysis population .
Randomization or Treatment Allocation
Treatment allocation in the dose escalation and confirmation phase (Arms 1, 2, and 3) will be 
accomplished by [CONTACT_148195] . Enrollment into Arm 2 (MK-1454 with
pembrolizumab combination therapy) will begin once :
1.At least 1 of the 3 triggering criteria are met in Arm 1 (MK-1454 monotherapy)
2.Adose escalation decision has been made
3.[ADDRESS_1044934] assignment between 
Arm 1 and Arm 2,starting with Arm 1, will be via IWRS . For example, once the dose 
cohort of Arm 1 (MK- 1454 monotherapy) and the dose cohort of Arm 2 (MK- 1454 
combination therapy with pembrolizumab) are open for enrollment, then the first subject will 
be allocated to Arm 1, the second subject will be allocated to Arm 2, the third subject will be 
allocated to Arm 1, etc. Subjects will be allocated to Arm 3 by [CONTACT_762607].
In the expansion phase, eligible subjects will be allocated to an appropriate open treatment 
arm by [CONTACT_10966] . For Cohorts A and B, 30 subjects will be allocated to each cohort. For 
Cohort C, 60 subjects will be allocated to treatment in total . There will be a cap at 15 subjects 
each for non MSI -H CRC andpancreatic cancer .
Stratification
No stratification based on age, sex, or other characteristics will be used in this trial .
Concomitant Medications /Vaccinations (Allowed and Prohibited)
Medications or vaccinations specifically prohibited in the exclusion criteria are not allowed 
during the ongoing trial.  If there is a clinical indication for any medication or vaccination 
specifically prohibited during the trial, discontinuation from trial therapy or vaccination may 
be required.  The investigator should discuss any questions regarding this with the Sponsor 
Clinical Director.  The final decision on any supportive therapy or vaccination rests with the 
investigator and/or the subject's primary physician.  However, the decision to continue the 
CCI
CCI
087V73
Product:   MK-1454 88
Protocol/Amendment No.: 001-[ADDRESS_1044935]’s welfare may be 
administered at the discretion of the investigator and in keepi[INVESTIGATOR_240290] . All concomitant medication will be recorded on the CRF including 
all prescription, OTC, herbal supplements, and IV medications and IV fluids . If changes 
occur during the trial period, then documentation of drug dosage, frequency, route, and date 
will also be included in the CRF.
All concomitant medications received within [ADDRESS_1044936] dose of study 
intervention are to be recorded ,as defined in Sectio n 7.2.
Subjects are prohibited from receiving the following therapi[INVESTIGATOR_315235], and 
Treatment Phases of this trial:
Immunotherapy not specified in this protocol.
Antineoplastic systemic chemotherapy or biological therapy not specified in this 
protocol .
Investigational agents not specified in this protocol.
Radiation therapy; radiotherapy for symptom management is allowed beyond Cycle 2
upon approval by [CONTACT_748929] .
Live vaccines within [ADDRESS_1044937] dose of trial treatment and while 
participating in the trial . Examples of live vaccines include, but are not limited to, the 
following: measles, mumps, rubella, chickenpox, yellow fever, rabies, Bacillus
Chalmette Guerin , and typhoid vaccine . Seasonal influenza vaccines for injection are 
generally killed virus vaccin es and are allowed . However, intranasal influenza 
vaccines (eg ,FluMist ®) are live attenuated vaccines, and are not allowed.
Systemic glucocorticoids for any purpose other than to modulate symptoms from an 
AE of suspected immunologic etiology. The use of physiologic doses of 
corticosteroids may be approved after consultation with the Sponsor.
Subject s who, in the assessment by [CONTACT_093], require the use of any of the 
aforementioned treatments for clinical management should be removed from the study. 
Subject s may receive other medications that the investigator deems to be medically 
necessary.
The Exclusion Criteria describe other medications which are prohibited in this trial.
There are no prohibited therapi[INVESTIGATOR_272460] -up visits.
087V73
Product:   MK-1454 89
Protocol/Amendment No.: 001-08 
MK-1454 -001-08 Final Protocol 27-Jul-2021
Confidential
Rescue Medica tions & Supportive Care
Supportive Care Guidelines
Subjects should receive appropriate supportive care measures as deemed necessary by [CONTACT_78017] . Suggested supportive care measures for the management of AEs with 
potential immunologic etiology are outlined along with the dose modification guidelines in 
Section 5.2. 3.2 (and Table 14). Where appropriate, these guidelines include the use of oral or 
IV treatment with corticosteroids, as well as additional anti -inflammatory agents if symptoms 
do not improve with administrati on of corticosteroids . Note that several courses of steroid 
tapering may be necessary as symptoms may worsen when the steroid dose is decreased . For 
each disorder, attempts should be made to rule out other causes such as metastatic disease or 
bacterial or viral infection, which might require additional supportive care. The treatment 
guidelines are intended to be applied when the investigator determines the events to be 
related to pembrolizumab. 
Note: If after the evaluation of the event, it is determined n ot to be related to pembrolizumab, 
the investigator does not need to follow the treatment guidance . Refer to Table 11for 
treatment guidelines for AEs that are related to MK-1454 treatment and to Table 15for 
guidelines regarding dose modification and supportive care for CRS . 
It may be necessary to perform conditional procedures such as bronchoscopy, endoscopy, or 
skin photography as part of evaluation of the event. 
Diet/Activity/Other Considerations
Diet
Subject s should maintain a normal diet unless modifications are required to manage AEs 
such as diarrhea, nausea, or vomiting.
Contraception
MK-[ADDRESS_1044938] should not be entered 
into the study.
Definitions
Women of Childbearing Potential (WOCBP)
A woman is considered fertile following menarche and until becoming postmenopausal 
unless permanently sterile (see below):
087V73
Product:   MK-1454 90
Protocol/Amendment No.: 001-08 
MK-1454 -001-08 Final Protocol 27-Jul-2021
ConfidentialIf fertility is unclear (eg, amenorrhea in adolescents or athletes) an d a menstrual cycle cannot 
be confirmed before first dose of study intervention, additional evaluation should be 
considered.
Women in the following categories are not considered WOCBP:
•Premenarchal
•Premenopausal female with 1 of the following:
-Docume nted hysterectomy
-Documented bilateral salpi[INVESTIGATOR_1656]
-Documented bilateral oophorectomy
For individuals with permanent infertility due to an alternate medical cause other than the 
above (eg, Mullerian agenesis, androgen insensitivity), investigator discretion should be 
applied to determining study entry.
Note: Documentation can come from the site personnel’s review of the subject ’s medical 
records, medical examination, or medical history interview.
•Postmenopausal female
-A postmenopausal state is defined as no menses for 12 months without an alternative 
medical cause.
◦A high FSH level in the postmenopausal range may be used to confirm a 
postmenopausal state in women not using hormonal contraception or HRT. 
However, in the absence of 12months of amenorrhea, confirmation with 2FSH 
measurements in the postmenopausal range is required.
-Females on HRT and whose menopausal status is in doubt will be required to use one 
of the nonhormonal highly effective contraception methods if they wish to continu e 
their HRT during the study. Otherwise, they must discontinue HRT to allow 
confirmation of postmenopausal status before study enrollment.
Male subjects receiving MK-[ADDRESS_1044939] sperm 
samples frozen and stored before tre atment.
Accept able Contraception Methods
Acceptable methods of contraception are as followsa:
Single method (one of the following is acceptable):
Progestogen -only subdermal contraceptive implantb,c
087V73
Product:   MK-1454 91
Protocol/Amendment No.: 001-08 
MK-1454 -001-08 Final Protocol 27-Jul-2021
ConfidentialIUSc,d
Nonhormonal IUD
Bilateral tubal occlusion
Azoospermic partner (vasectomized or secondary to medical cause)
This is a highly effective contraception method provided that the partner is the sole 
male sexual partner of the WOCBP and the absence of sperm has been confirmed. If 
not, an additional highl y effective method of contraception should be used. A 
spermatogenesis cycle is approximately 90 days.
Note: Documentation of azoospermia can come from the site personnel’s review of 
the subject ’s medical records, medical examination, or medical history int erview.
Sexual Abstinence
Sexual abstinence is considered a highly effective method only if defined as 
refraining from heterosexual intercourse during the entire period of risk associated 
with the study intervention. The reliability of sexual abstinence needs to be evaluated 
in relation to the duration of the study and the preferred and usual lifestyle of the 
subject .
a Contraceptive use by [CONTACT_762608] s of clinical studies . Where local regulations require monthly pregnancy 
testing, see Appendix 12.5.
b  If locally required, in accordance with CTFG guidelines, acceptable contraceptive implants are limited to 
those that inhibit ovulation.
c  Male condoms must be used in addition to hormonal contraception.
d  IUS is a progestin releasing IUD.
Note: The following are not acceptable methods of contraception:
-  Periodic abstinence (calendar, symptothermal, postovulation methods), withdrawal (coitus interruptus), 
spermicides only, and LAM.
-  Male condom with cap, diaphragm, or sponge with spermicide.
-  Male and female condom should not be used together (due to risk of failure with friction).
‡If a contraceptive method listed above is restricted by [CONTACT_427]/guidelines, then 
it does not qualify as an acceptable method of contraception for subjects participating at 
sites in this country/region.
Please see Appendix 12.[ADDRESS_1044940]:   MK-1454 92
Protocol/Amendment No.: 001-[ADDRESS_1044941]’s status until the pregnancy has 
been compl eted or terminated . The outcome of the pregnancy will be reported to the Sponsor
without delay and within 24 hours if the outcome is a serious adverse experience (eg, death, 
abortion, congenital anomaly, or other disabling or life-threatening complication to the 
mother or newborn) . The study investigator will make every effort to obtain permission to 
follow the outcome of the pregnancy and report the condition of the fetus or newborn to the 
Sponsor . If a male subject impregnates his female partner the study personnel at the site must 
be informed immediately and the pregnancy reported to the Sponsor and followed as 
described above and in Section 7.2.2.
Use in Nursing Women
It is unknown whether MK-[ADDRESS_1044942] Withdrawal/Discontinuation Criteria
Discontinuation of Treatment
Disconti nuation of treatment does not represent withdrawal from the trial.
As certain data on clinical events beyond treatment discontinuation may be important to the 
study, they must be collected through the subject’s last scheduled follow -up, even if the 
subject has discontinued treatment.  Therefore, all subjects who discontinue trial treatment 
prior to completion of the treatment will still continue to participate in the trial as specified in 
Section 6.0 -Schedule of Activities and Section 7.1.5. 4 –Discontinu ed Subjects Continuing 
to be Monitored in the Trial.
Subjects may discontinue treatment at any time for any reason or be dropped from treatment 
at the discretion of the investigator should any untoward effect occur.  In addition, a subject 
may be discontin ued from treatment by [CONTACT_26354], the trial plan is violated, or for administrative and/or other safety reasons.  
Specific details regarding procedures to be performed at treatment discontinuation are 
provided in Section 7.1.4 –Other Procedures.
A subject must be discontinued from treatment but continue to be monitored in the trial for 
any of the following reasons:
○The subject or subject’s legally acceptable representative requests to discontinue 
treatment .
oConfirmed radiographic disease progression outlined in Section [IP_ADDRESS] (exception if the 
Sponsor approves treatment continuation).
087V73
Product:   MK-1454 93
Protocol/Amendment No.: 001-[ADDRESS_1044943] interrupts trial medication administration for more than 12 consecutive 
weeks .
oAny progression or recurrence of any malignancy, or any occurrence of another 
malignancy that requires active treatment .
oIntercurrent illness other than another malignancy as noted above that prevents further 
administration of treatment .
oRecurrent Grade [ADDRESS_1044944] has a medical condition or personal circumstance which, in the opi[INVESTIGATOR_26334]/or Sponsor , placed the subject at unnecessary risk from continued 
administration of study drug .
oThe subject has a confirmed positive serum pregnancy test.
oSide effects and/or concomitant medications required for treatment of HIV and/or its 
complications that are incompatible with continued study treatment (exceptions are 
permissible but should be discussed with the Sponsor).
For subjects who are discontinued from treatment but continue to be monitored in the trial, 
see Section 6.0–Schedule of Activities and Section 7.1.5. 4–Discontinued Subjects
Continuing to be Monitored in the Trial for those procedures to be completed at each 
specified visit.
For subjects who progress on monotherapy MK -[ADDRESS_1044945] meet sthe crossover eligibility criteria stated in Section 5.1.4 and 
Section 5.1.5. Subjects who cross over from Arm 1 into Arm 2 will enter Arm 2 at the start of 
Arm 2 (at screening) .
Withdrawal From the Trial
If a subject fails to return for scheduled visits and/o r if the study site is unable to contact [CONTACT_762609] (ie, is lost to follow -up), the procedures to be performed are 
outlined in Section [IP_ADDRESS].
If a subject decides not to continue receiving study medication, the subject is to be 
encouraged to continue visits in the study for follow -up, imaging, and vital status assessment.
Participants Who Withdraw Consent During the Study
If the participant or participant’s legally acceptable representative withdraws consent, the 
participant must be withdrawn from the study.
Section 7.4.[ADDRESS_1044946]:   MK-1454 94
Protocol/Amendment No.: 001-08 
MK-1454 -001-08 Final Protocol 27-Jul-2021
ConfidentialAny AEs that are present at the time of withdrawal should be followed in accordance with 
the safety requirements outlined in Section [IP_ADDRESS] and Section 7.2.
Subject Replacement Strategy
A subject who discontinues from the trial will not be replaced except as described in 
Section 5.2.7Replacement of Subjects During the DLT Evaluation Period . 
Beginning and End of the Trial
The overall study begins when the first subject (or their legally acceptable representative) 
provides written documented informed consent. The overall study ends when the last subject 
completes the last study -related contact, withdraws consent, or is lost to follow -up (ie, the 
subject is unable to be contact[CONTACT_19379]) .
Clinical Criteria for Early Trial Termination
The clinical trial may be terminated early if the extent (incidence and/or severity) of 
emerging effects/clinical endpoints is such that the risk/benefit ratio to the trial population as 
a whole is unacceptable.  In addition, further recruitment in the trial or at (a) particular trial 
site(s) may be stopped due to insufficient compliance with the protocol, GCP and/or other 
applicable regulatory requirements, procedure -related problems or the number of 
discontinuations for administrative reasons is too high.
087V73
Product:   MK-1454 95
Protocol/Amendment No.: 001-08 
MK-1454 -001-08 Final Protocol 27-Jul-2021
Confidential6.0SCHEDULE OF ACTIVITIES
Schedule of Activities for PartI -Dose Escalation and Confirmation (Arms 1, 2, and 3)
Schedule of Activities for Initial Screening for Arm s1 Through 3and for Crossover Into Arm [ADDRESS_1044947] be obtained prior to performing any 
protocol -specific procedures . An ICFsigned >28 days prior to C1D1 does not 
need to be replaced.
Informed Consent for FBR (Optional) X
Subject Identification Card X
Inclusion/Exclusion Criteria X X
Demographics and Medical History X X
For Crossover into Arm 2, update only . Assessments obtained during Arm [ADDRESS_1044948] for Arm 2if they were obtained within 28 
days of treatment initiation in toArm 2.Prior Medication and Concomitant 
Medication ReviewX X
Disease Details and Prior Oncology 
Treatment History X X
HPV status XHPV testing results by [CONTACT_762610] (eg, p16 IHC; multiplex NASBA or other PCR -based assays) should be 
recorded if available, as determined per institutional standard.
Tumor genetic alteration(s)XTumor genetic alteration(s) ,if available ,as determined by [CONTACT_762611]
(eg, BRCA1, MSI -H).
Efficacy Procedures See also: Imaging Manual
Tumor Imaging , RECIST v.1.1,
irRECIST , and/or itRECIST Response 
Assessment X X Baseline tumor imaging (CT, PET/CT, or MRI , as indicated for tumor type ) 
and/or medical photography of cutaneous lesions should be performed within 28 
days of enrollment . Medical photography may be performed more often as 
medically warranted.Medical Photography (Cutaneous Lesions) X X
IWG Revised Response Criteria for 
Lymphoma X X
CTCL Response Assessment X XThe pretreatment evaluation and scoring of response parameters should be done 
at baseline ( screening ).
087V73
Product:   MK-1454 96
Protocol/Amendment No.: 001-08 
MK-1454 -001-08 Final Protocol 27-Jul-2021
ConfidentialScheduled DayInitial 
ScreeningCrossover 
ScreeningNotes
Screening and Day 1 cannot be on the same day.
-28 to -1 -28 to -1
Bone Marrow Biopsy/ Aspi[INVESTIGATOR_337] 
(Lymphoma Subject sOnly [excluding 
CTCL subjects] ) X XMust be performed if not previously done within [ADDRESS_1044949] crosses over into Arm 2 if bone marrow 
biopsy results were negative at Screening in Arm 1 . 
Safety Assessments and Procedures See Procedures Manual for collection and management of tissue samples
Full Physical Examination X X
Height X
Weight X X
12-lead Electrocardiogram ( ECG ) X XECG will be obtained within 7 days prior to MK-1454 IT administration on 
C1D1.
Vital Signs X X Temperature, pulse, respi[INVESTIGATOR_697], blood pressure, and oxygen (O 2) saturation
ECOG Performance Status X X Additional ECOG assessments may be performed as clinically indicated .
Tumor Markers X X
Perform all screening clinical laboratory tests within [ADDRESS_1044950] is 
performed within the specified time frame . Specific tumor markers (eg, CEA, 
CA-125, CA -19-9, and alpha fetoprotein )areto be obtained as clinically 
indicated.CBC with Differential X X
PT/INR and PTT or aPTT X X
Chemistry Panel X X
LDH, GGT X X
Lipase and Amylase X X
Urinalysis X X
Thyroid Function (TSH ,T3, FT3, T4,FT4) X X
Pregnancy Test for WOCBP –Urine or 
Serum hCGX XPerform within 7days prior to treatment initiation .If a urine pregnancy test 
cannot be confirmed as negative, a serum pregnancy test is required . Perform 
pregnancy testing per local regulations.
Hepatitis B and C XInclude HCV antibody or HCV RNA (qualitative) and HBsAg . HIV by [CONTACT_762612], unless testing is required by [CONTACT_427].
Laboratory Procedures/Assessments: Analysis performed by
[CONTACT_762613].
Serum for Cytokine Panel and C -Reactive 
Protein (CRP) for MK-1454
Pharmacodynamics X XBlood samples for serum cytokine panels and CRP taken at Screening should be 
obtained either both in the morning (8 AM to 12 PM) or both in the afternoon 
(1PM to 5 PM) . Collect with the samples for MK-[ADDRESS_1044951]:   MK-1454 97
Protocol/Amendment No.: 001-08 
MK-1454 -001-08 Final Protocol 27-Jul-2021
ConfidentialScheduled DayInitial 
ScreeningCrossover 
ScreeningNotes
Screening and Day 1 cannot be on the same day.
-28 to -1 -28 to -1
aPTT = a ctivated partial thromboplastin time ;CBC = complete blood count; hCG = Beta-human chorionic gonadotropin ;CRP = C -reactive protein; CT = computed 
tomography; CTCL = cutaneous T -cell lymphoma; ECOG = Eastern Cooperative Oncology Group; FBR = future biomedical research; GGT = gamma glutamyl transferase; 
HIV = human immunodeficiency virus; HNSCC = Head and Neck S quamous Cell Carcinoma ;HPV = human papi[INVESTIGATOR_28597] ;INR = international normalized ratio; IT = 
intratumoral; IWG = International Working Group; LDH = lactate dehydrogenase; MRI = magnetic resonance imaging; NASBA = nucleic acid sequence -based amplification ; 
PET = positron emission tomography; PT = prothrombin time; PTT = partial thromboplastin time; RNA = ribonucleic acid; RECIST v1.1 = Response Evaluation Criteria In 
Solid Tumors, version 1.1; irRECIST = immune -related RECIST; (F)T3 = (free) t riiodothyronine ;(F)T4 = (free) thyroxine ;TSH = thyroid -stimulating hormone; WOCBP = 
women of child bearing potential.
a.) All subjects will be required to provide a sample biopsy of the tumor to be injected with MK-1454 and a sample biopsy from a distant, discrete noninjected site (at least 
2biopsies at each site) at Screening, unless deemed medically unsafe by [CONTACT_093] . This predose tumor biopsy at Screening will be performed on both the tumor lesion 
that is intended for treatment with IT administration of MK -1454, as well as on the distant lesion that is not intended for IT administr ation with MK -1454 . For the tumor lesion 
intended for treatment with IT administration of MK-1454, the sample will be obtained by [CONTACT_762614], or ultrasound guided biopsy for 
subcutaneous lesions, or cross -sectional image -guided biopsy for visceral and deeper tumor lesions . For distant, discrete tumor lesions that are not intended for IT 
administration with MK -1454, the sample biopsy will be obtained by [CONTACT_762615], ultrasound guided biopsy for subcutaneo us lesions/visceral lesions, or 
cross -sectional image -guided biopsy, such as CT-guided biopsy, for visceral and deeper tumor lesions . Method of biopsy will be per guidance of the investigator as well as 
discussion with the Sponsor. 
Instructions for tissue collection, processing, and shipment are provided in the Procedures Manual . Leftover main study tissue will be stored for FBR if the subject consents to 
FBR . Samples of archival tumor tissue collected at Screening should be freshly cut, and the slides from this freshly cut archival tumor tissue should be submitted to the testing 
laboratory within [ADDRESS_1044952]:   MK-1454 98
Protocol/Amendment No.: 001-08 
MK-1454 -001-08 Final Protocol 27-Jul-2021
Confidential
Schedule of Activ ities for the Treatment Period, Intratumoral Administration for Arm 1 (Monotherapy) and Arm 2 
(Combination Therapy –Including Crossover to Arm 2)
Trial PeriodTreatment Phase
MK-1454 Monotherapy Cycle = 21 Days
MK-1454 and Pembrolizumab Combination Therapy Cycle = 21 Days
Notes Cycle Cycle 1 Cycle 2 Cycle 3Cycle 4 
and 
Beyond
Scheduling Day 1 8 15 1 8 15 1 8 15 1
Scheduled Window ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3
Administrative Procedu res
Informed Consent XAdditional consent is required for treatment beyond disease 
progression.
Prior Medication and 
Concomitant Medication 
ReviewX X X X X X X X X X
MK-1454 Administration
(Arm 1 and Arm 2)(Table 3)There will be an at least a 24 -hour inpatient observation 
period following MK-1454 administration on C1D1 . In 
Arm 2, MK-1454 will be administered within 0.5 to 4 h
after completion of pembrolizumab IV infusion . See 
Procedures Manual for dose preparation.
Pembrolizumab Administration 
(Arm 2)(Table 4)X X X XThis is only for combination therapy in Arm 2. See 
Pembrolizumab Pharmacy Manual.
Efficacy ProceduresSee Imaging Manual – All imaging visits have a ± 7day 
window
Tumor Imaging, RECIST , 
irRECIST , and/or itRECIST
Response Assessment X XFor solid tumors, perform at 9weeks (±7days) after first 
dose, and then Q9W . For lymphoma, assess at 12 weeks
(±7days) , and then Q12W . Tumor imaging (CT, PET/CT,
or MRI , as indicated for tumor type ),and medical 
photography should be performed on the same schedule, 
following calendar days, and should not be adjusted for 
delays in cycle starts . Continue imaging schedule until 
disease progression, discontinuation, or EOT . Medical 
photography can be perf ormed more often as medically 
warranted.Medical Photography 
(Cutaneous Lesions) X X
IWG Revised Response Criteria 
for Lymphoma (excluding 
CTCL)X
CCI
087V73
Product:   MK-1454 99
Protocol/Amendment No.: 001-08 
MK-1454 -001-08 Final Protocol 27-Jul-2021
ConfidentialTrial PeriodTreatment Phase
MK-1454 Monotherapy Cycle = 21 Days
MK-1454 and Pembrolizumab Combination Therapy Cycle = 21 Days
Notes Cycle Cycle 1 Cycle 2 Cycle 3Cycle 4 
and 
Beyond
Scheduling Day 1 8 15 1 8 15 1 8 15 1
Scheduled Window ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3
CTCL Clinical Response 
Assessment (ISCL/ Modified 
Severity Weighted Assessment 
Tool –[mSWAT])X X X XFor CTCL, assess response and perform medical 
photography on Day [ADDRESS_1044953] 4 weeks 
is recommended.
Bone Marrow Biopsy/ Aspi[INVESTIGATOR_337] 
(Lymphoma Subject s Only)========================== ========== =============== For subjects with a negative bone marrow biopsy at 
screening, follow -up bone marrow biopsy need not be 
performed . Follow -up bone marrow biopsy may be 
performed to confirm a CR if the subject was initially 
positive or if it is clinically indicated. 
Safety Assessments and ProceduresSee Procedures Manual for Collection And 
Management of Samples.
AEMonitoring ========================================= 
Full Physical Examination X X X X
Directed Physical Examination XX XX
Weight X X X X
12-lead ECG X X XObtain within 72 h prior to MK -1454 IT administration on 
C1D1, C2D1, and C3D1. Does not need to be repeated on 
C1D1 if screening ECG wasdone within 72 hours prior to 
C1D1 . A postdose ECG will be obtained on C1D1 within 
30min and at 3 to 4 h following MK -1454 IT 
administration .
Vital Signs
(temperature, pulse, respi[INVESTIGATOR_862], blood pressure, and 
oxygen (O 2) saturation)X X X X X X X X X XCollect VS predose within 1 h (± 30 min) of MK-[ADDRESS_1044954] VS postdose
on C1D1 at 2, 4, 6, 8, and 12 h (± 30 min for each time 
point) after MK -[ADDRESS_1044955] VS at 1 h (±15 min) after MK -1454
administration. Additional VS monitoring may be obtained 
as clinically indicated.
ECOG Performance Status X X X X Additional ECOG can be performed as clinically indicated.
Tumor Markers X X X XSpecific tumor markers (eg, CEA, CA -125, CA -19-9, or 
alpha fetoprotein) to be obtained as clinically indicated .
087V73
Product:   MK-1454 100
Protocol/Amendment No.: 001-08 
MK-1454 -001-08 Final Protocol 27-Jul-2021
ConfidentialTrial PeriodTreatment Phase
MK-1454 Monotherapy Cycle = 21 Days
MK-1454 and Pembrolizumab Combination Therapy Cycle = 21 Days
Notes Cycle Cycle 1 Cycle 2 Cycle 3Cycle 4 
and 
Beyond
Scheduling Day 1 8 15 1 8 15 1 8 15 1
Scheduled Window ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3
CBC with Differential X X X X X X X X X X
Required within 72 h of C1D1 . Does not need to be 
repeated if screening labs were done within 72 hours of 
C1D1 . May be performed up to 72 h prior to dosing for 
subsequent cycles when scheduled .PT/INR and PTT or aPTT X X X X
Chemistry Panel X X X X X X X X X X
LDH, GGT X X X X
Urinalysis X X X X
Lipase and Amylase X X X X
Pregnancy Test for WOCBP –
Urine or Serum hCGXRequired within 24hprior to first dose of study 
medication . Does not need to be repeated if screening test 
wasdone within 24hours of C1D1 .If a urine pregnancy 
test cannot be confirmed as negative, a serum pregnancy 
test is required . Pregnancy testing must be done as required 
by [CONTACT_1295]. Where local regulations require 
monthly pregnancy testing per CTFG guidelines, see 
Appendix 12.5.
Thyroid Function (TSH, T3, 
FT3, T4, FT4)X X XRequired within 72 hours prior to Day 1 of C1, C3, C5, C7, 
C9, C11, and at every other subsequent treatment cycle.
Does not need to be repeated if screening labs were done 
within 72 hours of C1D1.
Pharmacokinetics (PK)/ Pharmacodynamics/ Future Biomedical Research/BiomarkersSee Procedures Manual for Collection and Management 
of Samples.
Serum for Cytokine Panel and 
CRP for MK -1454
Pharmacodynamics bX X XcCytokine and CRP samples should be obtained predose on 
C1D1 ,C2D1 and C5D1, either both in the morning (8 AM 
to 12 PM) or both in the afternoon (1 PM to 5 PM) . 
Postdose serum samples for cytokine panels and CRP will 
be collected on C1D1 ,C2D1, and C5D1, and if applicable, 
on Day [ADDRESS_1044956] dose escalation of MK -1454 . Postdose samples 
will be collected at 4 h(±15 min) and 6 h(±15 min) after 
MK-1454 administration . On C1D1, an addition al serum 
sample will be collected at 12 h (± 2h) and 24h (± 4 h) 
following MK -[ADDRESS_1044957]:   MK-1454 101
Protocol/Amendment No.: 001-08 
MK-1454 -001-08 Final Protocol 27-Jul-2021
ConfidentialTrial PeriodTreatment Phase
MK-1454 Monotherapy Cycle = 21 Days
MK-1454 and Pembrolizumab Combination Therapy Cycle = 21 Days
Notes Cycle Cycle 1 Cycle 2 Cycle 3Cycle 4 
and 
Beyond
Scheduling Day 1 8 15 1 8 15 1 8 15 1
Scheduled Window ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±[ADDRESS_1044958] postdose samples on C1D1 and C2D1 atthe
following time points: end of IT injection (up to +15 min), 
0.5h(±15min) ,1h(±15 min), 1.5h(±15 min), 4h(±15 
min) , and 6h (±15 min) .Additional postdose samples will 
be collected at 12h (±2 h) and 24h(±4h) following MK -
[ADDRESS_1044959] samples predose 0 to 4 h 
before pembrolizumab IV infusion on C1D1, C2D1, C4D1, 
and on Day 1 of every 4 cycles thereafter (ie, C8, C12, 
etc.). Collect pembrolizumab and MK -[ADDRESS_1044960] prior to MK -1454 administration (Arm 1) and prior 
to pembrolizumab administration (Arm 2) on C2D1 and 
C5D1. Blood for Serum Biomarker 
Analysis X X
Blood for RNA Analysis XcCollect predose 0-[ADDRESS_1044961] postdose 6 h(±15 min) after MK -[ADDRESS_1044962]:   MK-1454 102
Protocol/Amendment No.: 001-08 
MK-1454 -001-08 Final Protocol 27-Jul-2021
ConfidentialTrial PeriodTreatment Phase
MK-1454 Monotherapy Cycle = 21 Days
MK-1454 and Pembrolizumab Combination Therapy Cycle = 21 Days
Notes Cycle Cycle 1 Cycle 2 Cycle 3Cycle 4 
and 
Beyond
Scheduling Day 1 8 15 1 8 15 1 8 15 1
Scheduled Window ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±[ADDRESS_1044963] postdose tumor biopsy on the same 
day as treatment, 5 h (± 2 h) following IT administration of 
MK-1454 on C3D15, and optionally on C6D1 at 5 h (± 2 h) 
following IT administration of MK -1454 . Biopsy of a 
distant, discrete, noninjected site is preferred on the same 
day as the IT administration of M K-1454 , but may be 
performed up to 3days after treatment of the injected 
lesion. The C6D1 biopsy time point is encouraged, but 
optional .
ADA = antidrug antibodies; AE = adverse event; aPTT = activated partial thromboplastin time;CBC = complete blood count; CRP = C-reactive protein; CT = computed 
tomograp hy; CTCL = cutaneous T-cell lymphoma; ECG = electrocardiogram ;ECOG = Eastern Cooperative Oncology Group; FBR = future biomedical research; GGT = 
gamma glutamyl transferase; hCG = human chorionic gonadotropin ;HIV = human immunodeficiency virus; HNSCC = Head and Neck Squamous Cell Carcinoma ; HPV = 
human papi[INVESTIGATOR_28597] ; IEC = Institutional Ethics Committee; INR = international normalized ratio; IRB= Institutional Review Board; ISCL = International Society for 
Cutaneous Lymphomas ;IT = intratumoral; LDH = lactate dehydrogenase; MRI = magnetic resonance imaging; PET = positron emission tomography; PT = prothrombin 
time; PTT = partial thromboplastin time; RNA = ribonucleic acid; RECIST v1.1 = Response Evaluation Criteria In Solid Tumors, version 1.1; irRECIST = immune -related 
RECIST; (F)T3 = (free) t riiodothyronine ;(F)T4 = (free) thyroxine ;TSH = thyroid -stimulating hormone; WOCBP = women of child bearing potential.
a) The inpatient observation period may be extended up to 48 hours at the discretion of the investigator, per local IRB/IEC , and/or Health Authority mandate . 
b) Up to 2 additional serum samples may be collected if deemed medically necessary (eg, in the setting of an AE) . 
c) In the event a subject has undergone intrasubject dose escalation of MK -1454, these samples for biomarker analysis will be collected on Day [ADDRESS_1044964] cycle of the 
escalated new dose.
d) This sample will be drawn for genetic variations in absorption, distribution, metabolism, and excretion ( ADME )and planned analysis of the association between genetic 
variants in DNA and drug response . If the IRB/IEC does not approve of the planned analysis of the association between DNA variation and drug resp onse, or if there is a 
local law or regulation prohibiting the same, then data analysis will be limited to investigate ADME genetic variations . If the sample is collected, leftover extracted DNA 
will be stored for FBR if the participant (or their legally a cceptable representative) provides documented informed consent for FBR. If the planned genetic analysis is not 
approved, but FBR is approved and consent is given, then this sample will be collected for the purpose of FBR.
All subjects will be required to provide a sample biopsy of the tumor to be injected with MK-1454 and a sample biopsy from a distant, discrete noninjected site (at least 
2biopsies at each site), unless deemed medically unsafe by [CONTACT_093] . For the tumor lesion intended for treatmen t with IT administration of MK-1454, the sample will 
be obtained by [CONTACT_762614], or ultrasound guided biopsy for subcutaneous lesions . For distant, discrete tumor lesions that are not intended for IT 
administration with MK-1454, the sample biopsy will be obtained by [CONTACT_762615], ultrasound guided biopsy for subcutaneous/viscer al lesions, or 
image -guided biopsy, such as CT-guided biopsy, for visceral and deeper tumor lesions . Method of biopsy will be per guidance of the investigator as well as discussion with 
the Sponsor . Instructions for tissue collection, processing, and shipment are provided in the Procedures Manual . Leftover main study tissue will be stored for FBR if the 
subject consents to FBR . Instru ctions for tissue collection, processing, and shipment are provided in the Procedures Manual .
087V73
Product:   MK-1454 103
Protocol/Amendment No.: 001-08 
MK-1454 -001-08 Final Protocol 27-Jul-2021
Confidential
Schedule of Activities for the Treatment Period ofArm 3(Visceral IT Administration)
Trial PeriodTreatment Phase
MK-1454 Monotherapy Cycle =  then Q3W
MK-1454 and Pembrolizumab Combination Therapy Cycle = 
21 Days
Notes Cycle Cycle 1 Cycle 2 Cycle 3Cycle 4 
and 
Beyond
Scheduling Day 1 8 15 1 8 15 1 1
Scheduled Window ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3
Informed Consent XAdditional consent is required for treatment beyond disease 
progression.
Prior Medication and 
Concomitant Medication 
ReviewX X X X X X X X
MK-1454 Administration  
(Arm 3) (Table 5)There will be an at least a [ADDRESS_1044965] tolera nce 
and clinical assessment of safety. 
*Administration on Day 8 and Day 15 of Cycles 1 and 2 will be based 
on cohort designation in Arm 3. See Procedures Manual for dose 
preparation.
Pembrolizumab Administration 
(Table 5)X X X X See Procedures Manual for dose preparation.
Efficacy Procedures See Imaging Manual –All imaging visits have a ± 7day window
Tumor Imaging, RECIST, 
irRECIST, and/or itRECIST
Response Assessment XFor solid tumors, to be performed at 9weeks after the first dose, and 
then every 9 weeks . For lymphoma, assess at 12 weeks, and then every 
12weeks . Tumor imaging (CT, PET/CT, or MRI, as indicated for 
tumor type), and medical photography should be performed on the 
same schedule, following calendar days, and should not be adjusted 
for delays in cycle starts . Continue imaging schedule until disease 
progression, discontinuation, or EOT . Medical photography can be 
performed more often as medically warranted.Medical Photography 
(Cutaneous Lesions) X
IWG Revised Response 
Criteria for Lymphoma X
Bone Marrow Biopsy/ Aspi[INVESTIGATOR_337] 
(Lymphoma Subject s Only)========================================= For subjects with a negative bone marrow biopsy at screening, follow -
up bone marrow biopsy need not be performed . Follow -up bone 
marrow biopsy may be performed to confirm a CR if the subject was 
initially positive or if it is clinically indicated. 
CCI
C
CI
087V73
Product:   MK-1454 104
Protocol/Amendment No.: 001-08 
MK-1454 -001-08 Final Protocol 27-Jul-2021
ConfidentialTrial PeriodTreatment Phase
MK-1454 Monotherapy Cycle = , then Q3W
MK-1454 and Pembrolizumab Combination Therapy Cycle = 
21 Days
Notes Cycle Cycle 1 Cycle 2 Cycle 3Cycle 4 
and 
Beyond
Scheduling Day 1 8 15 1 8 15 1 1
Scheduled Window ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3
Safety Assessments and ProceduresSee Procedure s Manual for Collection And Management of 
Samples.
AEMonitoring ========================================= 
Full Physical Examination X X X X
Directed Physical Examination X X X X
Weight X X X X
12-lead ECG X X XObtain within 72 h prior to MK -1454 IT administration on C1D1, 
C2D1, and C3D1. Does not need to be repeated on C1D1 if screening 
ECG wasdone within 72 hours of C1D1 . A postdose ECG will be 
obtained on C1D1 within 30 min and at 3 to 4 h following MK-1454 
IT administration . 
Vital Signs
(temperature, pulse, respi[INVESTIGATOR_862], blood pressure, and 
oxygen (O 2) saturation)X X X X X X X XCollect VS predose within 1 h (± 30 min) MK -[ADDRESS_1044966] VS postdose on C1D1 at 2, 4, 6, 8, and 
12 h (± 30 min for each time point) after MK -[ADDRESS_1044967] VS at 1 h (±15 min) after 
MK-1454 administration. Additional VS monitoring may be obtained 
as clinically indicated.
ECOG Performance Status X X X X Additional ECOG can be performed as clinically indicated.
Tumor Markers X X X XSpecific tumor markers (eg, CEA, CA-125, CA -19-9, or alpha 
fetoprotein) to be obtained as clinically indicated
CBC with Differential X X X X X X X X
Required within 72 h of C1D1 .Does not need to be repeated if 
screening labs were done within 72 hours of C1D1 . May be performed 
up to 72 h prior to dosing for subsequent cycles when scheduled .PT/INR and PTT or aPTT X X X X
Chemistry Panel X X X X X X X X
LDH, GGT X X X X
Urinalysis X X X X
Lipase and Amylase X X X X
Pregnancy Test for WOCBP –
Urine or Serum hCGXRequired within 24h prior to first dose of study medication. Does not 
need to be repeated if screening test was done within 24hours of 
C1D1 . If a urine pregnancy test cannot be confirmed as negative, a 
serum pregnancy test is required . Pregnancy testing must be done as 
required by [CONTACT_1295]. Where local regulations require monthly 
pregnancy testing per CTFG guidelines, see Appendix 12.5.
CCI
087V73
Product:   MK-1454 105
Protocol/Amendment No.: 001-08 
MK-1454 -001-08 Final Protocol 27-Jul-2021
ConfidentialTrial PeriodTreatment Phase
MK-1454 Monotherapy Cycle = , then Q3W
MK-1454 and Pembrolizumab Combination Therapy Cycle = 
21 Days
Notes Cycle Cycle 1 Cycle 2 Cycle 3Cycle 4 
and 
Beyond
Scheduling Day 1 8 15 1 8 15 1 1
Scheduled Window ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3
Thyroid Function (T4, FT4, T3, 
FT3, TSH) X X XTo be performed within 72 hours prior toDay 1 of C1, C3, C5, C7, 
C9, C11, and at every other subsequent treatment cycle. Does not need 
to be repeated if screening labs were done within 72 hours of C1D1.
Pharmacokinetics (PK)/ Pharmacodynamics/ Future Biomedical Research/BiomarkersSee Procedures Manual for Collection and Management of 
Samples.
Serum for Cytokine Panel and 
CRP for MK -1454 
PharmacodynamicsbX X XbCytokine and CRP samples should be obtained predose on C1D1 and 
C2D1 either both in the morning (8 AM to 12 PM) or both in the 
afternoon (1 PM to 5 PM). Postdose serum samples for cytokine 
panels and CRP will be collected on C1D1, C2D1, and C5D1 . 
Postdose samples will be collected at 4 h (±15 min) and 6 h (±15 min) 
after MK -1454 administration . On C1D1, an additional serum sample 
will be collected at 12 h (± 2 h) and 24 h (± 4 h)following MK-[ADDRESS_1044968] postdose samples on C1D1 and C2D1 at the following time 
points:   end of IT injection (up to +15 min), 0.5 h (±15 min), 1.0 h 
(±15 min), 1.5 h (±15 min), 4 h (±15 min), and 6 h (±15 min). 
Additional postdose samples will be collected at 12 h (± 4h) and 24 h 
(±4h)following MK-[ADDRESS_1044969] samples predose 0 to 4 h before pembrolizumab IV infusion 
on C1D1, C2D1, C4D1, and on Day 1 of every 4 cycles thereafter (ie, 
C8, C12, etc.) . 
Collect with plasma samples for MK -[ADDRESS_1044970] prior to MK -1454 administration (Arm 1) and prior to 
pembrolizumab administration (Arm 2 and Arm 3) on C2D1 and 
C5D1.Blood for Serum Biomarker 
Analysis X X
CCI
087V73
Product:   MK-1454 106
Protocol/Amendment No.: 001-08 
MK-1454 -001-08 Final Protocol 27-Jul-2021
ConfidentialTrial PeriodTreatment Phase
MK-1454 Monotherapy Cycle =  then Q3W
MK-1454 and Pembrolizumab Combination Therapy Cycle = 
21 Days
Notes Cycle Cycle 1 Cycle 2 Cycle 3Cycle 4 
and 
Beyond
Scheduling Day 1 8 15 1 8 15 1 1
Scheduled Window ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±[ADDRESS_1044971] postdose 6 h (±15 min) after MK -[ADDRESS_1044972] predose tumor biopsy on the same day as treatment 
prior to IT administration of MK -1454 on C3D1, or up to 3 days prior 
to treatment on C3D1, and optionally on C6D1 prior to IT 
administration of MK -1454 , or up to 3 days prior to treatment on 
C6D1 . If available, b iopsy of a distant, discrete, noninjected site is 
preferred on the same day as the IT administration of MK -1454 but
may be performed up to 3 days after treatment of the injected lesion. 
The C6D1 biopsy time point is encouraged, but optional .
ADA = antidrug antibodies; AE = adverse event; aPTT = activated partial thromboplastin time; CBC = complete blood count; CRP = C-reactive protein; CT = computed 
tomography; CTCL = cutaneous T -cell lymphoma; DNA = deoxyribonucleic acid; ECG = electrocardiogram ; ECOG = Eastern Cooperative Oncology Group; FBR = future 
biomedical research; GGT = gamma glutamyl transferase; hCG = human chorionic gonadotropin ;HIV = human immunodeficiency virus; HNSCC = Head and Neck 
Squamous Cell Carcinoma ; HPV = human papi[INVESTIGATOR_28597] ; IEC = Institutional Ethics Committee; INR = international normalized ratio; IRB = Institutional Review Board; 
irRECIST = immune -related RECIST; ISCL = International Society for Cutaneous Lymphomas ;IT = intratumoral; LDH = lactate dehydrogenase; MRI = magnetic 
resonance imaging; PET = positron emission tomography; PT = prothrombin time; PTT = partial thromboplastin time; RECIST v1.1 = Response Evaluation Criteria In Solid 
Tumors, version 1.1; RNA = ribonucleic acid; (F)T3 = (free) triiodothyronine ;(F)T4 = (free) thyroxine ;TSH = thyroid -stimulating hormone; WOCBP = women of 
child bearing potential.
a)The inpatient observation period may be extended up to 48 hours at the discretion of the investigator , per local IRB/IEC , and/or Health Authority mandate . 
b) Up to 2 additional serum samples may be collected if deemed medically necessary (eg, in the setting of an AE) . 
c) This sample will be drawn for genetic variations in ADME and planned analysis of the association between genetic variants in DNA and drug response . If the IRB/IEC 
does not approve of the planned analysis of the association between DNA variation and drug response, or if there is a local law or regulation prohibiting the same, data 
analysis will be limited to investigate ADME genetic variations . If the sample is collected, leftover extracted DNA will be stored for FBR if the participant (or their 
legally acceptable representative) provides documented informed consent for FBR. If the planned genetic analysis is not approved, but FBR is approved and consent is 
given, this sample will be collected for the purpose of FBR.
d) All subject s will be r equired to provide a sample biopsy of the tumor to be injected with MK -1454 and a sample biopsy from a distant, discrete noninjected site (at least 2 
biopsies at each site), unless deemed medically unsafe by [CONTACT_093] . The sample will be obtained by[CONTACT_762599] -sectional imaging (CT/MRI) 
guidance . Method of biopsy will be per guidance of the investigator as well as discussion with the Sponsor . Instructions for tissue collection, processing, and shipment are 
provided in the Procedures Manual . Leftover main study tissue will be stored for FBR if the subject consents to FBR . Instructions for tissue collection, processing, and 
shipment are provided in the Procedures Manual . 
CCI
087V73
Product:   MK-1454 107
Protocol/Amendment No.: 001-08 
MK-1454 -001-08 Final Protocol 27-Jul-2021
Confidential
Discontinuation / End of Treatment and Posttreatment Follow -upfor Arms 1 to 3
Trial Period EOT/ DiscontinuationPosttreatment Period
Notes30-Day Safety 
Follow -up VisitSurvival 
Follow -up 
Scheduling Day30 days post last 
doseQ12W
Scheduled Window ±7 +7 ±[ADDRESS_1044973], and/or 
itRECIST Response Assessment X
Medical Photography (Cutaneous Lesions) X
IWG Revised Response Criteria for Lymphoma 
(excluding CTCL)X
CTCL Response Criteria X
Survival Status MonitoringUpdated survival status may be 
requested by [CONTACT_762616]. Upon 
Sponsor notification, all subjects who 
do not/will not have a scheduled study 
visit or study contact [CONTACT_762617] 
(excluding subjects that have a death 
event previously recorded).
Safety Assessments and ProceduresSee Procedures Manual for collection 
and management of samples.
AEsMonitoring X X
Full Physical Examination X X
Weight X X
12-lead ECG X
Vital Signs X XTemperature, pulse, respi[INVESTIGATOR_697], 
blood pressure, and O 2saturation
ECOG Performance Status X X
CBC with Differential X X
Chemistry Panel X X
Lipase and Amylase X X
087V73
Product:   MK-1454 108
Protocol/Amendment No.: 001-08 
MK-1454 -001-08 Final Protocol 27-Jul-2021
ConfidentialTrial Period EOT/ DiscontinuationPosttreatment Period
Notes30-Day Safety 
Follow -up VisitSurvival 
Follow -up 
Scheduling Day30 days post last 
doseQ12W
Scheduled Window ±7 +7 ±[ADDRESS_1044974] for WOCBP  –Urine or Serum hCG XFor WOCBP, perform as required 
locally . If a urine pregnancy test cannot 
be confirmed as negative, a serum 
pregnancy test is required . 
Thyroid Function ( TSH ,T3, FT3, T4, FT4) X
PK/Pharmacodynamics/ Future Biomedical Research/BiomarkersSee Procedures Manual for collection 
and management of samples.
Serum for Pembrolizumab PK X Only for pembrolizumab -treated 
subject s. Serum for A DA X
Blood for Plasma Biomarker Analysis X
Blood for Serum Biomarker Analysis X
ADA = antidrug antibodies; AE = adverse event; CBC = complete blood count; CTCL = cutaneous T -cell lymphoma; DNA = deoxyribonucleic acid; ECG = e lectrocardiogram ; 
ECOG = Eastern Cooperative Oncology Group; EOT = end of treatment; (F)T3 = (free) triiodothyronine ;(F)T4 = (free) thyroxine ; hCG = human chorionic gonadotropin ;
irRECIST = immune -related RECIST; PK = pharmacokinetic; RECIST = Response Evaluation Criteria In Solid Tumor s; RNA = ribonucleic acid; TSH = thyroid -stimulating 
hormone; WOCBP = women of child bearing potential.
087V73
Product:   MK-1454 109
Protocol/Amendment No.: 001-08 
MK-1454 -001-08 Final Protocol 27-Jul-2021
Confidential
Schedule of Activities for Part II -Expansion Cohorts
Schedule of Activities for Part II-Expansion Cohorts Screening and Treatment Period, MK-1454 Intratumoral 
Administration With Pembrolizumab Combination Therapy
Trial PeriodScreeningTreatment Phase
MK-1454 Cycle = , then Q3W; or Q3W
Pembrolizumab Cycle = 21 Days
Notes Cycle Cycle 1 Cycle 2 Cycle 3Cycle 4 
and 
Beyond
Scheduling Day -28 to -1 1 8 15 1 8 15 1 8 15 1
Scheduled Window ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±[ADDRESS_1044975] be obtained prior 
to performing any protocol -specific procedures . An ICF
signed >28 days prior to C1D1 does not need to be 
replaced . Additional informed consent is required for 
treatment beyond progression.
Informed Consent for 
FBR (Optional)X
Subject Identification 
CardX
Inclusion/Exclusion 
CriteriaX
Demographics and 
Medical History X
Prior Medication and 
Concomitant 
Medication ReviewX X X X X X X X X X X
HPV status XHPV testing results of HNSCC and other squamous cell 
carcinoma tumors (eg, p16 IHC; multip lex NASBA or other 
PCR -based assays) should be collected if available, as 
determined per institutional standard.
Tumor genetic 
alteration(s)XTumor genetic alteration(s), if available, as determined by [CONTACT_762618] (eg ,BCRA1, MSI -H.).
CCI
087V73
Product:   MK-1454 110
Protocol/Amendment No.: 001-08 
MK-1454 -001-08 Final Protocol 27-Jul-2021
ConfidentialTrial PeriodScreeningTreatment Phase
MK-1454 Cycle =  then Q3W; or Q3W
Pembrolizumab Cycle = 21 Days
Notes Cycle Cycle 1 Cycle 2 Cycle 3Cycle 4 
and 
Beyond
Scheduling Day -28 to -1 1 8 15 1 8 15 1 8 15 1
Scheduled Window ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3
MK-1454
Administration
(Table 8)There will be an at least an 8-hour observation period 
following MK-1454 administration on C1D1 . MK-1454 will 
be administered within 0.5 to 4 hafter completion of 
pembrolizumab IV infusion . See Procedures Manual for dose 
preparation.
Pembrolizumab 
Administration 
(Table 8)X X X X See Pembrolizumab Pharmacy Manual.
Efficacy ProceduresSee Imaging Manual –All imaging visits have a ± 7day 
window
Tumor Imaging, 
RECIST, irRECIST, 
and/or itRECIST 
Response Assessment 
Cohort BX X XTobe performed at 9weeks (±7days) after the first dose, 
and then every 9 weeks thereafter . Tumor imaging (CT, 
PET/CT, or MRI , as indicated for tumor type ),and medical 
photography should be performed on the same schedule, 
follow ingcalendar days ,and should not be adjusted for 
delays in cycle starts . Continue imaging schedule until 
disease progression, discontinuation, or EOT . Medical 
photography can be performed more often as medically 
warranted.Medical Photography 
(Cutaneous Lesions) X X X
Safety Assessments and ProceduresSee Procedures Manual for Collection And Management 
of Samples.
AEMonitoring ========================================= 
Full Physical 
Examination X X X X X
Directed Physical 
ExaminationX X X X
Weight X X X X X
Height X
12-lead ECG X
CCI
C
CI
087V73
Product:   MK-1454 111
Protocol/Amendment No.: 001-08 
MK-1454 -001-08 Final Protocol 27-Jul-2021
ConfidentialTrial PeriodScreeningTreatment Phase
MK-1454 Cycle =  then Q3W; or Q3W
Pembrolizumab Cycle = 21 Days
Notes Cycle Cycle 1 Cycle 2 Cycle 3Cycle 4 
and 
Beyond
Scheduling Day -28 to -1 1 8 15 1 8 15 1 8 15 1
Scheduled Window ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3
Vital Signs
(temperature, pu lse, 
respi[INVESTIGATOR_697], blood 
pressure, and oxygen 
(O2) saturation)X X X X X X X X X X XCollect VS predose within 1 h(± 30 min) of MK -[ADDRESS_1044976] VS postdose on 
C1D1 at 2, 4, 6, and 8h(± 30 min for each time point) after 
MK-[ADDRESS_1044977] VS at 1 h(±15 min) after MK-1454 administration.
Additional VS monitoring may be obtained as clinically 
indicated.
ECO G Performance 
Status X X X X XAdditional ECOG can be performed as clinically indicated.
Tumor Markers X X X X XSpecific tumor markers (eg, CEA, CA-125, CA -19-9, or alpha 
fetoprotein) to be obtained as clinically indicated .
CBC with Differential X X X X X X X X X X X Perform all screening clinical laboratory tests within [ADDRESS_1044978] be performed within 72hprior to dosing when 
scheduled .Does not need to be repeated on C1D1 if 
screening labs were done within 72 hours of C1D1 .PT/INR and PTT or 
aPTTX X X X X
Chemistry Panel X X X X X X X X X X X
LDH, GGT X X X X X
Urinalysis X X X X X
Lipase and Amylase X X X X X
Pregnancy Test for 
WOCBP –Urine or 
Serum hCGX XRequired within 24hprior to first dose of study medication . 
Does not need to be repeated if screening test was done 
within 24hours of C1D1 . If a urine pregnancy test cannot be 
confirmed as negative, a serum pregnancy test is required . 
Pregnancy testing must be done as required by [CONTACT_21482]. Where local regulations require monthly 
pregnancy testing per CTFG guidelines, see Appendix 12.5.
Thyroid Function 
(TSH, T3, FT3, T4, 
FT4)X X X XRequired within 72 hours prior to Day 1 of C1, C3, C5, C7, 
C9, C11, and at every other subsequent treatment cycle. Does 
not need to be repeated on C1D1 if screening labs were done 
within 72 hours of C1D1 .
HIV, Hepatitis B and 
C screen (per site 
SOP)XInclude HCV antibody or HCV RNA (qualitative) and 
HBsAg . 
CCI
087V73
Product:   MK-1454 112
Protocol/Amendment No.: 001-08 
MK-1454 -001-08 Final Protocol 27-Jul-2021
ConfidentialTrial PeriodScreeningTreatment Phase
MK-1454 Cycle =  then Q3W; or Q3W
Pembrolizumab Cycle = 21 Days
Notes Cycle Cycle 1 Cycle 2 Cycle 3Cycle 4 
and 
Beyond
Scheduling Day -28 to -1 1 8 15 1 8 15 1 8 15 1
Scheduled Window ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3
Laboratory Procedures/Assessments: Analysis performed by
[CONTACT_762619].
Serum for Cytokine 
Panel and CRP for 
MK-1454 
Pharmacodynamics bX X X X,Cytokine and CRP samples should be obtained at Screening, 
and predose on C1D1 ,C2D1 and C5D1, either both in the 
morning (8 AM to 12 PM) or both in the afternoon (1 PM to 5 
PM). Postdose serum samples for cytokine panels and CRP 
will be collected on C1D1, C2D1, and C5D1. Postdose 
samples will be collected at 4 h (±15 min )and 6 h(±15 min) 
after MK-[ADDRESS_1044979] es on C1D1 and C2D1 at the 
following time points:  end of IT injection (up to +15 min), 
0.5 h ( ±15min), 1 h ( ±15 min ), 1.5 h ( ±15 min ), 4 h ( ±15 
min), and 6 h (±15 min ). Collect samples at the same time as 
for cytokines and CRP, and for pembrolizumab PK, when 
feasible.
CCI
087V73
Product:   MK-1454 113
Protocol/Amendment No.: 001-08 
MK-1454 -001-08 Final Protocol 27-Jul-2021
ConfidentialTrial PeriodScreeningTreatment Phase
MK-1454 Cycle =  then Q3W; or Q3W
Pembrolizumab Cycle = 21 Days
Notes Cycle Cycle 1 Cycle 2 Cycle 3Cycle 4 
and 
Beyond
Scheduling Day -28 to -1 1 8 15 1 8 15 1 8 15 1
Scheduled Window ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±[ADDRESS_1044980] samples predose 0 to 4 hbefore pembrolizumab IV 
infusion on C1D1, C2D1, C4D1, and on Day 1 ofevery 4 
cycles thereafter (ie, C8, C12, etc.) . Collect pembrolizumab 
and MK -[ADDRESS_1044981] prior to MK-1454 administration (Arm 1) and prior to 
pembrolizumab administration (Arm 2) on C2D1 and C5D1.
Blood for Serum 
Biomarker Analysis X X
Blood for RNA 
Analysis XCollect predose 0-[ADDRESS_1044982] postdose 6 h (±15 min )after MK-[ADDRESS_1044983] predose tumor biopsy on the same day as 
treatment prior to IT administration of MK -1454, or up to 5
days prior to treatment on C 2D1 and on C 3D1(optional). If 
available, b iopsy of a distant, discrete ,noninjected sitemay 
be performed up to 5days before treatment of the injected 
lesion.
AE = adverse event; aPTT = a ctivated partial thromboplastin time ;CBC = complete blood count; CRP = C -reactive protein; CT = computed tomography; CTCL = cutaneo us T-
cell lymphoma; ECOG = Eastern Cooperative Oncology Group; EOT = end of treatment; FBR = future biomedical research; (F)T3 = (free) triiodothyronine ; (F)T4 = (free) 
thyroxine ;GGT = gamma glutamyl transferase; hCG = human chorionic gonadotropin ;HCV = hepatitis C virus; HIV = human immunodeficiency virus; HNSCC = Head and 
Neck Squamous Cell Carcinoma ; HPV = human papi[INVESTIGATOR_28597] ; INR = international normalized ratio; irRECIST = immune -related RECIST; ISCL = International Society for 
Cutaneous Lymphomas ;IT = intratumoral; LDH = lactate dehydrogenase; MRI = magnetic resonance imaging; NASBA = nucleic acid sequence -based amplification; PET = 
positron emission tomography; PK = pharmacokinetics; PT = prothrombin time; PTT = partial thromboplastin time; RECIST v1.1 = Response Evaluation Criteria In Solid 
Tumors, version 1.1; RNA = ribonucleic acid; TSH = thyroid -stimulating hormone; WOCBP = women of child bearing potential.
CCI
087V73
Product:   MK-1454 114
Protocol/Amendment No.: 001-08 
MK-1454 -001-08 Final Protocol 27-Jul-2021
ConfidentialTrial PeriodScreeningTreatment Phase
MK-1454 Cycle =  then Q3W; or Q3W
Pembrolizumab Cycle = 21 Days
Notes Cycle Cycle 1 Cycle 2 Cycle 3Cycle 4 
and 
Beyond
Scheduling Day -28 to -1 1 8 15 1 8 15 1 8 15 1
Scheduled Window ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3
a) The observation period may be extended at the discretion of the investigator , per local IRB/IEC, and/or Health Authority mandate . 
b) Up to 2 additional serum samples may be collected if deemed medically necessary (eg, in the setting of an AE) . 
c) This sample will be drawn for genetic variations in ADME and planned analysis of the association between genetic variants in DNA a nd drug response . If the IRB/IEC does 
not approve of the planned analysis of the association between DNA variation and drug respons e, or if there is a local law or regulation prohibiting the same, then data 
analysis will be limited to investigate ADME genetic variations . If the sample is collected, leftover extracted DNA will be stored for FBR if the participant (or their legally 
acceptable representative) provides documented informed consent for FBR. If the planned genetic analysis is not approved, but FBR is approved and consent is given, then 
this sample will be collected for the purpose of FBR.
d) All subjects will be required to prov ide a sample biopsy of the tumor to be injected with MK -1454 and , if available, a sample biopsy from a distant, discrete noninjected site 
(at least 2 biopsies at each site), unless deemed medically unsafe by [CONTACT_093] . For the tumor lesion intended for treatment with IT administration of MK-1454, the 
sample will be obtained by [CONTACT_762614], or ultrasound guided biopsy for subcutaneous lesions . If available, for distant, discrete tumor lesions 
that are not intended for IT administration with MK-1454, the sample biopsy will be obtained by [CONTACT_762615], ultrasound guided biopsy for 
subcutaneous/visceral lesions, or image -guided biopsy, such as CT-guided biopsy, for visceral and deeper tumor lesions . Meth od of biopsy will be per guidance of the 
investigator as well as discussion with the Sponsor . Instructions for tissue collection, processing, and shipment are provided in the Procedures Manual . Leftover main study 
tissue will be stored for FBR if the subje ct consents to FBR . Instructions for tissue collection, processing, and shipment are provided in the Procedures Manual . 
CCI
087V73
Product:   MK-1454 115
Protocol/Amendment No.: 001-08 
MK-1454 -001-08 Final Protocol 27-Jul-2021
Confidential
Discontinuation / End of Treatment and Posttreatment Follow -up for P artII –Expansion Cohorts
Trial PeriodEnd of Treatment (EOT)/ 
DiscontinuationPosttreatment Period
Notes30-Day Safety 
Follow -up VisitSurvival 
Follow -up 
Scheduling Day30 days post last 
doseQ12W
Scheduled Window ±7 +7 ±[ADDRESS_1044984], and/or 
itRECIST Response Assessment X
Medical Photography (Cutaneous Lesions) X
Survival Status MonitoringUpdated survival status may be 
requested by [CONTACT_762616]. Upon 
Sponsor notification, all subjects who 
do not/will not have a scheduled study 
visit or study contact [CONTACT_762620] s 
(excluding subjects that have a death 
event previously recorded).
Safety Assessments and ProceduresSee Procedures Manual for collection 
and management of samples.
AEMonitoring X X
Full Physical Examination X X
Weight X X
12-lead ECG X
Vital Signs X XTemperature, pulse, respi[INVESTIGATOR_697], 
blood pressure, and O 2saturation
ECOG Performance Status X X
CBC with Differential X X
Chemistry Panel X X
Lipase and Amylase X X
Pregnancy Test for WOCBP  –Urine or Serum hCG XFor WOCBP, perform as required 
locally . If a urine pregnancy test cannot 
be confirmed as negative, a serum 
pregnancy test is required . 
087V73
Product:   MK-1454 116
Protocol/Amendment No.: 001-08 
MK-1454 -001-08 Final Protocol 27-Jul-2021
ConfidentialTrial PeriodEnd of Treatment (EOT)/ 
DiscontinuationPosttreatment Period
Notes30-Day Safety 
Follow -up VisitSurvival 
Follow -up 
Scheduling Day30 days post last 
doseQ12W
Scheduled Window ±7 +7 ±14
Thyroid Function (TSH, T3, FT3, T4, FT4)  X
Pharmacokinetics (PK)/Pharmacodynamics/ Future Biomedical Research/BiomarkersSee Procedures Manual for collection 
and management of samples.
Serum for Pembrolizumab PK X Only for pembrolizumab -treated 
subjects. Serum for A DA X
Blood for Plasma Biomarker Analysis X
Blood for Serum Biomarker Analysis X
ADA = antidrug antibodies; AE = adverse event; CT = computed tomography; DNA = deoxyribonucleic acid; ECG = electrocardiogram; ECOG = Eastern Cooperative 
Oncology Group; (F)T3 = (free) triiodothyronine; (F)T4 = (free) thyroxine; hCG = human chorionic gonadotropin ;irRECIST = immune -related RECIST; MRI = magnetic 
resonance imaging; PET = positron emission tomography; RECIST v1.1 = Response Evaluation Criteria In Solid Tumors, version 1.1; RNA = ribonucleic acid; TSH = thyroid -
stimulating hormone; WOCBP = women of child bearing potential.
087V73
Prod uct:  MK-1454 117
Protocol/Amendment No.: 001-08 
MK-1454 -001-08 Final Protocol 27-Jul-2021
Confidential7.0TRIAL PROCEDURES
Trial Procedures
The Schedule of Activities -Section 6.0summarizes the trial procedures to be performed at 
each visit.  Individual trial procedures are described in detail below.  It may be necessary to 
perform these procedures at unscheduled time points if deemed clinically necessary by [CONTACT_1275].
Furthermore, additional evaluations/testing may be deemed necessary by [CONTACT_26357]. In some cases, such evaluation/testing 
may be potentially sensitive in nature (e.g., HIV, Hepatitis C, etc.), and thus local regulations 
may require that additional informed consent be obtained from the subject.  In these cases, 
such evaluations/testing will be performed in accordance with those regulations.
Administrative Procedures
Informed Consent
The investigator or qualified designee must obtain documented consent from each potential 
subject or each subject’s legally acceptable representative prior to participating in a clinical 
trialor FBR .If there are changes to the participant’s status during the study (eg, health or age 
of majority requirements), the investigator or medically qualified designee must ensure the 
appropriate documented informed consent is in place. 
[IP_ADDRESS].[ADDRESS_1044985]’s dated signa ture or by [CONTACT_423]’s legally 
acceptable representative’s dated signature [INVESTIGATOR_2394] a consent form along with the dated signature 
[CONTACT_63564]. 
A copy of the signed and dated consent form should be given to the subject befor e 
participation in the trial.
The initial informed consent form, any subsequent revised informed consent form and any 
written information provided to the subject must receive the IRB/ERC’s approval/favorable 
opi[INVESTIGATOR_19349].  The subject or his/h er legally acceptable representative should be 
informed in a timely manner if new information becomes available that may be relevant to 
the subject’s willingness to continue participation in the trial.  The communication of this 
information will be provide d and documented via a revised consent form or addendum to the 
original consent form that captures the subject’s dated signature [INVESTIGATOR_4388] [CONTACT_423]’s legally 
acceptable representative’s dated signature.
Specifics about a trial and the trial population will be added to the consent form template at 
the protocol level.  
The informed consent will adhere to IRB/ERC requirements, applicable laws and regulations 
and Sponsor requirements.
087V73
Prod uct:  MK-1454 118
Protocol/Amendment No.: 001-08 
MK-1454 -001-08 Final Protocol 27-Jul-2021
Confidential7.[IP_ADDRESS] Consent and Collection of Specimens for Future Biomedical Research
The invest igator or qualified designee will explain the FBR consent to the subject , or the 
subject’s legally acceptable representative , answer all of his/her questions, and obtain 
documented informed consent before performing any procedure related to FBR .A copy of 
the informed consent will be given to the subject before performing any procedure related to 
FBR.
Inclusion/Exclusion Criteria
All inclusion and exclusion criteria will be reviewed by [CONTACT_762621] f or the trial.
Subject Identification Card
All subjects will be given a Subject Identification Card identifying them as participants in a 
research trial. The card will contain trial site contact [CONTACT_3031] (including direct telephone 
numbers) to be utilized in the event of an emergency. The investigator or qualified designee 
will provide the subject with a Subject Identification Card immediately after the subject 
provides documented infor med consent. At the time of treatment allocation/randomization, 
site personnel will add the treatment/randomization number to the Subject Identification 
Card.
The subject identification card also contains contact [CONTACT_19430] a health care provider can obtain information about trial 
medication/vaccination in emergency situations where th e investigator is not available.
Medical History
A medical history will be obtained by [CONTACT_27404] . Medical history 
will include all active conditions, and any condition diagnosed within the prior [ADDRESS_1044986]:  MK-1454 119
Protocol/Amendment No.: 001-08 
MK-1454 -001-08 Final Protocol 27-Jul-2021
Confidential
Prior and Concomitant Medications Review
[IP_ADDRESS].[ADDRESS_1044987] has been enrolled in this trial will be recorded separately and should not be listed in 
prior medications.
[IP_ADDRESS].[ADDRESS_1044988] 
all medications related to reportable SAEs and ECIs.
All medications related to reportable SAEs and ECIs should be recorded as defined in 
Section 7.2 –Assessing and Recording Adverse Events.
Assignment of Screening Numb er
All consented subjects will be given a unique screening number that will be used to identify 
the subject for all procedures that occur prior to randomization or treatment allocation.  Each 
subject will be assigned only one screening number.  Screening n umbers must not be re -used 
for different subjects.
Any subject who is screened multiple times will retain the original screening number 
assigned at the initial screening visit.
Subjects who crossed over into Arm 2 will retain the original screening number assigned at 
the initial screening visit. Specific details on the screening visit requirements (screening/
rescreening ) are provided in Section [IP_ADDRESS] . 
Assignment of Treatment/ Randomization Number
Part I
All eligible subjects will be allocated, by [CONTACT_762622], and will receive a treatment
number . The treatment number identifies the subject for all procedures occurring after 
treatment allocation . The assigned screening number will become the subjects' treatment 
number . Once a treatment number is assigned to a subject, it can never be reassigned to 
another subject.
A single subject cannot be assigned more than [ADDRESS_1044989]:  MK-1454 120
Protocol/Amendment No.: 001-08 
MK-1454 -001-08 Final Protocol 27-Jul-2021
ConfidentialPart II
Treatment allocation will be accomplished by [CONTACT_762623] . When more
than one cohort is open for enrollment, investigator assessment of tumor histology, 
eligibility, and lesion accessibility to IT therapy will determine allocation . 
Trial Compliance (Medication/Diet/Activity/Other)
Interruptions from the protocol specified treatment plan for ≥3weeks require consultation 
between the investigator and the Sponsor and written documentation of the collaborative 
decision on subject management.
All doses of MK-1454 and pembrolizumab will be administered under the supervision of a 
qualified physician and/or designee experienced in the use of anticancer agents.
Instructions for preparing and administering study drugs will be provided in the Procedure s
Manual.
Trial Co mmunication Plan Summary
Safety data from individual subjects will be closely followed by [CONTACT_079] 
[INVESTIGATOR_619612] (typi[INVESTIGATOR_762552]). The safety and tolerability of all subjects, including those undergoing DLT 
evaluation as well as those who have completed DLT evaluation, will be reviewed prior to 
the start of the next cohort. The Sponsor and principal investigators will assess the 
appropriateness of dose escalation a nd assess safety and tolerability at the completion of each 
cohort ,and prior to the opening of enrollment for the next cohort . The subsequent dose level 
to be tested in the next cohort of subjects will be communicated to the investigator or 
designee follo wing each dose escalation decision meeting . A memorandum will be sent to 
each site to communicate the specified next dose level . Subjects will be enrolled and 
allocated via IWRS according to the dose escalation and confirmation guidelines outlined in 
Secti on 5.2. The dose at each cohort will be specified via IWRS . Cohorts will be opened or 
closed through IWRS to assure correct dosing in each cohort . 
Clinical Procedures/Assessments
Adverse Event Monitoring
The investigator or qualified designee will assess each subject to evaluate for potential new 
or worsening AEs as specified in the Schedule of Activities and more frequently if clinically 
indicated . AEswill be graded according to NCI CTCAE Version 4. Toxicities will be 
characterized in terms of seriousness, causality, toxicity grade ,and action taken with regard 
to trial treatment. 
All AEs of unknown etiology associated with MK -1454 and pembrolizumab exposure should 
be evaluated to determine if it is an ECI of a potentia l immunologic aletiology (irAE) . See 
Section 7.2.[ADDRESS_1044990]:  MK-1454 121
Protocol/Amendment No.: 001-08 
MK-1454 -001-08 Final Protocol 27-Jul-2021
ConfidentialThis is a dose escalation trial to establish the MTD of MK-1454 alone and MK-1454 in
combination with pembrolizumab . Therefore, each dose escalation will be based on the 
safety and tolerability experienced by [CONTACT_762624] . The safety and tolerability 
of each cohort for the DLT evaluation period will be reviewed prior to the start of the next 
cohort . The Sponsor and the principal investigators or subinvestigators will review the safety 
and tolerability of each trial treatment, assess the appropriateness of dose escalation, decide 
the completion of each cohort , and decide the opening of enrol lment for the next cohort . 
Frequency of these communications will depend on the enrollment of each cohort, as well as 
any potential new information regarding a safety concern in this trial or other relevant trials.
As a Phase 1 trial, there is no plan for an external safety reviewer . Data from individual 
subjects will be closely followed on an ongoing basis by [CONTACT_079] [INVESTIGATOR_484568].
Full Physical Examination
The investigator or qualified designee will perform a complete physical exam during the 
screening period and at additional time points as defined in the Schedule of Activities
(Section 6.0). Clinically significant findings from the screening exam should be recorded as 
medical history. 
A directed physical exam should be repeated according to the frequency defined in the 
Schedule of Activities (Section 6.0). After the first dose ofstudy treatment , new clinically 
significant abnormal findings should be recorded as AEs.
Vital Signs and Weight
Vital s igns include temperature, pulse, respi[INVESTIGATOR_697], blood pressure ,and oxygen saturation
(pulse oximetry )at the frequency defined in the Schedule of Activities (Section 6.0).
Weight will be obtained at Screening, at C1D1 of each treatment cycle, at EOT, and at the 
30-day Safety Follow -up Visit . Height will be obtained at Screening only.
Electrocardiogram
A standard 12-lead ECG will be performed using local standard procedure at Screening, with 
any clinically significant abnormal findings recorded as medical history. 
Additional time points for ECGs are according to the Schedule of Activities (Section 6.0).
Clinically significant abnormal findings seen on all ECGs performed after Screening should 
be recorded as AEs.
Eastern Cooperative Oncology Group Performance Status
The investigator or qualified designee will assess the ECOG performance status as the time
points specified in the Schedule of Activities (Section 6.0) . Additional ECOG testing may be 
performed as clinically indicated.
087V73
Prod uct:  MK-1454 122
Protocol/Amendment No.: 001-08 
MK-1454 -001-08 Final Protocol 27-Jul-2021
Confidential
Tumor Imaging and Medical Photography
The initial PET/ CT scan or MRI for solid tumor imaging as well as medical photography for
cutaneous lesions must be performed within [ADDRESS_1044991] and PET scans be performed at screening . 
Part I –Dose Escalation and Confirmation
For Arms 1, 2, and 3 (Part I), tumor imaging and/ormedical photography should be repeated 
every 9weeks for solid tumors or every [ADDRESS_1044992] s with CTCL, medical photography will be performed at each treatment 
cycle, however, tumor imaging will be repeated only to document and confirm PR, CR, or
PD. 
Part II –Expansion Cohorts
For Cohort A (HNSCC) and Cohort B (TNBC) , imaging will begin at 9weeks and occur 
every [ADDRESS_1044993](with PET for CTCL, as clinically indicated) . 
For subcutaneous lesions, imaging by [CONTACT_762625] [ADDRESS_1044994] is contraindicated or for imaging ofthe brain . The same imaging technique 
and the same imaging modality with/without the use of contrast should be performed for 
assessment of response in a subject throu ghout the trial to optimize visualization of existing 
and new tumor burden . Tumor imaging schedule is based on calendar days from the first 
drug administration ,and will notbe postponed due to delays in treatment cycles . Additional 
tumor imaging and /ormedi cal photography may be performed as clinically indicated.
Please refer to the Site Imaging Manual for detailed instructions regarding tumor imaging 
and medical photography.
A central imaging vendor will bemade available for possible future independent rev iew. 
Response Assessment
[IP_ADDRESS].[ADDRESS_1044995] (irRECIST )is 
RECIST 1.[ADDRESS_1044996]:  MK-1454 123
Protocol/Amendment No.: 001-[ADDRESS_1044997] 1.1 will be used with the foll owing adaptations:
If radiologic imaging by [CONTACT_762626], tumor assessment should be 
repeated at least 4 weeks later in order to confirm PD,with the option of continuing 
treatment while awaiting radiologic confirmation of progression ,as described below . 
If repeat imaging shows <20% increase in tumor burden compared to nadir, stable ,or 
improved previous new lesion ( that may have been identified as the cause for initial PD), and 
stable/improved nontarget disease (that may have been identified asthecause for initial PD), 
then PD is not confirmed . Treatment may be continue dand will then follow the regular 
imaging schedule . 
If repeat imaging confirms PD due to any of the scenarios listedbelow , then subjects will be 
discontinued from study therapy . The initial date of Progression will be recorded as the PD 
date.
In determining whether the tumor burden has increased or decreased, the investigator should 
consider all target lesions as well as non target lesions . For purposes of this pr otocol, biopsied 
lesions will not be target lesions for RECIST 1.[ADDRESS_1044998].
Scenarios where PD is confirmed at repeat imaging:
Tumor burden increase remains ≥ 20% and at least 5 mm absolute increase compared to 
nadir
Nontarget disease resulting in initial PD is worse (qualitative)
New lesion resulting in initial PD is worse (qualitative)
Additional new lesion(s) since last evaluation
Additional new non target progression since last evaluation
In subjects who have initial evidenc e of radiological PD, it is at the discretion of the 
investigator whether to continue a subject on study treatment until repeat imaging is 
obtained . This clinical judgment decision should be based on the subject’s overall clinical 
condition, including performance status, clinical symptoms, and laboratory data. Subjects 
may receive study treatment while waiting for confirmation of PD,if they are clinically 
stable as defined by [CONTACT_4868]:
Absence of symptoms and signs indicating clinically significant progression of 
disease, including worsening of laboratory values
No decline in ECOG performance status
Absence of rapid pro gression of disease
Absence of progressive tumor at critical anatomical sites (eg, cord compression) 
requiring urgent alternative medical intervention
When feasible, subjects should not be discontinued until progression is confirmed . This 
allowance to continue treatment despi[INVESTIGATOR_762553] 
087V73
Prod uct:  MK-1454 124
Protocol/Amendment No.: 001-[ADDRESS_1044999] repeat imaging for confirmation of PD. 
NOTE :  In subjects who discontinue study therapy without documented disease progression, 
every effort should be made to continue monitoring oftheir disease status by [CONTACT_762627] 9weeks (± 7 days) until:(1) the start of new anticancer treatment, (2) disease 
progression (3) death, or (4) the end of the study, whichever occurs first.
Confirmation of PR and CR is required at least 4weeks after the initial response assessment 
of PR and CR.
[IP_ADDRESS].[ADDRESS_1045000] (itRECIST)
itRECIST is a response assessment that is tailored to IT immunotherapy, is aligned with 
RECIST 1.1 overall response assessment [3]and is further described in Appendix 12.4. 
itRECIST :
provides a guidance on baseline categorization of target and nontarget lesions 
(Figure 5);
provides guidance on recategorization of lesions during therapy ( Figure 6);
allows for separate response assessment ininjected and noninjected lesions 
(Figure 7);
for injected lesions, provides aniterative response assessment process that adapts to 
changes in lesion selection for IT immunotherapy (an example is provided in
Figure 8); and
provides guidelines on prioritization of lesion injection during the course of 
intratumoral immunotherapy (see Appendix 12. 3)
itRECIST supports standardized collection of data from IT immunotherapy clinical trials to 
facilitate exploratory response analysi s.
[IP_ADDRESS].[ADDRESS_1045001]/PET,bone marrow biopsy ,and clinical 
information including physical exam and symptoms, using the IWG Revised Response 
Criteria for Malignant Lymphomas [25]. Information collected includes : 
1.At a minimum, thoracic, abdominal, and pelvic CT scans will be performed even if 
those areas were not initially involved because of the unpredictable pattern of 
recurrence in malignant lymphoma . Neck CT should be performed at Screening, and 
at follow -up visits if there is nodal involvement in the neck at screening . 
Fluorodeoxyglucose -PET scans may be obtained to supplement the anatomic 
087V73
Prod uct:  MK-1454 125
Protocol/Amendment No.: 001-[ADDRESS_1045002] be confirmed by [CONTACT_117145], 
laboratory assessments, repeat bone marrow biopsy [25],and CT scan. Subjects with 
suspected relapse or disease progression should continue to follow study procedures until 
they need another therapy . If a subject requires another therapy, date of treatment and type of 
treatment will be recorded, and they will then be removed from the tri al. 
Tumor progression is defined as ≥50% increase from nadir in the sum of the products of 
diameters (SPD), of target lesions, or by [CONTACT_762628] a single nodal target lesion, or by [CONTACT_762629], or the appearance of new lesions, as defined inthe IWG revised 
response criteria for malignancy lymphoma [25]. 
Table 16 Response Criteria for Malignant Lymphoma
Response 
CategoryPhysical 
Examination Nodal Masses Spleen, Liver Bone Marrow
Complete 
ResponseDisappearance of 
all evidence of 
disease(a) FDG -avid or 
PET positive prior 
to therapy; mass of 
any size permitted 
if PET negative
(b) Variably FDG -
avid or PET 
negative; 
regression to 
normal size on CTNot palpable, 
nodules 
disappearedInfiltrate cleared on 
repeat biopsy; if 
indeterminate by 
[CONTACT_5293], 
immunohistochemistry 
should be negative
Partial 
ResponseNo progression of 
palpable disease 
and no new sites≥ 50% decrease in 
SPD of up to [ADDRESS_1045003] dominant 
masses; no 
increase in size of 
other nodes
(a) FDG -avid or 
PET positive prior 
to therapy; one or 
more PET positive 
at previously 
involved site
(b) Variably FDG -
avid or PET 
negative; 
regression on CT≥ 50% decrease in 
SPD of nodules 
(for single nodule 
in gr eatest 
transverse 
diameter); no 
increase in size of 
liver or spleenIrrelevant if positive 
prior to therapy; cell 
type should be 
specified
087V73
Prod uct:  MK-1454 126
Protocol/Amendment No.: 001-08 
MK-1454 -001-08 Final Protocol 27-Jul-2021
ConfidentialResponse 
CategoryPhysical 
Examination Nodal Masses Spleen, Liver Bone Marrow
Stable DiseaseFailure to attain 
CR/PR or PD(a) FDG -avid or 
PET positive prior 
to therapy; PET 
positive at prior 
sites of disease and 
no new sites on CT 
or PET
(b) Variably FDG -
avid or PET 
negative; no 
change in size of 
previous lesions on 
CT
Relapse/ 
ProgressionAny new lesion or 
increase by ≥50% 
of previously 
involved sites from 
nadirAppearance of a 
new lesion(s) _ 
1.5cm in any axis, 
≥50% increase in 
SPD of more than 
one node, or 
≥50% increase in 
longest diameter of 
a previously 
identified node 
>1cm in short axis 
Lesions PET 
positive if FDG -
avid lymphoma or 
PET positive prior 
to therapy≥50% increase 
from nadir in the 
SPD of any 
previous lesionsNew or recurrent 
involvement
Abbreviations: CT = computed tomography; FDG = fluorodeoxyglucose ; PET = positron -emission tomography; 
SPD = sum of the product of the longest bidimensional diameters
[IP_ADDRESS].4 Response Assessment Criteria for C TCL
The Modified Severity Weighted Assessment Tool (mSWAT -Table 17) will be used to 
evaluate the extent of disease in the CTCL subject s prior to treatment at each cycleper the 
SoA. Imaging (CT scans and medical photography) will be performed at screening/baseline 
forall CTCL subject s. In those patients with advanced disease at baseline (maximum/current 
stage greater than or equal to Stage IIB [T3N0M0B0 ]), repeat imaging studies should be 
performed at the time of PR and CRby [CONTACT_762630], and any time there is a 
question of ne w or PD in the lymph nodes or the viscera; and at theend of the study [2].
Each scheduled response assessment will include evaluations of skin (Table 18), lymph 
nodes (Table 19), viscera (Table 20), and blood (Table 21); and will determine a global
response score ( Table 22) for CTCL subject s. Medical photography will also be performed at 
the time of each response assessment (see SoA), or more often as warranted.
087V73
Prod uct:  MK-1454 127
Protocol/Amendment No.: 001-08 
MK-1454 -001-08 Final Protocol 27-Jul-2021
ConfidentialTable 17 Modified Severity Weighted Assessment Tool
Body Regions% BSA in 
Body 
RegionAssessment of Involvement in Patient’s Skin
PatchaPlaquebTumorc
Head 7
Neck 2
Anterior trunk 13
Arms 8
Forearms 6
Hands 5
Posterior trunk 13
Buttocks 5
Thighs 19
Legs 14
Feet 7
Groin 1
Subtotal of lesion 
BSA
Weighting factor×1 ×2 ×4
Subtotal lesion BS A
× weighting factor
Abbreviations: BSA =body surface area; mSWAT =modified Severity Weighted Assessment Tool
NOTE:  mSWAT score equals summation of each column line
a.Any size lesion without induration of significant elevation above the surrounding uninvolved skin; 
poikiloderma may be present.
b. Any size lesion that is elevated or indurated, crusting, ulceration, or poikiloderma may be present.
c.Any solid or nodular lesion ≥1cm in diameter with evidence of deep infiltration in the skin and/or vertical 
growth.
087V73
Prod uct:  MK-1454 128
Protocol/Amendment No.: 001-08 
MK-1454 -001-08 Final Protocol 27-Jul-2021
ConfidentialTable 18 Response in Skin (C TCL )
Response Definition
CR 100% clearance of skin lesions
PR 50%-99% clearance of skin disease from baseline without new tumors (T 3) 
in patients with T 1, T2or T4only skin disease
SD <25% increase to <50% clearance in skin disease from baseline without new 
tumors (T 3) in patients with T 1, T2, or T 4only skin disease
PD Whichever criterion occurs first:
≥25% increase in skin disease from baseline 
OR 
New tumors (T 3) in patients with T 1, T2or T4only skin disease
OR
Loss of response: in those with complete or partial response, increase of skin 
score of greater than the sum of nadir plus 50% baseline score
Relapse Any disease recurrence in those with complete response
Abbreviations: CR = complete response; PD = progressive disease; PR = partial response; SD = stable 
disease
NOTE. Based on Modified Severity Weighted Assessment Tool (mSWAT) score. A biopsy of normal 
appearing skin is unnecessary to assign a complete response. However, a skin biopsy should be performed of 
a representative area of the skin if there is any question of residual disease (persistent erythema or 
pi[INVESTIGATOR_138716]) where otherwise a complete response would exist. If histologic features are suspi[INVESTIGATOR_15665] o r 
suggestive of mycosis fungoides/Sézary syndrome, the response should be considered a partial response 
only.
087V73
Prod uct:  MK-1454 129
Protocol/Amendment No.: 001-08 
MK-1454 -001-08 Final Protocol 27-Jul-2021
ConfidentialTable 19 Response in Lymph Nodes (C TCL )
Response Definition (peripheral and/or central lymph nodes)
CR All lymph node s are now ≤1.[ADDRESS_1045004] transverse (long axis) diameter 
by [CONTACT_762631]; in addition, lymph nodes that were N 3classification and ≤1.5 cm 
in their long axis and >[ADDRESS_1045005] now be ≤1 
cm in their short axis or biopsy negative for lymphoma
PR Cumulative reduction ≥50% of the SPD of each abnormal lymph node at 
baseline and no new lymph node >1.5 cm in the diameter of the long axis or 
>1.[ADDRESS_1045006]:
≥50% increase in SPD from baseline of lymph nodes 
OR
Any new node >1.5 cm in the long axis or >1 cm in the short axis if 1 -1.5 
cm in the long axis that is proven to be N 3histologically 
OR
Loss of response: >50% increase from nadir in SPD of lymph nodes in those 
with PR
Relapse Any new lymph nod e >1.5 cm in the long axis in those with CR proven to be 
N3histologically
Abbreviations: CR = complete response; PD = progressive disease; PR = partial response; SD = stable 
disease; SPD = sum of the product of the longest bidimensional diameters
087V73
Prod uct:  MK-1454 130
Protocol/Amendment No.: 001-08 
MK-1454 -001-08 Final Protocol 27-Jul-2021
ConfidentialTable 20 Response in Viscera (C TCL )
Response Definition
CR Liver or spleen or any organ considered involved at baseline should not be 
enlarged on physical exam and should be considered normal by [CONTACT_9661]; no 
nodules should be present on imaging of liver or spleen; any posttreatment 
mass must be determined by [CONTACT_460348] ≥50% regression in any splenic or liver nodules, or in measurable disease 
(SPD) in any organs abnormal at baseline; no increase in size of liver or 
spleen and no new sites of involvement
SD Fails to attain the criteria for CR, PR, or PD
PD Whichever criterion occurs first:
>50% increase in size (SPD) of any organs inv olved at baseline 
OR
New organ involvement 
OR
Loss of response: >50% increase from nadir in the size (SPD) of any 
previous organ involvement in those with PR
Relapse New organ involvement in those with CR
Abbreviations: CR = complete response; PD = pr ogressive disease; PR = partial response; SD = stable 
disease; SPD = sum of the product of the longest bidimensional diameters
087V73
Prod uct:  MK-1454 131
Protocol/Amendment No.: 001-08 
MK-1454 -001-08 Final Protocol 27-Jul-2021
ConfidentialTable 21 Response in Blood (C TCL )
ResponseaDefinition
CRbB0
PRc>50% decrease in quantitative measurements of blood tumor burden from 
baseline in those with high tumor burden at baseline (B 2)
SD Fails to attain criteria for CR, PR, or PD
PD Whichever criterion occurs first:
B0to B2
OR
>50% increase from baseline and at least 5,000 neoplastic cells/µL [35]
OR
Loss of response: in those with PR who were originally B 2at baseline, 
>50%increase from nadir and at least 5,000 neoplastic cells/µL
Relapse Increase of neoplastic blood lymphocytes to ≥ B1in those with CR
Abbreviations: CR = complete response; PD = progressive disease; PR = partial response; SD = stable 
disease
aAs determined by [CONTACT_206894]/ µL.
bIf a bone marrow biopsy was performed at baseline and deter mined tounequivocally be indicative of 
lymphomatous involvement, then to confirm aglobal CR where blood assessment now meets criteria for B0, 
a repeat bone marrow biopsy must show no residual disease, or the response should be considered a PR only.
cThere is no PR in those with B 1disease at baseline as the difference within the range of neoplastic cells that 
define B 1is not considered significant and should not affect determination of global objective response.
Table [ADDRESS_1045007] CR/NI
PR Regression of measurable disease CR All categories do not have a 
CR/NI and no category has a PD
PR No category has a PD and if any 
category involved at baseline, at 
least one has a CR or PR
SD Failure to attain CR, PR, or PD 
representative of all diseasePR No category has a PD and if any 
category involved at baseline, no 
CR or PR in any
SD CR/NI, PR, SD in any category 
and no category has a PD
PD Progressive disease PD in any category
Relapse Recurrence disease in prior CR Relapse in any category
087V73
Prod uct:  MK-1454 132
Protocol/Amendment No.: 001-08 
MK-1454 -001-08 Final Protocol 27-Jul-2021
ConfidentialGlobal
ScoreaDefinition Skin Nodes, Blood, Viscera
Abbreviations: CR=complete response; NI =noninvolved; PD, progressive disease; PR=partial response; SD
=stable disease.
aIt is recommended that not only the proportion of patients who achieve a response or an unfavorable outcome  
be calculated but a life table account for the length of the interval during which each patient is under 
observation also be generated.
Laboratory Procedures/Assessments
Details regarding specific laboratory procedures/assessments to be performed in this trial are 
provided below. The total amount of blood/tissue to be drawn/collected over the course of 
the trial (from pre-trial to post-trial visits), including approximate blood/tissue volumes 
drawn/collected by [CONTACT_176752].
Laboratory Safety Evaluations (Hematology, Chemistry ,and Urinalysis)
Laboratory tests for hematology, chemistry ,and urinalysis are specifi ed in Table 23.
Table 23 Laboratory Tests
Hematology Chemistry Urinalysis Other
Hematocrit Albumin Blood FSHa
Hemoglobin Alkaline phosphatase Glucose Serum hCG
Platelet count ALT Protein Hepatitis
WBC (total and 
differential)bAST Specific gravity HIV
RBC Carbon Dioxide or BicarbonateMicroscopic exam, if 
abnormal results are 
notedT3 or FT3
PT or INR Calcium Urine pregnancy testaT4 or F T4
PTT or aPTT Chloride TSH
CreatininedHPVe
GGT
Glucose
Phosphorus
Potassium
Sodium
Total Bilirubin  
Direct Bilirubin, if total bilirubin 
is elevated above the ULN
Total protein
BUNe
LDH
Uric acid
087V73
Prod uct:  MK-1454 133
Protocol/Amendment No.: 001-08 
MK-1454 -001-08 Final Protocol 27-Jul-2021
ConfidentialHematology Chemistry Urinalysis Other
ALT= alanine aminotransferase ;aPTT=activated partial thromboplastin time; AST=aspartate aminotransferase; 
BUN=blood urea nitrogen; FT3=free triiodothyronine; FT4=free thyroxine; FSH=follicle stimulating hormone; 
GGT=gamma glutamyl transpeptidase; HCG= human chorionic gonadotropin ; HNSCC = head and neck squamous cell 
carcinoma; HPV=human papi[INVESTIGATOR_27509]; INR=International Normalized Ratio; LDH=lactic dehydrogenase; 
PT=prothrombin time; PTT=partial thromboplastin time; RBC=red blood count; SCC = squamous cell carcinoma;
T3=total triiodothyronine; T4=total thyroxine; TSH=thyroid stimulating hormone; ULN=upper limit of normal; 
WBC=white blood count ; WOCBP = women of childbearing potential. .
aPerform on WOCBP only. If urine pregnancy results cannot be confirmed as negative, a serum pregnancy test will be 
required.
bAbsolute or % acceptable per institutional standard
cFor subjects with a baseline calculated creatinine clearance that isbelow the normal institutional laboratory range, a 
baseline measured creatinine clearance should be performed. GFR can be used in place of creatinine clearance .
dHNSCC or other SCC subjects only
eBUN is preferred; if not available urea may be tested
Laboratory safety tests for screening should be performed within 28days prior to first dose 
of study medication , unless otherwise specified in the SoA . After Cycle 1, predose laboratory 
tests can be performed up to [ADDRESS_1045008] be reviewed by [CONTACT_762632].
Pharmacokinetic/Pharmacodynamic Evaluations
[IP_ADDRESS].1 Blood Collection for MK -1454 and Pe mbrolizumab PK
Blood sample collection, storag e, and shipment instructions will be provided in the 
Procedures Manual . MK-1454 PK samples can be used for metabolite analysis. 
Pembrolizumab PK and ADA samples can be discontinued based on early data.
[IP_ADDRESS].2 Blood Collection for Anti -Pembrolizumab Antibodies (ADA)
Blood sample collection, storage ,and shipment instructions for ADA analysis will be 
provided in the Procedure sManual.
[IP_ADDRESS].3 Blood for Pharmacodynamic Markers
Blood sample collection, storage ,and shipment instructions for PD analysis will be provided 
in the Procedure sManu al.
The time points for PD sampling are described in Section 6.0 -Schedule of Activities . 
[IP_ADDRESS].4 Tumor Biopsy
Tumor samples will be collected at the time points described inSection 6.0–Schedule of 
Activities .
All subject swill be required to provide a sample biopsy of the tumor to be injected with 
MK-1454 and a sample biopsy from a distant, discrete noninjected site(if feasible) (at least 2 
biopsies at each site) after IT administration of MK-1454, unless deemed medic allyunsafe 
by [CONTACT_093] . For Part II Expansion Cohort, only the injected tumor biopsy is required, 
087V73
Prod uct:  MK-1454 134
Protocol/Amendment No.: 001-[ADDRESS_1045009] be ≥[ADDRESS_1045010] diameter 
for non -nodal lesions, or ≥1.[ADDRESS_1045011] superficial lesions amendable to 
intratumoral injection will be eligible (cutaneous lesions injected via visual inspection, and 
subcutaneous lymph nodes injected via ultrasound guidance or palpation ). No lymphoma 
subject s with exclusive lydeep lymph nodes will be included in this study . Lymphoma 
subject swho have both superficial and deep lymph nodes will be eligible for enrollment into 
this study, however only the superficial lymph nodes will be injected. 
A predose tumor biopsy will be performed at screening on both the tumor lesion which is 
intended fo r treatment with IT injection of MK -1454, as well as on the distant lesion which is 
not intended for IT injection with MK-1454. For Part II Expansion Cohort, only the injected 
tumor biopsy is required, unless deemed medically unsafe by [CONTACT_093].
For the tumor lesion intended for treatment with ITinjection of MK -1454, the sample will be 
obtained by [CONTACT_762614], by [CONTACT_762633] /visceral lesions, or by [CONTACT_12783] -sectional imaging guidance for visc eral lesions .   
For distant discrete tumor lesions which are not intended for ITinjection with MK-1454, the 
sample biopsy will be obtained by [CONTACT_080]: punch biopsy for cutaneous lesions, 
ultrasound guided biopsy for subcutaneous /visceral lesions, or image -guided biopsy, such as 
CT-guided biopsy for visceral lesions and deeper tumor lesions . On-treatment biopsy site 
location may vary from baseline biopsy site location based on lesion accessibility and subject
tolerance . Method of biopsy will be per guidance of the investigator , as well as discussion 
with the Sponsor .   
For visceral lesions, the sample biopsy will be obtained via ultrasound guidance or cross -
sectional imaging (CT/MRI) guidance .
Leftover main study tissue will be stored for FBR if the subject consents to FBR .
Samples of archival tumor tissue collected at screening should be freshly cut, and the slides 
from this freshly cut archival tumor tissue should be submitted to the testing laboratory 
within [ADDRESS_1045012]:  MK-1454 135
Protocol/Amendment No.: 001-08 
MK-1454 -001-08 Final Protocol 27-Jul-2021
Confidential
Planned Genetic Analysis Sample Collection
Sample collection, storage and shipment instructions for Planned Genetic Analysis samples 
will be provided in the Procedures Manual . This sample should be drawn for planned 
analysis of the association between genetic variants in DNA and drug response. If there is 
either a documented law or regulation prohibiting collection, or if the IRB/IEC does not 
approve the collection of the sample for these purposes, then this sample will not be collected 
at that site. If the sample is collected, leftover extracted DNA will be stored for FBR if the 
subject provides documented informed consent for FBR . If the planned genetic analysis is 
not approved, but FBR is approved and consent is given, this sample will be collected for the 
purpose of FBR.
Future Biomedical Research Sample s
The following specimens are to be obtained as part of FBR :
DNA for future research
In addition, any tissue obtained for protocol -specified assessments that is remaining after the 
assessment is completed will be stored for future research, including:
RNA 
Serum 
Plasma 
Tumor tissue
Bone marrow biopsy/aspi[INVESTIGATOR_762554] 12. 2.
Other Procedures
Withdrawal/Discontinuation
It has been well documented that a higher rate of withdrawal can render a study 
uninterpretable; therefore, unne cessary withdrawal of subjects should be avoided. As clinical 
event data are important to study endpoints, subjects who discontinue/withdraw from 
treatment prior to completion of the treatment regimen should be encouraged to continue to 
be followed for allremaining study visits for follow -up and vital status assessments as 
outlined in the SoA .
When a subject discontinues/withdraws from participation in the trial , all applicable activities 
scheduled for the final trial visit should be performed at the time of discontinuation. Any AEs
which are present at the time of discontinuation/withdrawal should be followed in accordance 
with the safety requirements outlined in Section 7.[ADDRESS_1045013]:  MK-1454 136
Protocol/Amendment No.: 001-[ADDRESS_1045014] to stop study procedures, they are encouraged to continue to be followed, 
which allows periodic survival follow -up and vital status data to be collected.
[IP_ADDRESS].[ADDRESS_1045015] the Sponsor using the designated mailbox 
([EMAIL_1250]).  Subsequently, the subject's consent for FBR 
will be withdrawn.   A letter will be sent from the Sponsor to the investigator confirming the 
withdrawal . It is the responsibility of the investig ator to inform the subject of completion of 
withdrawal .  Any analyses in progress at the time of request for withdrawal or already 
performed prior to the request being received by [CONTACT_762634].  No new analyses would be generated after the 
request is received.
In the event that the medical records for the main trial are no longer available (e.g., if the 
investigator is no longer required by [CONTACT_121275]) or 
the specimens have been completely anonymized, there will no longer be a link between the 
subject’s personal information and their specimens.  In this situation, the request for 
specimen withdrawal cannot be processed.
[IP_ADDRESS].[ADDRESS_1045016] fails to return to the clinic for a required study visit and/or if the site is unable to 
contact [CONTACT_423], the following procedures are to be performed:
The site must attempt to contact [CONTACT_75359] . If the 
subject is contact[INVESTIGATOR_530], the subject should be counseled on the importance of 
maintaining the protocol -specified visit schedule.
The investigator or designee must make every effort to regain contact [CONTACT_90071] (eg,phone calls and/o r a certified letter to the 
subject’s last known mailing address or locally equivalent methods) . These 
contact [CONTACT_9300]’s medical record.
Note:  A subject is not considered lost to follow -up until the last scheduled visit 
for the individual subject . The amount of missing data for the subject will be 
managed via the pre specified data handling and analysis guidelines.
Subject Blinding/Unblinding
This is an open -label trial; there is no blinding for this trial.
087V73
Prod uct:  MK-1454 137
Protocol/Amendment No.: 001-08 
MK-1454 -001-08 Final Protocol 27-Jul-2021
Confidential
Domiciling
Subjects in Part I (Arms 1 2, and 3) will report to the CRU on C1D1 and will remain for 
inpatient observation forat least 24hours post MK-[ADDRESS_1045017] MK-1454 administration on C1D1 may be extended to 
48hours, based on the discretion of the investigator , and/or local IRB/IEC , and/or Health 
Authority mandate.
This requirement may be waived at the discretion of the Sponsor and will be communicated 
to sites via a memorandum. 
Subjects in Part II (Expansion Cohorts A, B, and C) will report to the CRU on C1D1 and will 
remain in the clinic for at least 8hours post MK-[ADDRESS_1045018] MK-1454 administration on C1D1 may be extended based on the 
discretion of the investigator and/or local IRB/IEC , and/or Health Authority mandate.
Calibration of Equipment
The investigator or quali fied designee has the responsibility to ensure that any device or 
instrument used for a clinical evaluation/test during a clinical trial that provides information
about inclusion/exclusion criteria and/or safety or efficacy parameters shall be suitably 
calibrated and/ormaintained to ensure that the data obtained is reliable and/or reproducible.  
Documentation of equipment calibration must be retained as source documentation at the 
trial site.
Visit Requirements
Visit requirements are outlined in Section 6.0–Schedule of Activites . Specific procedure -
related details are provided above in Section 7.1 -Trial Procedures.
Screening
Up to28 days prior to treatment allocation/ randomization, potential subjects will be 
evaluated to determine ifthey fulfill the entry requirements as set forth in Section 5.1. Tests 
performed as part of routine clinical management prior to the subject signing consent are 
acceptable in lieu of a screening test, if these tests are performed within the specified time 
frame of 28 days prior to treatment allocation/randomization . Bone marrow biopsy results for 
lymphoma subjects are permissible up to 8 weeks prior to screening.
Screening procedures may be repeated after consultation with the Sponsor.
Treatment Period
The treatment period in each treatment arm or expansion cohort (Arm 1, Arm 2, and Arm 3; 
Cohorts A, B, and C) begins with Cycle 1 and may continue for up to 35 cycles 
(approximately 2 years) from the start of treatment until disease progression ,unacceptable 
AE(s), intercurrent illness that prevents further administration of treatment, investigator ’s 
decision to withdraw the subject, subject withdraws consent, pregnancy of the subject, 
noncompl iance with trials treatment or procedure requirements, or administrative reasons 
requiring cessation of treatment .Subjects who cross over from Arm [ADDRESS_1045019]:  MK-1454 138
Protocol/Amendment No.: 001-08 
MK-1454 -001-08 Final Protocol 27-Jul-2021
Confidentialfor up to 35 cycles of treatment within Arm 2, regardless of the number of cycles of
MK-1454 treatment received in Arm 1 .Each cycle includes study drug administration and all 
associated assessments as outlined in the Schedule of Activities (see Section 6.0 ). 
Specific procedure -related details are provided throughout Section 7.0.
Treatment Period Beyond Disease Progression
See Section [IP_ADDRESS] .
Discontinued Subjects Continuing to be Monitored in the Trial
The Discontinuation Visit should occur at the time study treatment is discontinued for any 
reason. If the Discontinuation Visit occurs [ADDRESS_1045020]
withdrawal and discontinuation are presented in Section 5.8 –Subject 
Withdrawal/Discontinuation Criteria.
30-Day Safety Follow -up Visit
The mandatory 30-day Safety Follow -up Visit should be conducted approximately 30 days 
(+7days) after the last dose of trial treatment or before the initiation of a new antineoplastic 
treatment, whichever comes first. All AEs that occur prior to the 30-day Safety Follow -up 
Visit should be recorded . Subjects with an AE of Grade >[ADDRESS_1045021] to follow -up, will 
be followed up for survival and will be contact[CONTACT_147464] 12 weeks (±14 days) 
to monitor survival status . Subject s who experience confirmed disease progre ssion or start a 
new anticancer therapy, will move into the Survival Follow -Up Phase and should be 
contact[CONTACT_80077] [ADDRESS_1045022].
To ensure current and complete survival data is available at the time of database locks, 
updated survival status may be requested during the course of the study by [CONTACT_1034] . For 
example, updated survival status may be requested prior to interim and/or final analysis . 
Upon Sponsor notification, all subject s who do not/will not have a scheduled study visit or 
study contact [CONTACT_19458] -defined time period will be contact[CONTACT_762635] 
087V73
Prod uct:  MK-1454 139
Protocol/Amendment No.: 001-08 
MK-1454 -001-08 Final Protocol 27-Jul-2021
Confidentialstatus (excluding subject s who have withdrawn consent or have a previously recorded death 
event in the collection tool).
Every effort should be made to collect information regarding disease status until the start of 
new antineoplastic therapy, disease progression, death, or the end of the s tudy.
Assessing and Recording Adverse Events      
An AE is defined as any untoward medical occurrence in a patient or clinical investigation 
subject administered a pharmaceutical product and which does not necessarily have to have a 
causal relationship with this treatment. An AE can therefore be any unfavourable and 
unintended sign (including an abnormal laboratory finding, for example), symptom, or 
disease temporally associated with the use of a medicinal product or protocol -specified 
procedure, whether ornot considered related to the medicinal product or protocol -specified 
procedure.  Any worsening (i.e., any clinically significant adverse change in frequency 
and/or intensity) of a preexisting condition that is temporally associated with the use of the 
Sponsor’s product, is also an AE.
Changes resulting from normal growth and development that do not vary significantly in 
frequency or severity from expected levels are not to be considered AEs.  Examples of this 
may include, but are not limited to, teething, typi[INVESTIGATOR_482566] a physiologically appropriate time.
Sponsor's product includes any pharmaceutical product, biological product, device, 
diagnostic agent or protocol -specified procedure, whether investigational (including placebo 
or active comparator medication) or marketed, manufactured by, licensed by, provided by [CONTACT_26363].
AEs may occur during clinical trials, or as prescribed in clinical practice, from overdose 
(whether accidental or intentional), from abuse and from withdrawal.
Progression of the cancer under study is not considered an AE.
All AEs that occur after consent is documented but before treatment 
allocation/randomization must be reported by [CONTACT_105943], or are the result of a protocol -specified intervention, including but 
not limited to washout or discontinuation of usual therapy, diet, placebo treatment or a 
procedure. From the time of treatment allocation/randomization through [ADDRESS_1045023] be reported by [CONTACT_093]. Such events will be 
recorded at each examination on the AE CRFs/worksheets.  The reporting timeframe for AEs 
meeting any serious criteria is described in section [IP_ADDRESS]. The investigator will make every 
attempt to follow all subjects with nonserious adverse events for outcome.
Electronic reporting procedures can be found in the EDC data entry guidelines. Paper 
reporting pro cedures can be found in the Investigator Trial File Binder (or equivalent).
AEs will not be collected for subjects during the pre-screening period (for determination of 
archival tissue status) as long as that subject has not undergone any protocol -specifie d 
procedure or intervention.  If the subject requires a blood draw, fresh tumor biopsy etc., the 
subject is first required to provide consent to the main study and AEs will be captured 
according to guidelines for standard AE reporting.
087V73
Prod uct:  MK-1454 140
Protocol/Amendment No.: 001-08 
MK-1454 -001-08 Final Protocol 27-Jul-2021
Confidential
Definition of an Overdose for This Protocol and Reporting of Overdose to the 
Sponsor
For purposes of this trial, an overdose will be defined as any dose exceeding the prescribed 
dose for MK-1454 by 20% of the indicated dose or a pembrolizumab dose of ≥1000 mg 
(≥5times the indicated dose) . No specific information is available on the treatment of 
overdose of MK-1454 or pembrolizumab . In the event of overdose, treatment with MK-1454 
and/or pembrolizumab should be discontinued and the subject should be observed closely for 
signs of toxicity.  Appropriate supportive treatment should be provided if clinically indicated.
If an AE(s) is associated with (“results from”) the overdose of Sponsor's product or vaccine, 
the AE(s) is/are reported as an SAE, even if no other seriousness criteria are met.
If a dose of Sponsor's product or vaccine meeting the protocol definition of overdose is taken 
without any associated clinical symptoms or abnormal laboratory results , the overdose is 
reported as a non-serious ECI, using the terminology “accidental or intentional overdose 
without adverse effect.”
All reports of overdose with and without an AE must be reported by [CONTACT_19452] 
24 hours to the Sponsor either by[CONTACT_26365]. Electronic reporting procedures 
can be found in the EDC data entry guidelines. Paper reporting procedures can be found in 
the Investigator Trial File Binder (or equivalent).
Reporting of Pregnancy and Lactation to the Sponsor
Although pregnancy and lactation are not considered AEs, it is the responsibility of 
investigator s or their designees to report any pregnancy or lactation in a subject 
(spontaneously reported to them) that occurs during the trial.
Pregnancies and lactations that occur after the consent form is signed but before treatment 
allocation/randomization must be reported by [CONTACT_105943], or are the result of a protocol -specified intervention, including but 
not limited to washout or discontinuation of usual therapy, diet, placebo treatment, or a 
procedure . Pregnancies and lactations that occur from the time of treatment 
allocation/randomization through 130 days following cessation of Sponsor’s product, or 
30days following cessation of trial treatment if the subject initiates new anticancer therapy, 
whichever is earlier, must be reported by [CONTACT_093] . All reported pregnancies must be 
followed to the completion/termination of the pregnancy . Pregnancy outco mes of 
spontaneous abortion, missed abortion, benign hydatidiform mole, blighted ovum, fetal 
death, intrauterine death, miscarriage and stillbirth must be reported as serious events 
(important medical events) . If the pregnancy continues to term, the outcom e (health of infant) 
must also be reported.
Such events must be reported within 24 hours to the Sponsor by [CONTACT_762636] . Electronic reporting procedures can be found in the EDC data entry guidelines . Paper 
reporting procedures can be fo und in the Investigator Trial File Binder (or equivalent).
087V73
Prod uct:  MK-1454 141
Protocol/Amendment No.: 001-08 
MK-1454 -001-08 Final Protocol 27-Jul-2021
Confidential
Immediate Reporting of Adverse Events to the Sponsor
Serious Adverse Events
An SAE is any AE occurring at any dose or during any use of Sponsor's product that:
●Results in death;
●Is life threatening;
●Results in persistent or significant disability/incapacity;
●Results in or prolongs an existing inpatient hospi[INVESTIGATOR_059];
●Is a congenital anomaly/birth defect;
●Is another important medical event .
Note: In addition to the above criteri a, AEs meeting either of the below criteria, although not 
serious per ICH definition, are reportable to the Sponsor in the same timeframe as SAEs to 
meet certain local requirements. Therefore, these events are considered serious by [CONTACT_762637] .
●Is a new cancer (that is not a condition of the study);
●Is associated with an overdose.
Refer to Table 24for additional details regarding each of the above criteria.
For the time period beginning when the consent form is signed until treatment 
allocation/randomization, any SAE, or follow up to a SAE, including death due to any cause, 
that occurs to any subject must be reported within [ADDRESS_1045024] to be excluded from the trial, or is the result of a protocol -specified intervention, 
including but not limited to washout or discontinuation of usual therapy, diet, placebo 
treatment or a procedure .
For the time period beginning at treatment allocation/randomization through [ADDRESS_1045025] initiates new anticancer therapy, whichever is earlier, any SAE, or follow up to an 
SAE, including death due to any cause, whether or not related to the Sponsor's product, must 
be reported within 24 hours to the Sponsor either by [CONTACT_26365]. Electronic 
reporting procedures can be found in the EDC data entry guidelines. Paper reporting 
procedures can be found in the Investigator Trial File Binder (or equivalent) .
Additionally, any SAE, considered by [CONTACT_19427] a qualified physician to be 
related to the Sponsor's product that is brought to the attention of the investig ator at any time 
following consent through the end of the specified safety follow -up period specified in the 
paragraph above, or at any time outside of the time period specified in the previous paragraph 
also must be reported immediately to the Sponsor.  
All subjects with SAEs must be followed up for outcome .
087V73
Prod uct:  MK-1454 142
Protocol/Amendment No.: 001-[ADDRESS_1045026] be reported to the 
Sponsor.
For the time period beginning when consent is documented until treatment 
alloc ation/randomization, any ECI, or follow up to an ECI, that occurs to any subject must be 
reported within [ADDRESS_1045027] to be excluded from the trial, 
or is the result of a protocol -specified intervention, including but not limited to washout or 
discontinuation of usual therapy, diet, placebo treatment or a procedure .
For the time period beginning at treatment allocation/randomization through [ADDRESS_1045028] initiates new anticancer therapy, whichever is earlier, any ECI, or follow up to an 
ECI, whether or not related to the Sponsor’s product, must be reported within 24 hours to the 
Sponsor, either by [CONTACT_26365].  Electronic reporting procedures can be found 
in the EDC data entry guidelines.  Paper reporting procedures can be found in the 
Investigator Trial File Binder (or equivalent).
Events of clinical interest for this trial include:
1. an overdose of Sponsor's product, as defined in Section 7.2.[ADDRESS_1045029] of protocol -specified l aboratory testing or unscheduled laboratory testing.*
*Note:  These criteria are based upon available regulatory guidance documents. The 
purpose of the criteria is to specify a threshold of abnormal hepatic tests that may require 
an additional evaluation f or an underlying etiology. The trial site guidance for assessment 
and follow up of these criteria can be found in the Investigator Trial File Binder (or 
equivalent).
Protocol -Specific Exceptions to Serious Adverse Event Reporting
Efficacy endpoints as outlined in this section will not be reported to the Sponsor as described 
in Section 7.2.3 . Any such event will be submitted to the Sponsor within 24 hours either by 
[CONTACT_131008].
Specifically, the suspected/actual events covered in this exception include any event that is 
disease progression of the cancer under study.
The Sponsor will monitor efficacy endpoint events and safety data to ensure the safety of the 
subjects in the trial. Any suspected endpoint which upon review is not progression of the 
cancer under study will be forwarded to global safety as anSAE within [ADDRESS_1045030]:  MK-1454 143
Protocol/Amendment No.: 001-08 
MK-1454 -001-08 Final Protocol 27-Jul-2021
Confidential
Evaluating Adverse Events
An investigator who is a qualified physician will evaluate all AEs according to the NCI 
CTCAE, version 4.0(Table 24). Any AEwhich changes CTCAE grade over the course of a 
given epi[INVESTIGATOR_762555] /worksheets.
All AEs regardless of CTCAE grade must also be evaluated for seriousness.
For studies in which multiple agents are administered as part of a combination regimen, the 
investigator may attribute each AEcausality to the combination regimen or to a single agent 
of the combination.  In general, causality attribution should be assign ed to the combination 
regimen (i.e., to all agents in the regimen). However, causality attribution may be assigned to 
a single agent if in the investigator’s opi[INVESTIGATOR_1649], there is sufficient data to support full 
attribution of the AEto the single agent.
087V73
Product:   MK-1454 144
Protocol/Amendment No.: 001-08 
MK-1454 -001-08 Final Protocol 27-Jul-2021
ConfidentialTable 24 Evaluating Adverse Events
An investigator who is a qualified physician, will evaluate all AEs as to:
V4.0 CTCAE 
GradingGrade 1 Mild; asymptomatic or mid symptoms; clinical or diagnostic observations only; intervention not indicated.
Grade 2 Moderate; minimal, local or noninvasive intervention indicated; limiting age -appropriate instrumental ADL.
Grade 3 Severe or medically significant but not immediately life -threatening; hospi[INVESTIGATOR_77991]; disabling; 
limiting self-care ADL.
Grade 4 Life threatening consequences; urgent intervention indicated.
Grade 5 Death related to AE
Seriousness AnSAE is any AEoccurring at any dose or during any use of Sponsor’s product that:
†Results in death ; or
†Is life threatening; orplaces the subject, in the view of the investigator, at immediate risk of death from the event as it occurred (Note: This doe s not include an AE
that, had it occurred in a more severe form, might have caused death.); or
†Results in a persistent or signi ficant disability/incapacity (substantial disruption of one’s ability to conduct normal life functions); or
†Results in or prolongs an existing inpatient hospi[INVESTIGATOR_059] (hospi[INVESTIGATOR_19357], regardless of length of stay, even if the 
hospi[INVESTIGATOR_2138] a precautionary measure for continued observation. (Note: Hospi[INVESTIGATOR_19358] a pre-existing condition that has not 
worsened is not anSAE .  A pre-existing condition is a clinical condition that is diagnosed prior to the use of a [COMPANY_006] product and is documented in the patient’s 
medical history.); or
†Is a congenital anomaly/birth defect (in offspring of subject taking the product regardless of time to diagnosis);or
Is anew cancer (that is not a condition of the study) (although not serious per ICH definition, is reportable to the Sponsor within 24 hours to meet certain local 
requirements); or
Is an overdose (whether accidental or intentional).  Any AEassociated with an overdose is considered anSAE for collection purposes . An overdose that is not 
associated with an AEis considered a nonserious ECIand must be reported within [ADDRESS_1045031] and may require medical or surgical intervention to preven t one of the outcomes listed previou sly 
(designated above by a †).
Duration Record the start and stop dates of the adverse event. If less than 1 day, indicate the appropriate length of time and units
Action taken Did the AEcause the Sponsor’s product to be discontinued?
Relationship 
to Sponsor’s 
ProductDid the Sponsor’s product cause the AE? The determination of the likelihood that the Sponsor’s product caused the AEwill be provided by [CONTACT_19427] a 
qualified physician. The investigator’s signed/dated initials on the source document or worksheet that supports the causality noted on the AE form, ensures that a 
medically qualified assessment of causality wasdone. This initialed document must be retained for the required regulatory time frame. The criteria below are intended 
as reference guidelines to assist the investigator in assessing the likelihood of a relationship between the test drug and th e AEbased upon the available information.
The following components are to be used to assess the relationship between the Sponsor’s product and the AE; the greater the correlation with the components 
and their respective elements (in number and/or intensity), the mor e likely the Sponsor’s product caused the AE:
Exposure Is there evidence that the subject was actually exposed to the Sponsor’s product such as: reliable history, acceptable compli ance assessment (pi[INVESTIGATOR_9650], diary, etc.), expected pharmacologic effect, or measurement of drug/metabolite in bodily specimen?
Time Course Did the AE follow in a reasonable temporal sequence from administration of the Sponsor’s product? 
Is the time of onset of the AE compatible with a drug -induced effect (applies to trials with investigational medicinal product)?
Likely Cause Is the AE not reasonably explained by [CONTACT_26369], other drug(s)/vaccine(s), or other host or environmental factors
087V73
Product:   MK-1454 145
Protocol/Amendment No.: 001-[ADDRESS_1045032] drug and the AE: (continued)
to Sponsor's 
Product
(continued) Dechallenge  Was the Sponsor’s product discontinued or dose/exposure/frequency reduced?
-If yes, did the AE resolve or improve?
◦ If yes, this is a positive dechallenge. If no, this is a negative dechallenge.
(Note: This criterion is not applicable if: (1) the AE resulted in death or permanent disability; (2) the AE resolved/improve d despi[INVESTIGATOR_77992]’s product; or (3) the trial is a single -dose drug trial); or (4) Sponsor’s produ ct(s) is/are only used one time.)
Rechallenge  Was the subject re -exposed to the Sponsor’s product in this study?
-If yes, did the AE recur or worsen?
◦ If yes, this is a positive rechallenge. If no, this is a negative rechallenge.
(Note: This criterion is not applicable if: (1) the initial AE resulted in death or permanent disability, or (2) the trial is a single -dose drug trial); or (3) 
Sponsor’s product(s) is/are used only one time).
NOTE: IF A RECHALLENGE IS PLANNED FOR AN AEWHICH WAS SERIO US AND WHICH MAY HAVE BEEN CAUSED BY [CONTACT_173608]'S PRODUCT, OR IF REEXPOSURE TO THE SPONSOR'S PRODUCT POSES ADDITIONAL POTENTIAL SIGNIFICANT RISK 
TO THE SUBJECT, THEN THE RECHALLENGE MUST BE APPROVED IN ADVANCE BY [CONTACT_762638].
Consistency 
with Trial 
Treatment 
ProfileIs the clinical/pathological presentation of the AE consistent with previous knowledge regarding the Sponsor’s product or drug class pharmacology 
or toxicology?
The assessment of relationship will be reported on the case report forms /worksheets by [CONTACT_19427] a qualified ph ysician according to his/her best clinical judgment, including 
consideration of the above elements.
Record one of the following Use the following scale of criteria as guidance (not all criteria must be present to be indicative of a Sponsor’s product relat ionship).
Yes, there is a reasonable 
possibility of Sponsor's product 
relationship.There is evidence of exposure to the Sponsor's product.  The temporal sequence of the AE onset relative to the administration of the Sponsor's 
product is reasonable.  The AE is more likely explained by [CONTACT_1034]'s product than by [CONTACT_5748].
No, there is not a reasonable 
possibility of Sponsor's product 
relationshipSubject did not receive the Sponsor's product OR temporal sequence of the AE onset relative to administration of the Sponsor' s product is not 
reasonable ORthe AE is more likely explained by [CONTACT_26372]’s product .  (Also entered for a subject with overdose without an 
associated AE.)
087V73
Product:   MK-1454 146
Protocol/Amendment No.: 001-08 
MK-1454 -001-08 Final Protocol 27-Jul-2021
Confidential
Sponsor Responsibility for Reporting Adverse Events SAEs
All Adverse Events SAEs will be reported to regulatory authorities, IRB/IECs and 
investigators in accordance with all applicable global laws and regulations , i.e., per ICH 
Topic E6 (R1) Guidelines for Good Clinical Practice .
8.0STATISTICAL ANALYSIS PLAN
This section outlines the statistical analysis strategies and procedures for the primary and key 
secondary analyses of the study . Exploratory and other non-confirmatory analyses will be 
outlined in a separate sSAP. 
If,after the study has begun, changes are made to the primary and/or secondary objectives , or 
the statistical methods related to those objectives , then the protocol will be amended 
(consistent with ICH Guideline E9). Changes to exploratory or other non-confi rmatory 
analyses made after the protocol has been finalized, but prior to the conduct of any analyses, 
will be documented in the sSAP as needed and referenced in the CSR for the study . Post hoc 
exploratory analyses will be clearly identified in the CSR.
Statistical Analysis Plan Summary
This section contains a brief summary of the statistical analyses for this trial. Full detail sare
in the Statistical Analysis Plan, Section s8.2through 8.12 .
Study Design Overview Phase 1 trial of MK-1454 IT as monotherapy and in combination with 
pembrolizumab in subjects with advanced/metastatic solid tumors or 
lymphomas. Part I, dose escalation and confirmation, includes 
monotherapy (cutaneous or s ubcutaneous lesions) (Arm 1) ,MK-1454 IT 
in combin ation with pembrolizumab (cutaneous or subcutaneous lesions )
(Arm 2) ,and MK-1454 IT in combination with pembrolizumab (visceral 
lesions) (Arm 3 ) in subjects with advanced/metastatic solid tumors or 
lymphomas . For Arm s1,2, and 3, the study applies a nATD followed by 
a modified TPI [INVESTIGATOR_762556] /MAD and to identify a preliminary RP2D in each treatment arm . In 
the expansion phase of this trial, Part II, Cohort A and B will begin 
enrolling after the preliminary RP2D is established from Arm 2 and will 
evaluate MK -1454 in com bination with pembrolizumab .Expansion 
Cohort C will begin enrolling after the preliminary RP2D is established 
from Arm 3 and will evaluate MK -1454 in combination with 
pembrolizumab.
Analysis Populations Safety (Primary): ASa and DLT e
PK (Secondary): PP
Efficacy (Secondary and Exploratory) : Full Analysis Set (FAS) 
Primary Endpoint(s) DLT
AE
Discontinuing study treatment due to an AE
087V73
Product:   MK-1454 147
Protocol/Amendment No.: 001-08 
MK-1454 -001-08 Final Protocol 27-Jul-2021
ConfidentialKey Secondary Endpoints PK parameters of MK -1454 monotherapy, PK parameters for MK -1454 
in combination with pembrolizumab, and PK param eters for 
pembrolizumab in combination with MK -1454.
ORR 
Statistical Methods for Key 
Efficacy/Immunogenicity/ 
Pharmacokinetic AnalysesPlasma concentrations of MK-1454 will be summarized by [CONTACT_762639]; PK parameters will be summarized by 
[CONTACT_2715]. For pembrolizumab, serum concentrations will be compared to the 
historical monotherapy pembrolizumab data.
ORR will be estimated using an exact method based on the binomial 
distribution (Clopper -Pearson interval) together with its 95% confidence 
interval
Treatment Assignment In Part I, s ubjects will be allocated to receive single -agent MK -1454 (Arm 
1),MK 1454 co -administered with pembrolizumab via cutaneous or 
subcutaneous IT injection (Arm 2 ), or MK 1454 co -administered with 
pembrolizumab via visceral IT injection (Arm 3 ) centrally through an 
IWRS. Subjects will be allocated by [CONTACT_210641]. Allocation 
will alternate between Arm 1 and Arm 2 when both arms are open for 
enrollment ,and alternating assignment begins with Arm 1 .In Part II, 
subjects will be allocated to one of 3cohorts depending on their tumor 
type and other characteristics through I WRS. The trial is open label.
Statistical Methods for Key 
Safety AnalysesSummary statistics (counts, percentage s, mean s, standard deviation s, etc.) 
will be provided for the safety endpoints as appropriate . The pool -
adjacent -violators -algorithm [31] will be used to estimate the DLT rate s
across doses. The estimates of the DLT rates among subjects treated at 
MTD (or MAD) of MK-1454 and the 80% Bayesian credible interval sfor 
the estimate swill be provided.
Interim Analyses An administrative analysis may be conducted to enable future trial 
planning at the Sponsor’s discretion and data will be examined on a 
continuous basis to allow for dose escalation and confirmation decisions.
For each expansion cohort (Cohorts A -C) in Part II, if there are no 
responders among approximately the first [ADDRESS_1045033]:   MK-1454 148
Protocol/Amendment No.: 001-08 
MK-1454 -001-08 Final Protocol 27-Jul-2021
Confidential
Responsibility for Analyses/In -house Blinding
The statistical analyse s of the data obtained from this study will be the responsibility of the 
Clinical Biostatistics department of the S ponsor .
Thetrial is open label, ie, subjects, investigator s, and Sponsor personnel will be aware of 
subject treatment assignmen tafter each subject is enrolled and treatment is assigned . 
Allocation to treatment will not be randomized.
Hypotheses /Estimation
Objectives and hypotheses of the study are outlin ed in Section 3.0 .
Analysis Endpoints
Efficacy and safety endpoints are listed below, followed by [CONTACT_762640] . 
Efficacy/Pharmacokinetic Endpoints
ORR in subjects treated with MK-[ADDRESS_1045034] 30% reduction in the sum of diameters of noninjected lesions, among participants with 
target noninjected lesions identified at baseline.
PKendpoints include concentrations of MK-1454 and pembrolizumab , as well asany 
derived PK parameters .
Safety Endpoints
The primary safety endpoint is the number/proportion of subject s with DLT (s), AE(s), and 
who discontinue study treatment due to AE(s) . A description of safety measures is provided 
in Section [IP_ADDRESS] .
Analysis Populations
Safety Analysi s Population
The ASaT population will be used for the analysis of safety data in this study . The ASaT 
population consists of all subjects who received at least one dose of study treatment . In case 
087V73
Product:   MK-1454 149
Protocol/Amendment No.: 001-[ADDRESS_1045035] iedwith the protocol 
sufficiently to ensure that the data they generated will be likely to exhibit the effects of 
treatment, according to the underlying scientific mode l. Compliance covers such 
considerations as exposure to treatment, availability of measurements ,and absence of major 
protocol violations . Major protocol violators will be identified ,to the extent possible ,by 
[CONTACT_26378]/c ompliance, and its analysis and interpretation . 
Any subjects or data values excluded from analysis will be identified, along with the reason s
for exclusion, in the CSR . At the end of the study, all subjects who were compliant with the 
study procedure s and have available data from at least one treatment will be potentially 
included in the PP analysis dataset. 
Efficacy Analysi s Populations
The FAS population will be used for analysis ofthe secondary andexploratory efficacy data 
in this study . Itconsist sof all subjects with a baseline scan that demonstrated measurable 
disease by [CONTACT_3138] , and who were administered a dose of study medicine . 
A supportive approach using modified FAS population may be performed for the efficacy 
endpoints. The modified FAS population includes FAS subjects without substantial dose 
interruption as defined in the sSAP . 
Statistical Methods
Statistical Methods for Efficacy Analyses
For the secondary endpoint of ORR, the point estimate and 95% CI will be evaluated in 
PartII subjects treated with MK-[ADDRESS_1045036] method based on the binomial distribution 
(Clopper -Pearson Interval). Other exploratory endpoints (eg,PFS) may also be examined 
within each expansion cohort. Of note, efficacy analyses for each Part II expansion cohort 
will pool Part I subjects who meet the inclusion criteria for the respective Part II tumor type 
and received the same dose level of MK -[ADDRESS_1045037]:   MK-1454 150
Protocol/Amendment No.: 001-08 
MK-1454 -001-08 Final Protocol 27-Jul-2021
ConfidentialAEs will be summarized by [CONTACT_762641] , arm, and cohort . 
Laboratory tests, vital signs, and other safety endpoints will be summarized as appropriate.
Dose -limiting toxicities will be listed , and further summarized by [CONTACT_762642]. The 
pool adjacent -violators -algori thm [31],which forces the DLT rate estimates to be 
nondecreasing with dose levels and pools adjacent violators for weighted estimates by 
[CONTACT_19462], will be used to estimate the DLT rates across dosesin each treatment arm. The 
estimate sof the DLT ratesamong subjects treated atthe MTDs (or MADs) andthe80% 
Bayesian credible interval s based on a prior distribution of Beta (1,1) for the estimat eswill 
be provided.
Summaries of Baseline Characteristics, Demographics, and Other Analyses
Demographic and Baseline Characteristics
Demographic variables, baseline characteristics, primary and secondary diagnoses, and prior 
and concomitant therapi[INVESTIGATOR_98501] l be summarized.
Pharmacokinetics and Pharmacodynamics Modeling Analysis
Plasma concentrations of MK-1454 will be summarized by [CONTACT_762643]; PK parameters will be summarized by [CONTACT_2715]. For pembrolizumab, serum 
concentrations will be compared to the historical monotherapy pembrolizumab data. Details 
of statistical analysis ofpharmacokinetics -pharmacodynamics analyse swill be documented 
in the sSAP.
Interim Analyses
An administrative analysis may be conducted to enable future trial planning at the Sponsor’s 
discretion and data will be examined on a continuous basis to allow for dose escalation and 
confirmation decisions.
An interim futility check will be performed for each of the select edsolid tumor cohorts in 
Part II (Cohorts Athrough C). For Cohort sA, B,and C, if there are no responders among 
approximately the first [ADDRESS_1045038] 
one postbaseline imaging assessment. If the true response rate is 10%, there is an 80% 
chance to observe at least 1responder among 15subjects, and an82% chance to observe at 
least 2responders among [ADDRESS_1045039]:   MK-1454 151
Protocol/Amendment No.: 001-08 
MK-1454 -001-08 Final Protocol 27-Jul-2021
Confidential
Sample Size and Power Calculations
The overall sample size for this Phase 1 trial is expected to be approximately 235subjects. 
Part I Sample Size
The overall sample size for Part Iis expected to be approximately 115 subjects 
(approximately 40 subjects each in Arm 1and Arm 2,and 35in Arm 3). Part A, Part C,and 
Part E(ATD phase) will be followed by [CONTACT_9524] B,Part D and Part F(mTPI [CONTACT_16303]) of all 
3Arms . The ATD phase will have single -subject cohorts that may enroll upto 3subjects to 
account for simultaneous enrollment . The mTPI [INVESTIGATOR_762557] 3 to 6 subjects per coho rt, 
based on the occurrence of DLTs; up to 14subjects may enroll per dose level . 
The sample size for Arm 1, Arm 2,and Arm 3of this study is dependent on the number of 
dose levels tested and on the emerging safety data. The following scenario provides an
example of the sample size . 
In Arm 1 and Arm 2, in the absence of DLTs, utilizing dose increments of up to 300% for the 
ATD phase ,and dose increments of 30% to 100% for the mTPI [CONTACT_16303] , there would be 
1subject per dose level treated at and 3 subjects per dose 
level treated at and 14subjects treated at a dose 
level of  The total sample size for both Arm 1 and Arm 2 would then be 30. 
InArm 3, in the absence of DLTs and with 2possible dose cohorts for the ATD phase and 
dose increments of 30% to 100% for the mTPI [CONTACT_16303], there would be [ADDRESS_1045040] per dose level 
treated at 
and 14subjects treated at a dose level of  The total sample 
size would then be 34 for Arm 3 . 
For dose escalation guidelines and specifications, see Section 5.2 and Table 3, Table 4,and 
Table 5 .
Part II S ample Size
The overall sample size for Part IIis expected to be approximately 120 subjects . For 
Cohort A (anti-PD-1/PD -L1 refractory HNSCC) and Cohort B (anti-PD-1/PD -L1treatment -
naïve or refractory unresectable locally advanced or metastatic TNBC) ,30subjects will be 
enrolled in each tumor cohort. For Cohort C(other anti-PD-1/PD -L1 treatment -naïve solid 
tumors with liver metastases) , [ADDRESS_1045041] 1.1.
Table 25and Table 26show the ORR estimate and the 95% CI (Clopper -Pearson) for N=30 
(Cohorts Aand B,and Cohort C subgroup of Non- CRC/pancreatic tumors) and N=60 
(Cohor t C)respectively.
CCI
CCI
CCI
CCI
CCI
087V73
Product:   MK-1454 152
Protocol/Amendment No.: 001-08 
MK-1454 -001-08 Final Protocol 27-Jul-2021
ConfidentialTable 25 Estimate and 95% CI of ORR (N=30)
Sample SizeNumber of 
Responses (PR/CR)Observed ORR 95% CI of ORR
Abbreviations: CI = confidence interval; CR = complete response; ORR = objective response rate; PR = 
partial response
Table 26 Estimate and 95% CI of ORR (N= 60)
Sample SizeNumber of 
Responses (PR/CR)Observed ORR 95% CI of ORR
Abbreviations: CI = confidence interval; CR = complete response; ORR = objective response rate; PR = 
partial response
Subgroup Analyses and Effect of Baseline Factors
For Cohort C, other solid tumors with liver metastases, subgroup analysis of the efficacy 
endpoint ORR will be conducted between non-MSI-HCRC patients, pancreatic ductal 
adenocarcinoma patients, and the remaining Cohort C patients. 
Other s ubgroup analyse sfor the Part II Expansion Cohorts A-C may be conducted as needed, 
for example by [CONTACT_762644].
Compliance (Medication Adherence)
Drug accountability data for study treatment will be collected during the trial. Any deviation 
from protocol -directed administration will be reported.
Extent of Exposure
The extent of exposure will be summarized as duration of treatment in cycles.
CCI
CCI
087V73
Product:   MK-1454 153
Protocol/Amendment No.: 001-[ADDRESS_1045042] Name & Potency Dosage FormSource/Additional 
Information
MK-1454, Solution for InjectionProvided centrally by [CONTACT_429].
MK-1454, Solution for InjectionProvided centrally by [CONTACT_429].
MK-1454, DiluentSolution for dosage 
preparationProvided centrally by [CONTACT_313590], subsidiary, or 
designee .
Pembrolizumab (MK -3475)
100 mg/4 mLSolution for InfusionProvided centrally by [CONTACT_429].
All supplies indicated inTable 27will be provided per the “Source/Additional Information” 
column depending on local country operational requirements .
Any commercially available product not included inTable 27will be provided by [CONTACT_90088], subsidiary or designee .Every attempt should be made to source these supplies from a 
single lot/batch number. The trial site is responsible for recording the lot number, 
manufacturer, and expi[INVESTIGATOR_460121].
Packaging and Labeling Information
Clinical supplies will be affixed with a clinical label in accordance with regulatory 
requirements.
In addition, [ADDRESS_1045043]:   MK-1454 154
Protocol/Amendment No.: 001-08 
MK-1454 -001-08 Final Protocol 27-Jul-2021
Confidential
Clinical Supplies Disclosure
This trial is open -label; therefore, the subject, the trial site personnel, the Sponsor and/or 
designee arenot blinded. Treatment (name, strength or potency ) is included in the label text; 
random code/ disclosure envelopes or lists are not provided.
Storage and Handling Requirements
Clinical supplies must be stored in a secure, limited -access location under thestorage 
conditions specified on the label.  
Receipt and dispensing of trial medication must be recorded by [CONTACT_78044].
Clinical supplies may not be used for any purpose other than that stated in the protocol.
Discard/Destruction/ Returns and Reconciliation
The investigator is responsible for keepi[INVESTIGATOR_26340], the amount dispensed to and returned by [CONTACT_762645]. For all trial sites, the local country Sponsor 
personnel or designee will provide appropriate documentation that must be completed for 
drug accountability and return, or local discard and destruction if appropriate.  Where local 
discard and destruction is appropriate, the investigator is responsible for ensuring that a local 
discard/destruction procedure is documented .
Standard Policies
Trial site personnel will have access to a central electronic treatment 
allocation/ randomization system (IWRS system) to allocate subjects, to assign treatment to 
subjects and to manage the distribution of clinical supplies. Each person accessing the IWRS
system must be assigned an individual unique PIN.  T hey must use only their assigned PIN to 
access the system, and they must not share their assigned PIN with anyone.
10.[ADDRESS_1045044], ethics review committee (IRB/ERC) or similar 
or expert committee; affiliated institu tion and employees, only under an appropriate 
understanding of confidentiality with such board or committee, affiliated institution and 
employees.  Data generated by [CONTACT_26384], 
except to the extent that it is included in a publication as provided in the Publications section 
of this protocol.
087V73
Product:   MK-1454 155
Protocol/Amendment No.: 001-[ADDRESS_1045045] Records
By [CONTACT_12570], the investigator agrees that the Sponsor (or Sponsor representative), 
IRB/ERC, or regulatory authority re presentatives may consult and/or copy trial documents in 
order to verify worksheet/case report form data.  By [CONTACT_17317], the subject 
agrees to this process.  If trial documents will be photocopi[INVESTIGATOR_88648]/ca se report form information, the subject will be identified by [CONTACT_19494]; 
full names/initials will be masked prior to transmission to the Sponsor.
By [CONTACT_12570], the investigator agrees to treat all subject data used and disclosed in 
conne ction with this trial in accordance with all applicable privacy laws, rules and 
regulations.
Confidentiality of Investigator Information
By [CONTACT_12570], the investigator recognizes that certain personal identifying 
information with respect to theinvestigator, and all subinvestigators and trial site personnel, 
may be used and disclosed for trial management purposes, as part of a regulatory 
submissions, and as required by [CONTACT_2371].  This information may include:
1.name, address, telephone number and e -mail address;
2.hospi[INVESTIGATOR_26342];
3.curriculum vitae or other summary of qualifications and credentials; and
4.other professional documentation.
Consistent with the purposes described above, this information may be transmi tted to the 
Sponsor, and subsidiaries, affiliates and agents of the Sponsor, in your country and other 
countries, including countries that do not have laws protecting such information.  
Additionally, the investigator’s name [CONTACT_26407] [CONTACT_26386].  By [CONTACT_12570], the investigator expressly consents to these uses and 
disclosures.
If this is a multicenter trial, in order to facilitate contact [CONTACT_26387], the Sponsor 
may share an investigator’s name [CONTACT_3669] [CONTACT_26388].
Confidentiality of IRB/IEC Information
The Sponsor is required to record the name [CONTACT_19525]/IEC that reviews and 
approves this trial.  The Sponsor is also required to document that each IRB/IEC meets 
regulatory and ICH GCP requirements by [CONTACT_26389]/IEC members and to make these records available for 
regulatory agency review upon request by [CONTACT_19496].
Compliance With Financial Disclosure Requirements
Financial Disclosure requirements are outlined in the US Food and Drug Administration 
Regulations, Financial Disclosure by [CONTACT_6230] (21 CFR Part 54).  It is the 
087V73
Product:   MK-1454 156
Protocol/Amendment No.: 001-08 
MK-1454 -001-08 Final Protocol 27-Jul-2021
ConfidentialSponsor's responsibility to determine, based on these regulations, whether a request for 
Financial Disclosure information is required.  It is the investigator's/subinvestigator's 
responsibility to comply with any such request.  
The investigator/subinvestigator(s) agree, if requested by [CONTACT_19489] 21 
CFR Part 54, to provide his/her financial interests in and/or arrangements with the Sponsor to 
allow for the submission of complete and accurate certification and disclosure statements.  
The investigator/subinvestigator(s) further agree to provide this information on a 
Certification/Disclosure Form, commonly known as a financial disclosure form, provided by 
[CONTACT_1034] . The investigator/subinvestigator(s) also consent to the transmission of this 
information to the Sponsor in the [LOCATION_002] for these purposes.  This may involve the 
transmission of information to countries that do not have laws protecting personal data.
Compliance With Law, Audit and Debarment
By [CONTACT_12570], the investigator agrees to conduct the trial in an efficient and 
diligent manner and in conformance with this protocol; generally accepted standards of Good 
Clinical Practice (e.g., International Conference on Harmonization of Technical 
Requirements for Registration of Pharmaceuticals for Human Use Good Clinical Practice: 
Consolidated Guidel ine and other generally accepted standards of good clinical practice); and 
all applicable federal, state and local laws, rules and regulations relating to the conduct of the 
clinical trial.
The Code of Conduct, a collection of goals and considerations thatgovern the ethical and 
scientific conduct of clinical investigations sponsored by [CONTACT_44873], is provided in Section 12.[ADDRESS_1045046] for Clinical Trials .
The investigator also agrees to allow monitoring, audits, IRB/ERC review and regulatory 
authority inspection of trial-related documents and procedures and provide for direct access 
to all trial -related source data and documents.
The investigator agrees not to seek reimbursement from subjects, their insurance providers or 
from gover nment programs for procedures included as part of the trial reimbursed to the 
investigator by [CONTACT_1034].
The investigator shall prepare and maintain complete and accurate trial documentation in 
compliance with Good Clinical Practice standards and applica ble federal, state and local 
laws, rules and regulations; and, for each subject participating in the trial, provide all data, 
and, upon completion or termination of the clinical trial, submit any other reports to the 
Sponsor as required by [CONTACT_78046].
Trial documentation will be promptly and fully disclosed to the Sponsor by [CONTACT_26391], 
copy ing, review and audit at reasonable times by [CONTACT_19502].  The investigator agrees to promptly take any reasonable steps that are 
requested by [CONTACT_14547] a result of an audit to cure deficiencies in the trial documentation 
and worksheets/case report forms.
The investigator must maintain copi[INVESTIGATOR_26343].  This 
087V73
Product:   MK-1454 157
Protocol/Amendment No.: 001-08 
MK-1454 -001-08 Final Protocol 27-Jul-2021
Confidentialdocumentation inclu des, but is not limited to, the protocol, worksheets/case report forms, 
advertising for subject participation, adverse event reports, subject source data, 
correspondence with regulatory authorities and IRBs/ERCs, consent forms, investigator’s 
curricula vitae, monitor visit logs, laboratory reference ranges, laboratory certification or 
quality control procedures and laboratory director curriculum vitae.  By [CONTACT_12570], 
the investigator agrees that documentation shall be retained until at least [ADDRESS_1045047] consult 
with and obtai n written approval by [CONTACT_26392]/or subject files.  
ICH Good Clinical Practice guidelines recommend that the investigator inform the subject’s 
primary physician about the subject’s participation in the trial if the subject has a primary 
physician and if the subject agrees to the primary physician being informed.
The investigator will promptly inform the Sponsor of any regulatory authority inspection 
conducted for this trial.
Persons debarred from conducting or working on clinical trials by [CONTACT_19500]’s trials.  The investigator 
will immediately disclose in writing to the Sponsor if any person who is involved in 
conducting the trial is debarred or if any proceeding for debarment is pending or, to the best 
of the investigator’s knowledge, threatened.
In the event the Sponsor prematurely terminates a particular trial site, the Sponsor will 
promptly notify that trial site’s IRB/IEC.
According to European legislation, a Sponsor must designate an overall coordinating 
investigator [INVESTIGATOR_8178] a multi -center trial (including multinational).  When more than one trial site 
is open in an EU country, [COMPANY_006], as the Sponsor, will designate, per country, a national 
principal coordinator (Protocol CI), responsible for coordinating the work of the principal 
investigators at the different trial sites in that Member State, according to national 
regulations.  For a single -center trial, the Protocol CI is the principal investigator .  In 
addition, the Sponsor must designate a principal or coordinating investigator [INVESTIGATOR_26344], to the best of his/her 
knowledge, the report accurately describes the conduct and results of the trial [Clinical Study 
Report (CSR) CI].  The Sponsor may consider one or more factors in the selection of the 
individual to serve as the Protocol CI and or CSR CI (e.g., availability of the Protocol/CSR 
CI during the anticipated review process, thoroug h understanding of clinical trial methods, 
appropriate enrollment of subject cohort, timely achievement of trial milestones).  The 
Protocol CI must be a participating trial investigator.
087V73
Product:   MK-1454 158
Protocol/Amendment No.: 001-[ADDRESS_1045048] (FDAAA) of 2007 
and the European Medicines Agency (EMA) clinical trial Directive 2001/20/EC, the Sponsor 
of the trial is solely responsible for determining whether the trial and its results are subject to 
the requirements for submission to http://www.clinicaltrials.gov, 
www.clinicaltrialsregister.eu or other local registries.  [COMPANY_006], as Sponsor of this trial, will 
review this protocol and submit the information necessary to fulfill these requirements. 
[COMPANY_006] entries are not limited to FDAAA or the EMA clinical trial directive mandated trials.  
Information posted will allow subjects to identify potentially appropriate trials for their 
disease conditions and pursue participation by [CONTACT_3379] a central contact [CONTACT_26393].  
By [CONTACT_12570], the investigator acknowledges that the statutory obligations under 
FDAAA, the EMA clinical trials directive or other locally mandated registries are that of the 
Sponsor and agrees not to submit any information about this trial or its results to those 
registries.
Quality Management System
By [CONTACT_12570], the Sponsor agrees to be responsible for implementing and 
maintaining a quality management system with written development procedures and 
functional area standard operating procedures (SOPs) to ensure that trials are conducted and 
data are generated, documented, and reported in compliance with the protocol, accept ed 
standards of Good Clinical Practice, and all applicable federal, state, and local laws, rules and 
regulations relating to the conduct of the clinical trial.
Data Management
The investigator or qualified designee is responsible for recording and verifyin g the accuracy 
of subject data.  By [CONTACT_12570], the investigator acknowledges that his/her 
electronic signature [CONTACT_26408] a written signature.  By [CONTACT_26394]/her electronic signature, the investigator confirms that all recorded data have been 
verified as accurate.
Detailed information regarding Data Management procedures for this protocol will be 
provided separately .
Publications
This trial is intended for publication, even if terminated prematurely. Publication may i nclude 
any or all of the following: posting of a synopsis online, abstract and/or presentation at a 
scientific conference, or publication of a full manuscript.  The Sponsor will work with the 
authors to submit a manuscript describing trial results within [ADDRESS_1045049]:   MK-1454 159
Protocol/Amendment No.: 001-[ADDRESS_1045050]'s last visit for the 
primary outcome, [ADDRESS_1045051] 
marketing (dispensed, administered, delivered or promoted), whichever is later.
These timelines may be extended for products that are not yet marketed, if additional time is 
needed for analysis, to protect intellectual property, or to comply with confidential ity 
agreements with other parties.  Authors of the primary results manuscript will be provided 
the complete results from the Clinical Study Report, subject to the confidentiality agreement. 
When a manuscript is submitted to a biomedical journal, the Sponso r's policy is to also 
include the protocol and statistical analysis plan to facilitate the peer and editorial review of 
the manuscript.  If the manuscript is subsequently accepted for publication, the Sponsor will 
allow the journal, if it so desires, to post on its website the key sections of the protocol that 
are relevant to evaluating the trial, specifically those sections describing the trial objectives 
and hypotheses, the subject inclusion and exclusion criteria, the trial design and procedures, 
the eff icacy and safety measures, the statistical analysis plan, and any amendments relating to 
those sections.  The Sponsor reserves the right to redact proprietary information.
For multicenter trials, subsequent to the multicenter publication (or after public disclosure of 
the results online at www.clinicaltrials.gov if a multicenter manuscript is not planned), an 
investigator and his/her colleagues may publish their data independently.  In most cases, 
publication of individual trial site data does not add value to complete multicenter results, 
due to statistical concerns.  In rare cases, publication of single trial site data prior to the main 
paper may be of value.  Limitations of single trial site observations in a multicenter trial 
should always be des cribed in such a manuscript.
Authorship credit should be based on 1) substantial contributions to conception and design, 
or acquisition of data, or analysis and interpretation of data; 2) drafting the article or revising 
it critically for important intelle ctual content; and 3) final approval of the version to be 
published. Authors must meet conditions 1, [ADDRESS_1045052] also been m ade to all three of the preceding authorship criteria.  Although 
publication planning may begin before conducting the trial, final decisions on authorship and 
the order of authors’ names will be made based on participation and actual contributions to 
the trial and writing, as discussed above. The first author is responsible for defending the 
integrity of the data, method(s) of data analysis and the scientific content of the manuscript.
The Sponsor must have the opportunity to review all proposed abstracts, manuscripts or 
presentations regarding this trial 45days prior to submission for publication/presentation. 
Any information identified by [CONTACT_26395]; this confidentiality does not include efficacy and safety results. Sponsor review 
can be expedited to meet publication timelines.
087V73
Product:   MK-1454 160
Protocol/Amendment No.: 001-[ADDRESS_1045053] OF REFERENCES
[1] Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ, et al. 
Revised response criteria for malignant lymphoma. J Clin Oncol 2007;25(6):579 -
86.
[2] Olsen EA, Whittaker S, Kim YH, Duvic M, Prince HM, Lessin SR, et al. Clinical 
end points and response criteria in mycosis fungoides and Sezary syndrome: a 
consensus statement of the International Society for Cutaneous Lymphomas, the
[LOCATION_002] Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma 
Task Force of the European Organisation for Research and Treatment of Cancer. 
J Clin Oncol. 2011 Jun 20;29(18):2598 -607.
[3] Goldmacher GV, Khilnani AD, Andtbacka RHI, Luke JJ, Hodi FS, Marabelle A, 
et al. Response criteria for intratumoral immunotherapy in solid tumors: 
itRECIST. J Clin Oncol. In press 2020.
[4] Corrales L, Glickman LH, McWhirter SM, Kanne DB, et al. Direct Activation of 
STING in the Tumor Microenvironment Leads to Potent and Systemic Tumor 
Regression and Immunity. Cell Rep. 2015 May 19;11(7):1018 -30.
[5] Fu J, Kanne DB, Leong M, Glickman LH, McWhirter SM, et al. STING agonist 
formulated cancer vaccines can cure established tumors resistant to PD-1 
blockade. Sci Tra nsl Med. 2015 Apr 15;7(283):283ra52.
[6] Baird JR, Friedman D, Cottam B, Dubensky TW Jr, Kanne DB, et al. 
Radiotherapy Combined with Novel STING -Targeting Oligonucleotides Results 
in Regression of Established Tumors. Cancer Res. 2016 Jan 1;76(1):50 -61.
[7] Glickman LH, Kanne DB, Kasibhatla S, Li J, Pferdekamper AC, Gauthier KS, et 
al. Activation in the tumor microenvironment with a synthetic human STING -
activating cyclic dinucleotide leads to potent anti-tumor immunity. Poster session 
presented at: 2016 AACR Annual Meeting; 2016 Apr 16 -20; New Orleans, LA.
[8] Woo SR, Corrales L, Gajewski TF. The STING pathway and the T cell-inflamed 
tumor microenvironment. Trends Immunol. 2015 Apr;36(4):250 -6.
[9] Disis ML. Immune regulation of cancer. J Clin Oncol 2010;28(29):4531 -8.
[10] Dudley ME, Wunderlich JR, Yang JC, Sherry RM, Topalian SL, Restifo NP, et 
al. Adoptive cell transfer therapy following non-myeloablative but 
lymphodepleting chemotherapy for the treatment of patients with refractory 
metastatic melanoma. J Clin Oncol 2005;23(10):2346 -57.
[11] Hunder NN, Wallen H, Cao J, Hendricks DW, Reilly JZ, Rodmyre R, et al. 
Treatment of metastatic melanoma with autologous CD4+ T cells against NY-
ESO -1. N Engl J Med 2008;358(25):[ADDRESS_1045054]:   MK-1454 161
Protocol/Amendment No.: 001-08 
MK-1454 -001-08 Final Protocol 27-Jul-2021
Confidential[12] Greenwald RJ, Freeman GJ, Sharpe AH. The B7 family revisited. Annu Rev 
Immunol 2005;23:515 -48.
[13] Okazaki T, Maeda A, Nishimura H, Kurosaki T, Honjo T. PD-1 immunoreceptor 
inhibits B cell receptor -mediated signaling by [CONTACT_13223] 2-domain -
containing tyrosine phosphatase 2 to phosphotyrosine. Proc Natl Acad Sci U S A 
2001;98(24):[ZIP_CODE] -71.
[14] Zhang X, Schwartz J-CD, Guo X, Bhatia S, Cao E, Chen L, et al. Structural and 
functional analysis of the costimulatory receptor programmed death -1. Immunity 
2004;20:337 -47.
[15] Chemnitz JM, Parry RV, Nichols KE, June CH, Riley JL. SHP-1 and SHP-2 
associate with immunoreceptor tyrosine -based switch motif of programmed death 
1 upon primary human T cell stimulation, but only receptor ligation prevents T 
cell activation. J Immunol 2004;173:945 -54.
[16] Sheppard K-A, Fitz LJ, Lee JM, Benander C, George JA, Wooters J, et al. PD-1 
inhibits T-cell receptor induced phosphorylation of the ZAP70/CD3zeta 
signalosome and downstream signaling to PKCtheta . FEBS Lett. 2004;574:37 -41.
[17] Riley JL. PD -1 signaling in primary T cells. Immunol Rev 2009;229:114 -25.
[18] Parry RV, Chemnitz JM, Frauwirth KA, Lanfranco AR, Braunstein I, Kobayashi 
SV, et al. CTLA -[ADDRESS_1045055] 
mechanisms. Mol Cell Biol 2005;25(21):9543 -53.
[19] Francisco LM, Sage PT, Sharpe AH. The PD-[ADDRESS_1045056] in tolerance and 
autoimmunity. Immunol Rev 2010;236:219 -42.
[20] Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD, et al. PD-1 
Blockade in tumors with mismatch repair deficiency. N Engl J Med. Forthcoming 
2015.
[21] Woo SR, Fuertes MB, Corrales L, Spranger S, Furdyna MJ, Leung MY, et al. 
STING -dependent cytosolic DNA sensing mediates innate immune recognition of 
immunogenic tumors. Immunity. 2014 Nov 20;41(5):830 -42.
[22] Ayers M, Lunceford J, Nebozhyn M, Murphy E, Loboda A, Kaufman DR, et al. 
IFN-gamma -related mRNA profile predicts clinical response to PD-[ADDRESS_1045057]. 2017 Aug;127(8):2930 -40.
[23] Yamazaki S, Skaptason J, Romero D, Lee JH, Zou HY, Christensen JG, et al. 
Pharmacokinetic -pharmacodynamic modeling of biomarker response and tumor 
growth inhibition to an orally available cMet kinase inhibitor in human tumor 
xenograft mouse models. Drug M etab Dispos. 2008 Jul;36(7):[ADDRESS_1045058]:   MK-1454 162
Protocol/Amendment No.: 001-08 
MK-1454 -001-08 Final Protocol 27-Jul-2021
Confidential[24] Nishino M, Giobbie -Hurder A, Gargano M, Suda M, Ramaiya NH, Hodi FS. 
Developi[INVESTIGATOR_007] a common language for tumor response to immunotherapy: immune -
related response criteria using unidimensional measurements. Clin Cance r Res. 
2013 Jul 15;19(14):3936 -43.
[25] Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ. 
Revised response criteria for malignant lymphoma. J Clin Oncol 2007;25(5):579 -
86.
[26] Olsen E, Vonderheid E, Pi[INVESTIGATOR_206815] N, Willemze R, Kim Y, Knobler R, et al. 
Revisions to the staging and classification of mycosis fungoides and Sezary 
syndrome: a proposal of the International Society for Cutaneous Lymphomas 
(ISCL) and the cutaneous lymphoma task force of the European Organization of 
Research and Treatment of Cancer (EORTC). Blood 2007;110(6):1713 -22.
[27] Hammond ME, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S, et al. 
American Society of Clinical Oncology/College Of American Pathologists 
guideline recommendations for immunohistochemical testing of estrogen and 
progesterone receptors in breast cancer. J Clin Oncol. 2010 Jun 1;28(16):2784 -
95.
[28] Nanda R, Chow LQ, Dees EC, Berger R, Gupta S, Geva R, et al. Pembrolizumab 
in patients With Advanced Triple -Negative Breast Cancer: Phase Ib KEYN OTE -
012 study. J Clin Oncol. 2016 Jul 20;34(21):2460 -7.
[29] Adams S, Loi S, Toppmeyer D, Cescon DW, De Laurentiis M, Nanda R, et al. 
Pembrolizumab monotherapy for previously untreated, PD-L1-positive, 
metastatic triple -negative breast cancer: cohort B of the phase II KEYNOTE -086 
study. Ann Oncol. 2019;30(3):405 -11.
[30] Adams S, Schmid P, Rugo HS, Winer EP, Loirat D, Awada A, et al. 
Pembrolizumab monotherapy for previously treated metastatic triple -negative 
breast cancer: cohort A of the phase II KEYNOTE -086 study. Ann Oncol. 
2019;30(3):397 -404.
[31] Ji Y, Li Y, Bekele BN. Dose -finding in phase l clinical trials based on toxicity 
probability intervals. Clin Trials 2007;4:235 -44.
[32] Nie L, Rubin EH, Mehrotra N, Pi[INVESTIGATOR_17872] J, Fernandes LL, Roy A, et al. Rendering 
the 3 + [ADDRESS_1045059]: more efficient approaches to oncology dose -finding trials 
in the era of targeted therapy. Clin Cancer Res. 2016 Jun 1;22(11):2623 -9.
[33] Yang S, Wang SJ, Ji Y. An integrated dose-finding tool for phase I trials in 
oncology. Contemp Clin Trials. 2015 Nov;45(Pt B):[ADDRESS_1045060]:   MK-1454 163
Protocol/Amendment No.: 001-08 
MK-1454 -001-08 Final Protocol 27-Jul-2021
Confidential[34] Ji Y, Wang S-J. Modified toxicity probability interval design: a safer and more 
reliable method than the 3 + 3 design for practical phase I trials. J Clin Oncol 
2013;31:1 -12.
[35] Cheson BD, Bennett JM, Grever M, Kay N, Keating MJ, O'Brien S, et al. 
National Cancer Institute -Sponsored working group guidelines for chronic 
lymphocytic leukemia: Revised guidelines for diagnosis and treatment. Blood 
1996;87(12):[ADDRESS_1045061]:   MK-1454 164
Protocol/Amendment No.: 001-[ADDRESS_1045062] for Clinical Trials
[COMPANY_006] *
Code of Conduct for Clinical Trials
I.Introduction
A. Purpose
[COMPANY_006], through its subsidiaries, conducts clinical trials worldwide to evaluate the safety and effectiveness of our 
products. As such, we are committed to designing, implementing, conducting, analyzing and reporting these trials in 
compliance with the highest ethical and scientific standards. Protection of subject safety is the overriding concern in 
the design of clinical trials. In allcases, [COMPANY_006] clinical trials will be conducted in compliance with local and/or 
national regulations and in accordance with the ethical principles that have their origin in the Declaration of Helsinki. 
B. Scope
Such standards shall be endorsed for all clinical interventional investigations sponsored by [CONTACT_75395] (parties) employed for their execution (e.g., contract research organizations, collaborative research efforts). This 
Code is not intended to apply to trials which are obser vational in nature, or which are retrospective. Further, this Code 
does not apply to investigator -initiated trials which are not under the control of [COMPANY_006].
II.Scientific Issues
A. Trial Conduct
1.Trial Design
Except for pi[INVESTIGATOR_19354], clinical trial protocols will be hypothesis -driven to assess safety, efficacy 
and/or pharmacokinetic or pharmacodynamic indices of [COMPANY_006] or comparator products.  Alternatively, [COMPANY_006] may 
conduct outcomes research trials, trials to assess or validate various endpoint measures, or trials to determine 
subject preferences, etc.  
The design (i.e., subject population, duration, statistical power) must be adequate to address the specific purpose 
of the trial.  Research subje cts must meet protocol entry criteria to be enrolled in the trial. 
2.Site Selection
[COMPANY_006] selects investigative sites based on medical expert[INVESTIGATOR_18700], access to appropriate subjects, adequacy of facilities 
and staff, previous performance in [COMPANY_006] trials, as well as budgetary considerations.  Prior to trial initiation, sites 
are evaluated by [CONTACT_75396].
3.Site Monitoring/Scientific Integrity
Trial sites are monitored to assess compliance with the trial protocol and general principles of Good Clinical 
Practice.  [COMPANY_006] reviews clinical data for accuracy, completeness and consistency. Data are verified versus source 
documentation according to standard operating procedures.  Per [COMPANY_006] policies and procedu res, if fraud, 
misconduct or serious GCP -non-Compliance are suspected, the issues are promptly investigated. When necessary, 
the clinical site will be closed, the responsible regulatory authorities and ethics review committees notified and 
data disclosed a ccordingly. 
B. Publication and Authorship
To the extent scientifically appropriate, [COMPANY_006] seeks to publish the results of trials it conducts.  Some early phase or 
pi[INVESTIGATOR_26346] -generating rather than hypothesis testing.  In such cases, publication of 
results may not be appropriate since the trial may be underpowered and the analyses complicated by [CONTACT_75397].
[COMPANY_006]’s policy on authorship is consistent with the requirements outlined in the ICH-Good Clinic al Practice 
guidelines. In summary, authorship should reflect significant contribution to the design and conduct of the trial, 
performance or interpretation of the analysis, and/or writing of the manuscript.  All named authors must be able to 
defend the tr ial results and conclusions.  [COMPANY_006] funding of a trial will be acknowledged in publications. 
087V73
Product:   MK-1454 165
Protocol/Amendment No.: 001-[ADDRESS_1045063] Protection
A.IRB/ERC review
All clinical trials will be reviewed and approved by [CONTACT_75398]/ERC before being initiated at each site.  
Significant changes or revisions to the protocol will be approved by [CONTACT_1201]/ERC prior to implementation, except that 
changes required urgentl y to protect subject safety and well-being may be enacted in anticipation of IRB/ERC 
approval. For each site, the IRB/ERC and [COMPANY_006] will approve the subject informed consent form. 
B.Safety
The guiding principle in decision -making in clinical trials is that subject welfare is of primary importance.  Potential 
subjects will be informed of the risks and benefits of, as well as alternatives to, trial participation. At a minimum, trial 
designs will take into account the local standard of care.  Subjects are ne ver denied access to appropriate medical care 
based on participation in a [COMPANY_006] clinical trial. 
All participation in [COMPANY_006] clinical trials is voluntary.  Subjects are enrolled only after providing informed consent for 
participation.  Subjects may withdraw from a [COMPANY_006] trial at any time, without any influence on their access to, or 
receipt of, medical care that may otherwise be available to them.
C.Confidentiality
[COMPANY_006] is committed to safeguarding subject confidentiality, to the greatest extent possible. Unless required by [CONTACT_2371], 
only the investigator, sponsor (or representative) and/or regulatory authorities will have access to confidential medical 
records that might identify the research subject by [CONTACT_2300].  
D.Genomic Research
Genomic Research will only be conducted in accordance with informed consent and/or as specifically authorized by 
[CONTACT_75399].
IV.Financial Considerations
A.Payments to Investigators
Clinical trials are time-and labor -intensive.  It is [COMPANY_006]’s policy to compensate investigators (or the sponsoring 
institution) in a fair manner for the work performe d in support of [COMPANY_006] trials.  [COMPANY_006] does not pay incentives to 
enroll subjects in its trials.  However, when enrollment is particularly challenging, additional payments may b e made 
to compensate for the time spent in extra recruiting efforts.
[COMPANY_006] does not pay for subject referrals.  However, [COMPANY_006] may compensate referring physicians for time spent on 
chart review to identify potentially eligible subjects.
B.Clinical Researc h Funding 
Informed consent forms will disclose that the trial is sponsored by [CONTACT_44873], and that the investigator or sponsoring 
institution is being paid or provided a grant for performing the trial.  However, the local IRB/ERC may wish to alter 
the wording of the disclosure statement to be consistent with financial practices at that institution.  As noted above, 
publications resulting from [COMPANY_006] trials will indicate [COMPANY_006] as a source of funding.
C.Funding for Travel and Other Requests
Funding of travel by [CONTACT_19488] (e.g.,to scientific meetings, investigator meetings, etc.) will be 
consistent with local guidelines and practices including, in the U.S., those established by [CONTACT_75401] (AMA). 
V. Investigator Commitment
Investigators will be expected to review [COMPANY_006]’s Code of Conduct as an appendix to the trial protocol, and in signing 
the protocol, agree to support these ethical and scientific standards.
* In this document, "[COMPANY_006]" refers to [COMPANY_006] Sharp & Dohme Corp. and Schering Corporation, each of which is a 
subsidiary of [COMPANY_006] & Co., Inc.  [COMPANY_006] is known as MSD outside of the [LOCATION_002] and Canada.  As warranted by 
[CONTACT_74647], [COMPANY_006] also includes affiliates and subsidiaries of [COMPANY_006] & Co., Inc. "
087V73
Product:   MK-1454 166
Protocol/Amendment No.: 001-08 
MK-1454 -001-08 Final Protocol 27-Jul-2021
Confidential
Collection and Management of Specimens for Future Biomedical Research
1.Definitions
a.Biomarker:  A biological molecule found in blood, other body fluids, or tissues that is a 
sign of a normal or abnormal process or of a condition or disease.  A biomarker may be 
used to see how well the body responds to a treatment for a disease or condition.1
b.Pharmacogenomics:  The investigation of variations of DNA and RNA characteristics as 
related to drug /vaccine response.2
c.Pharmacogenetics:  A subset of pharmacogenomics, pharmacogenetics is the influence of 
variations in DNA sequence on drug /vaccine response.2
d.DNA:  Deoxyribonucleic acid.
e.RNA:  Ribonucleic acid.
2.Scope of Future Biomedical Research
The specimens consented and/or collected in this trial as outlined in Section [IP_ADDRESS] –
Future Biomedical Research Samples will be used in various experiments to understand:
oThe biology of how drugs/vaccines work
oBiomarkers responsible for how a drug/vaccine enters and is removed by [CONTACT_193451]/vaccines may interact with
oThe biology of disease
The specimen(s) may be used for future assay development and/or drug/vaccine 
development.
It is now well recognized that information obtained from studying and testing clinical 
specimens offers unique opportunities to enhance our understanding of how individuals 
respond to drugs /vaccines , enhance our understanding of human disease and ultimately 
improve public health through development of novel treatments targeted to populations 
with the greatest need.  All specimens will be used by [CONTACT_75402] .
3.Summary of Procedures for Future Biomedical Research
a.Subjects for Enrollment
All subjects enrolled in the clinical trial will be considered for enrollment in Future 
Biomedical Research.
b.Informed Consent
Informed consent for specimens (i.e., DNA, RNA, protein, etc.) will be obtained 
during screening for protocol enrollment from all subjects or legal guardians, at a trial 
visit by [CONTACT_20616] r or his or her designate.  Informed consent for Future 
Biomedical Research should be presented to the subjects on the visit designated in the 
trial flow chart .  If delayed, present consent at next possible Subject Visit.   Consent 
forms signed by [CONTACT_762646].  
087V73
Product:   MK-1454 167
Protocol/Amendment No.: 001-08 
MK-1454 -001-08 Final Protocol 27-Jul-2021
ConfidentialA template of each trial site’s approved informed consent will be stored in the 
Sponsor’s clinical document repository.
c.eCRF Documentation for Future Biomedical Re search Specimens
Documentation of subject consent for Future Biomedical Research will be captured in 
the electronic Case Report Forms (eCRFs). Any specimens for which such an 
informed consent cannot be verified will be destroyed .
d.Future Biomedical Research Specimen(s)
Collection of specimens for Future Biomedical Research will be performed as 
outlined in the trial flow chart. In general, if additional blood specimens are being 
collected for Future Biomedical Research, these will usually be obtained at a time 
when the subject is havin g blood drawn for other trial purposes .
4.Confidential Subject Information for Future Biomedical Research 
In order to optimize the research that can be conducted with Future Biomedical Research 
specimens, it is critical to link subject' clinical informat ion with future test results. In fact 
little or no research can be conducted without connecting the clinical trial data to the 
specimen. The clinical data allow specific analyses to be conducted. Knowing subject 
characteristics like gender, age, medical history and treatment outcomes are critical to 
understanding clinical context of analytical results.
To maintain privacy of information collected from specimens obtained for Future 
Biomedical Research, the Sponsor has developed secure policies and procedures . All 
specimens will be single -coded per ICH E15 guidelines as described below . 
At the clinical trial site, unique codes will be placed on the Future Biomedical Research 
specimens.  This code is a random number which does not contain any personally 
identi fying information embedded within it. The link (or key) between subject identifiers 
and this unique code will be held at the trial site.  No personal identifiers will appear on 
the specimen tube.  
5.Biorepository Specimen Usage
Specimens obtained for theSponsor will be used for analyses using good scientific 
practices.  Analyses utilizing the Future Biomedical Research specimens may be 
performed by [CONTACT_1034] , or an additional third party (e.g., a university investigator) 
designated by [CONTACT_1034] . The investigator conducting the analysis will follow the 
Sponsor’s privacy and confidentiality requirements. Any contracted third party analyses 
will conform to the specific scope of analysis outlined in future biomedical research 
protocol and consent . Future Biomedical Research specimens remaining with the third 
party after specific analysis is performed will be reported to the Sponsor .
6.Withdrawal From Future Biomedical Research 
Subjects may withdraw their consent for Future Biomedical Research and ask that their 
biospecimens not be used for Future Biomedical Research.   Subjects may withdraw 
consent at any time by [CONTACT_59554] [INVESTIGATOR_75306]. If medical 
records for the main trial are still available, the investigator will contac t the Sponsor 
using the designated mailbox ([EMAIL_1250]). 
087V73
Product:   MK-1454 168
Protocol/Amendment No.: 001-[ADDRESS_1045064]'s specimens will be flagged in the biorepository and restricted 
to main study use only. If specimens were collected from study participants speci fically 
for Future Biomedical Research, these specimens will be removed from the biorepository 
and destroyed. Documentation will be sent to the investigat or confirming withdrawal 
and/or destruction, if applicable. It is the responsibility of the investigator to inform the 
subject of completion of the withdrawal and/or destruction, if applicable.  Any analyses 
in progress at the time of request for withdrawal/destruction or already perfor med prior to 
the request being received by [CONTACT_75406]. No new analyses would be generated after the request is 
received.
In the event that the medical records for the main trial are no longer available (e.g., if the 
investigator is no longer required by [CONTACT_193453]) or the specimens have been completely anonymized, there will no longer be a 
link between the subject’s personal informat ion and their specimens. In this situation, the 
request for withdrawal of consent and/or destruction cannot be processed.
7.Retention of Specimens 
Future Biomedical Research specimens will be stored in the biorepository for potential 
analysis for up to [ADDRESS_1045065] results are accessible only to the 
authorized Sponsor representatives and the designated trial administrator research 
personnel and/or collaborators .Database user authentication is highly secure, and is 
accomplished using network security policies and practices based on international 
standards to protect against unauthorized access.
9.Reporting of Future Biomedical Research Data to S ubjects
No information obtained from exploratory laboratory studies will be reported to the 
subject, family, or physicians .Principle reasons not to inform or return results to the 
subject include: Lack of relevance to subject health, limitations of predic tive capability, 
and concerns regarding misinterpretation.
If important research findings are discovered, the Sponsor may publish results, present 
results in national meetings, and make results accessible on a public website in order to 
rapi[INVESTIGATOR_762558].  Subjects will not be identified by 
087V73
Product:   MK-1454 169
Protocol/Amendment No.: 001-[ADDRESS_1045066] been identified as no additional specimens are being collected 
for Future Biomedical Research (i.e., only leftover samples are being retained).
The Sponsor has developed strict security, policies and proc edures to address subject data 
privacy concerns.  Data privacy risks are largely limited to rare situations involving 
possible breach of confidentiality.  In this highly unlikely situation there is risk that the 
information, like all medical information, m ay be misused.
12.Questions
Any questions related to the future biomedical research should be e-mailed directly to 
[EMAIL_1250].
13.References
1.National Cancer Institute: http://www.cancer.gov/dictionary/?searchTxt=biomarker
2.International Conference on Harmonization: DEFINITIONS FOR GENOMIC 
BIOMARKERS, PHARMACOGENOMICS, PHARMACOGENETICS, GENOMIC 
DATA AND SAMPLE CODING CATEGORIES - E15; 
http://www.ich.org/LOB/media/MEDIA3383.pdf
3.Industry Pharmacogenomics Working Group. Understanding the Intent, Scope and 
Public Health Benefits of Exploratory Biomarker Research: A Guide for IRBs/IECs 
and Investigational Site Staff. Available at http://i -pwg.org/
4.Industry Pharmacogenomics Working Group. Pharmacogenomics Informational 
Broch ure for IRBs/IECs and Investigational Site Staff. Available at http://i -pwg.org/
087V73
Product:   MK-1454 170
Protocol/Amendment No.: 001-08 
MK-1454 -001-08 Final Protocol 27-Jul-2021
Confidential
Prioritization of Intratumoral Lesion Injection
The selection and prioritization of lesions for intratumoral injection is a complex set of 
decisions made by [CONTACT_762647]. Ultimately, lesion prioritization is 
based on clinical judgment and patient tolerance ;however, aset of guiding principles can be 
described. 
Patient Safety
The first priority is patient safety. Lesions are to be selected that minimize the potential for 
procedural complications and maximize patient comfort. One important safety factor is 
vascularity within a lesion, and adjacent to a lesion . Injection into intratumoral vessels should 
be avoided to minimize systemic administration. Vessels adjacent to a tumor should not be 
traversed to minimize bleeding risk, and areas of vascular encasement should be avoided in
high risk locations (eg,inferior vena cava encasement for liver lesions, or carotid artery
encasement for head and neck tumors).
Lesion A ccessibility
The next prioritization factor is accessibility . Preference should be given to cutaneous lesions 
which are visible, and superficial subcutaneous lesions and lymph nodes that are easily 
palpable. Deeper lesions, including nonpalpable lymph nodes and nonpalpable extranodal 
lesions in viscera or body cavities, may be more difficult to access . These deeper lesio ns
typi[INVESTIGATOR_762559] ,which increases procedural complexity, and must be 
balanced against the clinical benefit that might result from their treatment, such as 
symptomatic relief.
Lesion Size,Tumor Necrosis, Amount of Viable Tumor Tissue , and Aggressive Tumors
At the initiation of therapy, the next factors that should guide lesion prioritization are the size 
of the lesion, and the amount of viable tumor tissue present in the lesion. Other factors being 
equal, larger lesions are preferred . Larger lesions may have a greater amount of tumor tissue ,
and are generally older in age than smaller lesions, and may have a greater breadth of tumor -
specific antigens to stimulate a broader repertoire of antigen -specific Tcells. 
Radiographically visible necrosis should be avoided . Direct intratumoral immuno therapy into
viable portions of a lesion. A larger lesion that is predominantly necrotic may be 
deprioritized compared to a smaller lesion with little or no radiographic necrosis. Another 
feature that should be considered is radiographic evidence of aggressiveness, such as local 
invasiveness . Aggressive lesions should be given higher pr iority.
087V73
Product:   MK-1454 171
Protocol/Amendment No.: 001-08 
MK-1454 -001-08 Final Protocol 27-Jul-2021
ConfidentialNew and/or Progressing Lesions
During therapy, lesions that are new or progressing should be given higher priority than 
lesions selected on the basis of size or on the basis of the imaging features described above . 
Safety and accessibility are ofcourse still the primary considerations . New and progressing 
lesions contain actively dividing cells, which may be more responsive to injection with an 
intratumoral immunotherapeutic. Also, new or progressing lesions may contain newly 
mutated tumor cells, allowing for a broader spectrum of antigen -specific T cells in response 
to injection with an intratumoral immunotherapeutic, and a subsequent improved systemic 
antitumor response . New lesions may contain novel tumor antigens compared topreviously 
injected lesions . 
087V73
Product:   MK-1454 172
Protocol/Amendment No.: 001-[ADDRESS_1045067] 1.1 
rules for measurability. Measurable lesions (those eligible for selection as target lesions) are 
then classified as target (selected to be followed quantitatively) ornontarget (selected to be 
followed qualitatively), and the decisions about which lesions are to be injected are made 
based on the prioritization rules discussed. Lesions selected for injection may be either target 
or nontarget in RECIST 1.[ADDRESS_1045068] 1.1, 
classified in aggregate as showing complete response, unequivocal progression, or neither 
(called non -CR/non -PD in RECIST 1.1).
087V73
Product:   MK-1454 173
Protocol/Amendment No.: 001-[ADDRESS_1045069]:   MK-1454 174
Protocol/Amendment No.: 001-[ADDRESS_1045070] 1.1, Response Evaluation Criteria in 
Solid Tumors, version 1.1; SOD.
087V73
Product:   MK-1454 175
Protocol/Amendment No.: 001-08 
MK-1454 -001-08 Final Protocol 27-Jul-2021
ConfidentialFigure 8Example of Iterative Assessment of Injected Lesion Response During Treatment
Abbreviations: iPR = immunotherapeutic partial response; iRECIST 1.1 =  immunotherapeutic Response 
Evaluation Criteria in Solid Tumors; NE = not evaluable; NT-I = nontarget injected; NT-NI = nontarget 
noninjected; PD = progressive disease; PR = partial response; SD =  stable disease; SOD = sum of diameters 
(longest diameters for extranodal lesions, short axis for lymph nodes); T-I = target injected; T-NI = target 
noninjected.
087V73
Product:   MK-1454 176
Protocol/Amendment No.: 001-08 
MK-1454 -001-08 Final Protocol 27-Jul-2021
ConfidentialThis is an illustration of overall, injected, and noninjected response assessmen t, with a 
particular focus on the iterative assessment of injected lesions. All lesions from a single 
patient are displayed in simple schematic form and are not meant to be anatomically 
adjacent. For purposes of this illustration, the yellow and green lesions were selected at 
baseline as target injected, and the purple and blue lesions were selected as target 
noninjected; there are no nontarget lesions. In this simplified example, a full imaging 
assessment is performed at each treatment visit just before the decision about which lesions 
to inject at that visit. The overall response at each visit was based on the change in SODs for 
all the target lesions together (because there are no nontarget lesions inthis example). Once 
progressive disease is observed (in this case, because of a new lesion), the overall response 
assessment thereafter is similar to that of iRECIST. The injected response is based on the 
change in SOD of the injected lesions from the assessment immediately before this one. The 
noninjected response is based on the changes in SOD from baseline and nadir and is 
considered nonevaluable once any lesion that was initially selected as T-NI is subsequently 
injected, as happens in this case with the purple lesion. If this lesion were to grow later, it
could contribute to an overall response of PD.
Source: [3]
087V73
Product:   MK-1454 177
Protocol/Amendment No.: 001-08 
MK-1454 -001-08 Final Protocol 27-Jul-2021
Confidential
Country -specific Requirements
For countries or sites that follow the CTFG guidance requiring monthly pregnancy testing, 
please use the following:
087V73
Product:   MK-1454 178
Protocol/Amendment No.: 001-08 
MK-1454 -001-08 Final Protocol 27-Jul-2021
ConfidentialSection 6.1.2 Schedule of Activities for the Treatment Period, Intratumoral Administration for Arm 1 (Monotherapy) and Arm 2 
(Combination Therapy –Including Crossover to Arm 2)
Trial PeriodTreatment Phase
MK-1454 Monotherapy Cycle = 21 Days
MK-1454 and Pembrolizumab Combination Therapy Cycle = 21 Days
Notes Cycle Cycle 1 Cycle 2 Cycle 3Cycle 4 
and 
Beyond
Scheduling Day 1 8 15 1 8 15 1 8 15 1
Scheduled Window ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±[ADDRESS_1045071] for WOCBP –
Urine or Serum hCGX X X XRequired within 24hprior to first dose of study 
medication . Does not need to be repeated if screening test 
wasdone within 24hours of C1D1 .If a urine pregnancy 
test cannot be confirmed as negative, a serum pregnancy 
test is required . Thereafter, pregnancy testing should be 
performed Day 1 of each subsequent cycle.
6.1.3 Schedule of Activities for the Treatment Period of Arm 3 (Visceral IT Administration)
Trial PeriodTreatment Phase
MK-1454 Monotherapy Cycle = 21 Days
MK-1454 and Pembrolizumab Combination Therapy Cycle = 21 Days
Notes Cycle Cycle 1 Cycle 2 Cycle 3Cycle 4 
and 
Beyond
Scheduling Day 1 8 15 1 8 15 1 8 15 1
Scheduled Window ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±[ADDRESS_1045072] for WOCBP –
Urine or Serum hCGX X X XRequired within 24hprior to first dose of study 
medication . Does not need to be repeated if screening test 
wasdone within 24hours of C1D1 .If a urine pregnancy 
test cannot be confirmed as negative, a serum pregnancy 
test is required . Thereafter, pregnancy testing should be 
performed Day [ADDRESS_1045073]:   MK-1454 179
Protocol/Amendment No.: 001-08 
MK-1454 -001-08 Final Protocol 27-Jul-2021
Confidential6.2.1 Schedule of Activities for Part II -Expansion Cohorts Screening and Treatment Period, MK -1454 Intratumoral Administration 
With Pembrolizumab Combination Therapy
Trial PeriodScreeningTreatment Phase
MK-1454 Cycle =  then Q3W; or Q3W
Pembrolizumab Cycle = 21 Days
Notes Cycle Cycle 1 Cycle 2 Cycle 3Cycle 4 
and 
Beyond
Scheduling Day -28 to -1 1 8 15 1 8 15 1 8 15 1
Scheduled 
Window±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±[ADDRESS_1045074] for 
WOCBP –Urine or 
Serum hCGX X X X XRequired within 24hprior to first dose of study medication . 
Does not need to be repeated if screening test was done within 
24hours of C1D1 . If a urine pregnancy test cannot be confirmed 
as negative, a serum pregnancy test is required . Thereafter, 
pregnancy testing should be performed Day [ADDRESS_1045075]:   MK-1454 180
Protocol/Amendment No.: 001-[ADDRESS_1045076] of Abbreviations and Definitions
Abbreviation Definition
Abscopal A phenomenon in the treatment of metastatic cancer where localized 
treatment of a tumor causes not only a shrinking of the treated tumor, but 
also a shrinking of tumors outside the scope of the localized treatment
ADA Anti-drug antibody
ADL Activities of daily living
ADME Absorption, distribution, metabolism, and excretion
AE Adverse event
AJCC American Joint Committee on Cancer
ALT Alanine aminotransferase
AMP Adenosine monophosphate
aPTT Activated partial thromboplastin time
ART Antiretroviral therapy
ASaT All-Subjects -as-Treated
ASCO -CAP American Society of Clinical Oncology/College Of American 
Pathologists
AST Aspartate aminotransferase
ATD Accelerated titration design
C1D1 Cycle 1 Day 1
CBC Complete blood count
CD Cluster of differentiation (eg, CD8, CD28)
CDN Cyclic dinucleotide
cGAMP Cyclic GMP -AMP
cGAS Cyclic (guanosine monophosphate -adenosine monophosphate) synthase
CI Confidence interval
CR Complete response
CRC Colorectal cancer
CrCl Creatinine clearance
CRF Case report form
CRP C-reactive protein
CRS Cytokine release syndrome
CRU Clinical research unit
CT Computed tomography
CTCAE Common Terminology Criteria for Adverse Events
CTFG Clinical Trials Facilitation and Coordination Group
CTLA -[ADDRESS_1045077]:   MK-1454 181
Protocol/Amendment No.: 001-[ADDRESS_1045078]
E/CIA Enzyme or chemiluminescence immunoassay
ECG Electrocardiogram
ECOG Eastern Cooperative Oncology Group
EDC Electronic data capture
EMA European Medicines Agency
EORTC European Organisation for Research and Treatment of Cancer 
EOT End of treatment
FBR Future biomedical research
FDAAA Food and Drug Administration Amendments Act
FDG -PET Fluorodeoxyglucose -positron emission tomography
FIH First in human
FSH Follicle -stimulating hormone
GCP Good Clinical Practice
GFR Glomerular filtration rate
GGT Gamma glutamyl transferase
GMP Guanosine monophosphate 
GRI Growth rate inhibition
GVHD Graft -versus -host disease
HBsAg/HBV Hepatitis B surface antigen/Hepati tis B virus
hCG Human chorionic gonadotropin
HCV Hepatitis C virus
Hep C Ab Hepatitis C Antibody
HIV Human immunodeficiency virus
HNSCC Head and neck squamous cell carcinoma
HRT Hormone replacement therapy
IB Investigator’s Brochure
ICF Informed consent form
ICH International Council for Harmonisation of Technical Requirements for 
Pharmaceuticals for Human Use
087V73
Product:   MK-1454 182
Protocol/Amendment No.: 001-[ADDRESS_1045079]:   MK-1454 183
Protocol/Amendment No.: 001-[ADDRESS_1045080]:   MK-1454 184
Protocol/Amendment No.: 001-[ADDRESS_1045081] Upper limit of normal
VL Viral load
VS Vital sign(s)
WOCBP Woman of childbearing potential
WT Wild -type
ZAP70 Zeta-chain -associated protein kinase [ADDRESS_1045082]:   MK-1454 185
Protocol/Amendment No.: 001-08 
MK-1454 -001-08 Final Protocol 27-Jul-2021
Confidential13.0 SIGNATURES
Sponsor's Representative
TYPED NAME
[CONTACT_26409]
I agree to conduct this clinical trial in accordance with the design outlined in this protocol 
and to abide by [CONTACT_19373] (including other manuals and documents 
referenced from this protocol).  I agree to conduct the trial in accordance with generally 
accepted standar ds of Good Clinical Practice.  I also agree to report all information or data in 
accordance with the protocol and, in particular, I agree to report any serious adverse events 
as defined in Section 7.0–TRIAL PROCEDURES (Assessing and Recording Adverse 
Events).  I also agree to handle all clinical supplies provided by [CONTACT_26403].  I understand that information 
that identifies me will be used and disclosed as described in the protocol, and that such 
information may be transferred to countries that do not have laws protecting such 
information.  Since the information in this protocol and the referenced Investigator’s 
Brochure is confidential, I understand that its disclosure to any third parties, other than those 
involved in approval, supervision, or conduct of the trial is prohibited.  I will ensure that the 
necessary precautions are taken to protect such information from loss, inadvertent disclosure 
or access by [CONTACT_26404].
TYPED NAME
[CONTACT_26410]
087V73